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Abstract  
The bone tissue engineering community has been striving to develop novel approaches that 
mimic natural bone formation. The rapid generation of mineralised bone tissue with a capacity for 
vascularisation and the selection of highly osteogenic cell sources are still the focus of research 
today. This study addresses three novel approaches in these key areas. 
Mineralisation in bone tissue involves stepwise cell – cell and cell – extracellular matrix (ECM) 
interactions. Regulation of the osteoblast culture microenvironment can manipulate osteoblast 
proliferation and mineralisation rates and consequently the quality and/or quantity of the final 
calcified tissue. Therefore, an in vitro model to investigate possible influential factors would be 
highly sought after. We developed a facile in vitro model through the modification of culture 
surfaces in which an osteoblast cell line and aggregate culture was used to mimic 
intramembranous ossification. Conventional monolayer culturing was used as a comparative 
control. The effects of multiple culture parameters, including culture duration and aggregate size, 
on mineralisation rates and subsequent mineral quantities and distributions have been examined 
by numerous well established methods alongside certain innovative techniques. 
Ultimately, spatial and temporal production of minerals differed depending upon aggregate size 
with larger aggregates mineralising faster with a distinct gene expression pattern compared to the 
smaller aggregates. We also demonstrated that mineralisation in the larger aggregates initiated 
from the periphery, whilst mineralisation in the smaller aggregates initiated from the centre. This 
implies that aggregate size influences mineral distribution and development over time. 
An in vivo study using a cell line and primary cell population was conducted to investigate how the 
observations noted during the short term in vitro studies would affect long term in vivo aggregate 
survival and bone formation. Both cell types saw similar results. The large aggregates appeared to 
disintegrate over the course of the experiment, whilst the small aggregates remained intact and 
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produced an abundant volume of extracellular material. A monolayer cell sample was again used 
as a comparative control and generated a lower material volume over the same period. The data 
obtained from this element of the project produced some invaluable insights into how the specific 
variables of cellular aggregation might affect possible bone formation in vivo. 
In addition, a novel substrate, substrate X, was used to identify and investigate the possibility of 
mesenchymal stem cell (MSC) subpopulations within mixed MSC populations and their donor-
dependent variations alongside their subsequent influences upon an individual’s osteogenic 
capacity. Substrate X successfully identified what are thought to be three subpopulations within 
individual MSC populations from multiple donors through distinct cellular attachments. Each of 
the subpopulations was shown to hold differing osteogenic capacities and their proportions were 
also shown to be donor-dependent. Subpopulation proportions were shown to correlate with 
specific cadherin levels and cellular aggregation potential was also shown to be donor-dependent. 
Furthermore, the novel aggregation technique developed by this study was pitted against a 
conventional aggregation technique to assess aggregate vascularisation and mineralisation 
simultaneously using cellular co-culturing. This study also investigated how mechanical 
stimulation would affect aggregate vascularisation and mineralisation. The method of aggregation 
developed earlier in this project was shown to create an inner-aggregate architecture that aided 
in specific cellular organisation and possible vascularisation more than the conventional 
aggregation technique. The mechanical stimulation reduced cellular migration from the aggregate 
body compared to a static culture equivalent but nodule mineralisation within the co-cultured 
aggregates was inconclusive due to the short culture period. 
To conclude, simple yet effective substrate chemistry modifications enabled us to evaluate a 
variety of parameters for refined bone tissue engineering. These included the development of an 
aggregate model for the study of developing mineralisation, possible MSC subpopulation 
identification, measurement and assessment and the evaluation of aggregate vascularisation. 
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Overview 
Knowledge of current research trends and accomplishments is essential before any additional 
research can be conducted efficiently and/or successfully. A researcher needs to understand and 
learn from the advantages and disadvantages of previously conducted studies if any level of 
success is to be achieved and novelty maintained. 
The following literature review describes natural bone formation pathways during growth and 
also regeneration following injury or defect. Current research trends designed to replace and/or 
replicate such processes are also discussed with the intention of providing a basic understanding 
as to why this research project was undertaken. 
1. Introduction 
The term ‘regenerative medicine’ was first coined back in 1992 by Leland Kaiser who forecasted 
that “a new branch of medicine will develop that attempts to change the course of chronic 
diseases and in many instances will regenerate tired and failing organ systems”1. Since then 
research has been carried out to find and develop new cell-based techniques and technologies 
that can aid in the regeneration of damaged tissues2. 
Regenerative medicine can be divided into two primary strategies for cell-based therapy. The first 
of which, known as ‘cell therapy’, simply involves the injection of cells into the circulation of 
damaged tissue. These cells are intended to replace those damaged cells within a tissue that 
impair its integrity or function. The second of which, is called ‘tissue engineering’. Tissue 
engineering has been described as a more complex approach that involves the addition of cells to 
a three-dimensional (3D) matrix. This cell/matrix construct is designed to replicate in vivo tissue 
which can be used to replace large portions of damaged or lost tissue or even whole organs2. This, 
however, is not exclusively the case as many studies have researched tissue engineering strategies 
that forego the need for additional 3D biomaterial matrices, such as pellet culture models3,4.The 
3 
 
transplantation of organs and tissues for the treatment of organ and tissue loss and/or failure has 
a number of drawbacks, most notably limited donor supply and often severe immune 
complications. Regenerative medicine strategies, however, may hold the potential to bypass such 
obstacles5. This is especially true for bone tissue with engineered bone tissue being deemed a 
conceivable alternative to more conventional bone grafts6. 
1.1 The anatomy and physiology of bone 
Bone can essentially be thought of in two different ways: as a tissue, bone simply includes the 
bone cells and mineralised matrix, but as an organ, bone includes numerous tissues, such as bone, 
cartilage, blood vessels, fibrous tissue and bone marrow3 (fig. 1.1). Bone tissue is comprised of 
three primary components: the first of which is the inorganic phase, consisting largely of 
hydroxyapatite (HA), the second being the organic phase which is made up of collagen, non-
collagenous proteins and lipids, and the third component being water. Various factors influence 
the ratios of these constituents, such as bone type, age, nutrition and health7. Typically though, 
bone consists of approximately 65% minerals, the majority of which are in the form of HA, and 
35% organic matrix8. Collagen type I (COL 1), being the most abundant protein in the extracellular 
matrix (ECM) of bone, accounts for nearly 90% of the matrix (organic matrix)9. The remaining 10% 
of the matrix is composed of smaller molecular-sized proteoglycans and non-collagenous 
proteins, such as osteocalcin (OCN) (Gla protein), which is of particular interest here because it is 
specific to bone tissue. Another important component in bone is the sialoprotein, osteopontin 
(OPN)8. 
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Figure 1.1: A dissected bone. Shown is the fundamental structure and primary components of bone (adapted from 
www.classes.midlandstech.edu, copyright © 2006 Pearson Education, Inc.) 
Whilst the human skeleton is on average composed of 80% cortical bone and 20% trabecular  
bone10, different bones and regions within such bones may have different ratios. The vertebra for 
example, comprise 25% cortical bone and 75% trabecular bone, the femoral head is 50% cortical 
bone and 50% trabecular bone, and the radial diaphysis is 95% cortical bone and 5% trabecular 
bone11. Cortical bone is a dense, solid tissue that surrounds the marrow space, whereas 
trabecular bone comprises a honeycomb-like network of trabecular plates and rods dispersed 
throughout the marrow space. Both cortical and trabecular bone are made up of osteons which in 
cortical bone are called Haversian systems and in trabecular bone are called packets10. Haversian 
systems are required to add to the permeability of the dense cortical bone through concentric 
layers of lamellae surrounding the Haversian canals. These canals carry the blood and nerve 
supply through the bone10. Surrounding the outer cortical surface of bone, except at joints where 
bone is lined by articular cartilage, is a fibrous connective tissue sheath called the periosteum. 
This sheath contains blood vessels and nerve fibres along with bone cells, osteoblasts and 
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osteoclasts. The periosteum is closely affixed to the outer cortical surface of bone by thick 
collagenous fibres, called Sharpey’s fibres, which reach into the underlying bone tissue. Counter 
to the periosteum is the endosteum. This is a membranous structure covering the inner surface of 
cortical bone, trabecular bone, and the blood vessel canals (Volkman’s canals). The endosteum is 
in contact with the bone marrow space, trabecular bone, and blood vessel canals and like the 
periosteum, contains blood vessels, osteoblasts, and osteoclasts11. 
1.1.1 Important extracellular matrix proteins 
The ECM of bone is composed of 85 – 90% collagenous proteins, predominantly COL 112. Trace 
amounts of types III, V and fibril-associated collagens with interrupted triple helices (FACIT 
collagens) are also present at certain stages of bone formation. FACIT collagens serve as 
molecular bridges that are important for the organisation and stability of the ECM and may help 
in determining collagen fibril diamter11. Conversely, non-collagenous proteins constitute 10 – 15% 
of total bone protein. Approximately 25% of such non-collagenous protein is exogenously derived, 
such as serum albumin and α2-HS-glycoprotein, which are thought to bind to HA because of their 
acidic properties. Serum-derived non-collagenous proteins may help in controlling matrix 
mineralisation, whilst α2-HS-glycoprotein could regulate bone cell proliferation. The remaining 
exogenously-derived non-collagenous proteins are composed of growth factors and numerous 
trace molecules that are thought to affect bone cell activity11. Non-collagenous proteins can be 
subdivided into several categories: proteoglycans, glycosylated proteins, glycosylated proteins 
with potential cell attachment activities and ϒ-carboxylated (Gla) proteins. Many of these proteins 
seem to play multiple roles, including the regulation of bone mineralisation and turnover and the 
regulation of bone cell activity11. Proteoglycans for example, are thought to obstruct 
mineralisation by cloaking collagen fibrils or occupying critical spaces within the fibrils diminishing 
the diffusion of calcium ions or calcium phosphate complexes13.Glycosylated proteins play a 
variety of roles. The main glycosylated protein present in bone is alkaline phosphatase (ALP). ALP 
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in bone is bound to osteoblast cell surfaces via an inositol phosphate linkage but it is also found 
free within mineralised matrix14. The ALP enzyme is thought to play a crucial role in bone 
mineralisation but exactly how is as of yet unidentified. It is thought, however, to regulate the 
transport of phosphate9. Another common glycosylated protein found in bone is osteonectin. 
Osteonectin is thought to affect osteoblast growth and/or proliferation and matrix 
mineralisation11. It is a bone cell marker produced by mature osteoblasts during mineralisation15 
and the presence of such is thought to initiate bone turnover as it is found in the more mature, 
mineralised matrix16,17. Fibronectin is an abundant glycosylated protein known to be present in 
the early stages of bone formation18 and in the bones of adult rats19. Its role in early bone 
formation is not yet fully understood but it is known to be involved in a number of other 
biological processes such as wound healing, haematopoiesis and development. Some studies have 
suggested that fibronectin may be necessary for the migration, adhesion, differentiation and 
proliferation of the mesoderm20. OPN is another multifunctional glycosylated protein found in 
numerous tissue types, but at higher levels in bone21. It has been shown to be an important 
protein for cell – matrix and cell – cell interactions, facilitating the attachment of osteoclasts to 
bone matrix via an interaction with cell surface ανβ3 integrin and CD4422. 
1.2 Natural bone formation and remodelling 
Bones continually undergo process of longitudinal and radial growth, modelling and 
remodelling11. Osteogenesis or ossification is the process of new bone formation23. 
1.2.1 Bone formation 
There are two distinct processes known to form bone tissue depending upon which or what type 
of bone is being developed: endochondral and intramembranous ossification. Endochondral 
ossification, which occurs in the long bones of the body, involves the development of a cartilage 
model prior to bone formation, whereas intramembranous ossification, which occurs in the flat 
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bones of the skull, involves the direct differentiation of mesenchymal stem cells (MSCs) into bone 
cells or osteoblasts24,25. The terminologies endochondral and intramembranous, when used in 
relation to bone formation, refer to tissue being replaced as opposed to the eventual synthesising 
of bone, which is actually the same process in both pathways. It should also be noted that there 
are occasions when endochondral and intramembranous ossification pathways are seen to work 
in unison. During the formation of the pelvis, vertebrae, scapula, clavicle, sternum and ribs for 
example, both sequences can be identified26. 
1.2.1.1 Endochondral ossification 
As mentioned, endochondral ossification requires the formation of a cartilage model prior to 
bone formation. This cartilage model is formed through the condensation and differentiation of 
MSCs into chondrocytes. These chondrocytes subsequently secrete the necessary components of 
a specific cartilage ECM which include COL 1 and the proteoglycan, aggrecan. Proliferation of the 
chondrocytes causes the model to expand. Hypertrophy of the chondrocytes within the mid-shaft 
of the bone and their further differentiation into osteoblasts surrounding this mid-shaft precedes 
the model’s ossification. 
The newly differentiated osteoblasts surrounding the mid-shaft are responsible for the deposition 
of a periosteal bone collar. To form the primary centre of ossification from this bone collar, blood 
vessels, osteoclasts, bone marrow and osteoblast precursor cells colonise the model. The 
osteoclasts then remove the cartilage ECM while the osteoblasts deposit bone on the remnants of 
cartilage to expand the primary ossification centre towards the ends of the model. For the 
formation of long bones, secondary ossification centres are then seen to form at each end of the 
cartilage model. At this point, a cartilaginous growth plate is present between the primary and 
secondary ossification centres with the future permanent articular cartilages at each end of the 
bone. This growth plate is responsible for the longitudinal growth of long bones. As the expanding 
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primary ossification centre continues to grow, it meets and combines with the secondary 
ossification centres, thus, eradicating the growth plate24 (fig. 1.2). 
 
Figure 1.2: Endochondral ossification. A simplified depiction of the primary process involved
27
. Permission for reuse 
granted, license number 3704811231973. 
1.2.1.2 Intramembranous ossification 
A specific sequence of events is required for intramembranous bone formation to occur. In the 
case of embryonic intramembranous ossification, connective tissue acts as a seed around which 
bone is deposited. During such a developmental period, intramembranous ossification plays a 
lesser role in bone formation and is restricted to the construction of the vault of the skull, the 
mandible, the maxilla and numerous other facial bones, along with certain parts of the clavicle. 
During adulthood, however, the intramembranous ossification pathway plays a more significant 
role and is often reactivated for fracture repair and the regeneration of certain bone tissue 
defects. In the case of fracture healing, the granulation tissue, that until that time synthesised the 
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blood clot, now functions as a matrix for bone ingrowth28. Intramembranous ossification involves 
the condensation of the mesenchyme which, with the formation of osteoblasts, then becomes 
vascularised. A number of specific ECM proteins are known to be secreted by differentiating 
osteoblasts, such as COL 1, OPN and OCN, fibronectin and bone sialoprotein. It is these proteins 
that form the osteoid seam which eventually mineralises to form bone9 (fig. 1.3). 
 
Figure 1.3: Intramembranous ossification. A simplified overview of the primary processes involved (adapted from 
Bradley et al.
29
) 
1.2.1.3 Bone vascularisation 
Vascularisation is an essential process during bone development that is known to precede 
mineralisation30. During endochondral bone formation, the ossification process begins with the 
vascular invasion of the calcified cartilage. The differentiation and proliferation of osteoblast 
precursors is subsequently confined to the proximate locality of the invading vessel sprout31. The 
osteoid-producing osteoblasts then arrange themselves as a monolayer of secretory cells with 
their bases positioned along the invading vessel endothelium and their secretory faces positioned 
towards the osteoid front, where a bone strut forms32. During intramembranous bone formation, 
the process begins with avascular mesenchymal condensation. The subsequent differentiation of 
central cells into pre-osteoblasts prior to their further differentiation into secretory osteoblasts 
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coincides with the vascular invasion of the bone nodule. This indicates a close relationship 
between the differentiation of osteoblasts and the processes of angiogenesis33. 
1.2.1.4 Mineralisation 
During the process of mineralisation, osteoblasts secrete osteoid which is the organic component 
of bone matrix comprised of collagen and non-collagenous proteins, such as glycoproteins and 
proteoglycans34. This organic bone matrix is subsequently mineralised by the deposition of 
calcium phosphate crystals and HA which gives the bone its hardness and strength35. Such 
minerals are initially deposited in the “hole” regions of collagen fibrils36, a process enabled by 
matrix extracellular vesicles. Such vesicles are produced by chondrocytes and osteoblasts and act 
as sheltered microenvironments where concentrations of calcium and phosphate can increase to 
the point of precipitating crystal formation37. 
1.2.2 Bone remodelling 
Bone is a dynamic tissue that is continuously being formed, resorbed and reformed by its own 
cells38 in response to stimuli, such as hormones, mechanical loading and/or growth factors35. The 
balance between two opposing actions, resorption and formation, ensures the microstructural 
nature and function of bone (fig. 1.4). Osteoclasts produce acids and enzymes that work on 
dissolving mineralised bone matrix. Osteoblasts, in contrast, secrete bone ECM which then 
subsequently mineralises39. Although acting in opposing directions, both cell types cooperate to 
synchronise and regulate bone remodelling. Osteoblasts express a number of factors that regulate 
the differentiation and activity of osteoclasts40, whilst osteoclasts, in turn, employ modulatory 
signals to influence osteoblastogenesis41. In addition, the functions of both cell types are 
controlled by a third, osteocytes, whose roles include the maintenance of mineral equilibrium and 
the target of distant organs such as the kidneys for the adjustment of mineral excretion42 (fig. 
1.4). 
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Figure 1.4: Bone remodelling. A simplified overview of the primary processes involved (adapted from Idris
43
) 
1.2.2.1 Osteoblasts 
Osteoblasts originate from multi-potential mesenchymal progenitors34 and are specialised stromal 
cells exclusively responsible for the formation, deposition and mineralisation of bone tissue40. 
Osteoblasts synthesise new collagenous matrix and regulate the mineralisation of such matrix by 
releasing small, membrane-bound matrix vesicles that subsequently concentrate calcium and 
phosphate and enzymatically-abolish mineralisation inhibitors, such as pyrophosphate or 
proteoglycans37. 
Alongside the secretion of osteoid, osteoblasts also produce a number of bone morphogenetic 
proteins (BMP) and growth factors such as insulin-like growth factor (IGF), transforming growth 
factor-β (TGF-β) which are then stored within the mineralised bone matrix39. Interestingly, under 
the regulation of the parathyroid hormone, osteoblasts have also been shown to secrete matrix 
metalloprotease-13 (MMP-13) which suggests that these cells may also contribute to the 
degradation of collagen during bone resorption39,44. Osteoblasts have also been shown to enhance 
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osteoclastogenesis through the release of macrophage-colony stimulating factor (M-CSF) which is 
known to be important for the proliferation of osteoclast progenitors and their differentiation 
into mature osteoclasts35. The fibroblast-like morphology of osteoblasts seen when cultured in 
vitro in a low density monolayer is indicative of those found in vivo in a resting or non-active state. 
Once activated in vivo, the cells’ morphology becomes ‘cuboidal’ which indicates their ability to 
now influence the bone surfaces around them and to lay down osteoid in which they will become 
entrapped transforming them into osteocytes45.  
Osteoblasts are known to possess a number of distinguishing properties, such as the ability to 
synthesis COL 1, osteonectin, OPN, OCN and ALP, as well as the ability to respond to certain 
hormones such as parathyroid hormone and growth factors such as epidermal growth factor 
(EGF). The changes in the levels of protein expression and cellular responsiveness seen within 
osteoblastic populations may be indicative of different stages in the cells’ maturity46. For example, 
in vitro models of osteoblast differentiation have shown increases and subsequent decreases in 
the levels of COL 1 and ALP. OPN expression becomes apparent before both bone sialoprotein and 
OCN. Bone sialoprotein is detected in differentiated osteoblasts and OCN is detected with 
mineralisation47–49. However, it is noted that one could argue that these changes in protein 
expression could be the work of already mature cells and so more work is needed to identify the 
earlier stages in cellular differentiation46. This work is currently ongoing and explained in more 
detail later in the review. 
1.2.2.2 Osteoclasts 
Osteoclasts are extremely large cells comprised of acidophilic cytoplasm and anywhere from 2 – 
100 nuclei derived from myeloid progenitors of the monocyte-macrophage lineage50. The 
multistep differentiation process is thought to be primarily mediated by two cytokines, the M-CSF 
and the receptor activator of nuclear factor-kappaB ligand (RANKL)51. Mature osteoclasts possess 
the unique ability to degrade bone for the processes of bone remodelling, bone morphogenesis, 
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the repair of microdamage and the adaptation to mechanical loading. On the bone surface, 
osteoclasts interchange between migratory phases and static resorption phases. Osteoclast 
resorption begins with the development of a sealing zone which subsequently leads to apicobasal 
polarisation and the formation of a ruffled border. Below this ruffled border, a resorption pit is 
formed. The degradation products derived from this pit are removed by a process called 
endocytosis and trafficked through the cell by a process called transcytosis before being released 
into the extracellular medium52. The sealing zone then disassembles via the action of a thyroid 
hormone, calcitonin39. The cell then moves away and forms a new adhesion structure next to the 
former resorption pit before the process starts again. The alternation between both phases can 
result in the formation of resorption pit trails on the bone surface52. 
1.2.2.3 Osteocytes 
Osteocytes are terminally differentiated osteoblasts that function with syncytial networks to 
support bone structure and facilitate metabolism. They lie within mineralised bone with extensive 
filipodial processes that stretch out within the canaliculi of mineralised bone53. Until recently it 
was theorised that an osteoid-producing osteoblast becomes entrapped within the mineralised 
matrix as neighbouring osteoblasts lay down osteoid over the embedding cell45. However, a 
number of arguments have developed disputing osteocytogenesis as being such a passive process.  
One of the first changes to occur within embedding cells is the formation of dendritic processes. 
Morphologically, the cell transforms from a polygonal shape to a cell with dendritic extensions 
outspreading from the mineralising front to either the vascular space or bone surface. Once 
embedded the cell has a polarity. The osteocyte now has two major functions, to regulate 
mineralisation and form connective dendrites. In addition to the osteocyte being able to control 
and regulate mineralisation54, osteocytogenesis has also been shown to be an actively invasive 
process with the cleavage of collagen and potentially other matrix proteins42. As an osteoblast 
transforms into an osteocyte, several molecules and proteins are known to fluctuate. Changes in 
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the distribution of actin-binding proteins, such as spectrin, filamin, villin and fimbrin, have been 
shown to correlate with osteocyte differentiation55 along with molecules required for cytoskeletal 
rearrangement such as macrophage-capping protein (CapG) and destrin56. Additionally, during 
this transition ALP is reduced, and casein kinase II (CK2) and OCN are raised57. 
Whilst osteocytes constitute 95% of the bone cells in the adult skeleton, with this amount 
increasing with age and bone size, they are not thought to play a major role in embryonic bone 
development and are suspected of playing only a secondary role in postnatal growth and 
development. They do, however, appear to play a crucial role in maintaining bone homeostasis 
within the adult skeleton. The osteocyte is thought to orchestrate bone remodelling by regulating 
both osteoblast and osteoclast activity. They also act as mechanosensors for the control of 
responses to mechanical loading placed on the skeleton and may be a target cell for the actions of 
the parathyroid hormone. Thus, the osteocyte appears to incorporate mechanical and hormonal 
signalling into the management of bone mass58. 
1.3 The processes of fracture repair 
The processes of fracture repair are postnatal but echo many of the processes that take place 
during embryonic skeletal development. The occurrence of such processes is thought to make 
fracture healing one of the few postnatal practices that is truly regenerative by restoring pre-
injury cellular composition, structure and biomechanical function (reviewed in59,60). All of the 
pathways utilised during embryonic skeletal development are expressed in fracture calluses61. 
1.3.1 Local inflammation 
During the initial inflammatory phase post-injury, specific cell-mediated immune functions 
remove necrotic tissues, promote angiogenesis and initiate bone repair62–64. The first step in 
fracture healing is the formation of a haematoma around the site of damage, without which 
healing would be delayed65. The haematoma not only contains the fracture debris but also 
15 
 
instigates a cascade of pro-inflammatory events by recruiting immune cells from the surrounding 
soft tissues. A low pH environment is formed within the haematoma within which the 
inflammatory cells secrete pro-inflammatory cytokines (tumour necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β), and interleukin-6 (IL-6)) in order to activate the polymorphonuclear 
neutrophils and pro-inflammatory or M1 macrophages66. The haematoma produces a fibrin 
network which acts as a temporary scaffold for the leukocytes. This pro-inflammatory phase has 
been shown to have a positive effect on fracture healing67 through the promotion of cell 
proliferation via IL-1β68 and basic fibroblast growth factor (FGF-2)69, and cell differentiation via 
matrix metalloproteinase-9 (MMP-9)70 and BMP71. During this pro-inflammatory phase lactate 
levels are also raised72–76 which results in an upregulation of angiogenic factors such as 
angiopoetin-1, platelet-derived growth factor (PDGF) and vascular endothelial growth factor 
(VEGF)77,78. Whilst the initiation of fracture healing is dependent upon the pro-inflammatory 
response, continued healing is dependent upon the cessation of the pro-inflammatory response. 
The anti-inflammatory phase is resultant of the phenotypic alteration of the macrophages to anti-
inflammatory or M2 macrophages. The now anti-inflammatory macrophages secrete a number of 
cytokines and growth factors to promote tissue repair and angiogenesis, such as interleukin-10 
(IL-10), PDGF, VEGF, TGF-β, EGF and arginase79. In addition, numerous studies have linked MSCs 
with the maintenance of a hypoimmunogenic state80 through the release of immunosuppressive 
paracrine factors81–83 or through their direct interactions with immune cell populations, such as T 
cells84,85. Such actions are thought to protect the developing tissues by stifling proliferation of T 
cells during stem cell recruitment and endochondral bone formation86. 
1.3.2 Angiogenesis 
Compromised angiogenesis during the onset of fracture healing has a significant negative effect 
on the progression of repair. Ischemia at the site of injury dramatically reduces the rate of 
fracture repair and can potentially lead to non-healing fractures, clinically termed “non-
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union”87,88. For this reason, the ischemic microenvironment created following injury activates a 
series of biological events leading to the regeneration or repair of bone. Such an environment 
firstly requires an oxygen and nutrient supply and so stimulates the hypoxia-inducible factor 1 
(HIF-1) pathway which results in the upregulation of angiogenic factors such as VEGF89. The 
expression of such growth factors triggers the migration of endothelial cells (EC) into the hypoxic 
zone arranged with oxygen sensing cells at the forefront followed by proliferating stalk cells  at 
the rear, thus, forming a vascular network89,90. Fibronectin is a major element of the ECM and is 
known to encourage cell migration, adhesion and spreading, and cytoskeletal organisation91. 
Given that its synthesis is upregulated during wound healing91–93, it is believed to play a vital role 
in MSC migration to the site of injury. 
Reiterating the need for adequate angiogenesis following injury are the studies showing hypoxia 
resulting in the decreased adipogenic and osteogenic differentiation capacity of MSCs94, whilst 
increasing the release of angiogenic factors that promote vascularisation95,96. Fundamentally, 
MSCs retain their stemness and remain undifferentiated until the hypoxic environment has been 
normalised via the infiltration of EC and the repair or construction of a viable vascular network. 
Once normoxic conditions have been restored, endochondral or intramembranous ossification is 
free to regenerate bone. 
1.3.3 Bone regeneration 
Histological studies have shown that the growth of regenerating bone is very similar to that of 
numerous stages of bone and cartilage growth explained above (fig. 1.5). Therefore, it is thought 
that the molecular sequences are at the very least similar97,98. These similarities have been 
outlined in several studies59,60,99. Depending upon the biophysical environment, bone 
regeneration can occur via different patterns, i.e. endochondral, primary, direct and distraction 
osteogenesis26. 
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Endochondral regeneration refers to bone growth by callus formation. This form of regeneration 
is mediated by the inner periosteal layer and marrow tissues which synthesise cartilage followed 
by woven and lamellar bone. Primary regeneration refers to direct contact repair which is 
mediated solely by intraosseous Haversian system osteoblasts (SOBL) and osteoclasts. This form 
of bone regeneration does not include a cartilage phase but instead involves the resorption of 
necrotic bone on either side of the fracture by osteoclasts, followed by the synthesis of lamellar 
bone by osteoblasts. Direct regeneration refers to gap repair or direct transformational repair. 
This process is again accomplished without the need for cartilage tissue formation and is 
mediated by marrow-derived vessels and mesenchymal cells. Distraction osteogenesis refers to a 
process called callotasis which again, is mediated by the inner periosteal layer and marrow tissue. 
Woven and then lamellar bone is synthesised within the gradually broadening gap26. 
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Figure 1.5: The processes of fracture repair
100
. Permission for reuse granted, license number 3705490402145. 
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1.4 Treatment strategies for damaged bone 
Large defects found within the bone are generally caused by trauma, infection or tumours and are 
worsened by atrophic non-union which is the result of an inadequate blood supply, the presence 
of soft tissue, or the aftermath of an infection101. There are numerous treatments available for the 
repair of bone defects and/or loss. 
1.4.1 Conventional treatment approaches 
One such treatment is with the use of cement102,103. Cement is versatile and readily conformable 
to fit the size and shape of the bone defect but over time it has been proven to be the least stable 
of several similar alternatives102. Cement is not a biological scaffold and may cause thermal 
necrosis of the surrounding bone and blood supply104,105. For this reason, it is mainly 
recommended for repairing small contained defects106. Another alternative is to simply secure the 
same cement with screws. This has been shown to result in a 30% decrease in displacement102,107 
with no signs of failure after 15 years102. Like cement alone, it is reliable, reproducible, easily 
preformed and inexpensive108. However, also like cement it carries the risk of thermal necrosis106 
and it is only recommended for small uncontained bone defects109. 
The use of metal augments is another treatment available for both femoral and tibial defects110. 
Their versatility and availability in various shapes and sizes makes them suitable to replace bone 
defects of various severities106. They do, however, run the risk of fretting and corrosion111–113 and 
in the long run the differences in elasticity between bone and metal may cause stress shielding 
and increase potential bone loss114. For these reasons this technique is mainly used in elderly, 
low-demand patients115. The gold standard for current treatments, however, is bone grafting with 
a novel treatment strategy being regenerative medicine101. 
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1.4.2 Bone grafting 
When treating bone disease, specifically large bone defects, autologous bone grafts are widely 
used and generally produce good clinical outcomes. The most common form of autograft is 
fragmented cancellous bone from the iliac crest which includes angiogenic factors from the bone 
marrow in order to promote the regeneration of vascularised bone. A similar treatment is an 
autologous fibula graft transfer or the transplant of an allogeneic bone graft. Alternatively, 
structural vascular autografts can be utilised for repair. However, each of these procedures has 
drawbacks. Given that autologous bone is a limited resource, such a graft is often accompanied by 
high rates of morbidity and allogeneic grafts are always shadowed by the possibility of an 
infection or the graft’s rejection116–118. 
1.4.3 Regenerative medicine 
Current graft treatments offered for orthopaedic defects are often associated with limitations or 
drawbacks116–118 and can result in decreased musculoskeletal function or even loss of the patient’s 
mobility. The worst case scenario for such diseases results in the patient’s loss of autonomy101. 
For this reason, recent years have seen many studies being conducted under the guise of 
regenerative medicine in the hope of enhancing natural bone healing and regeneration and to 
even generate functional bone tissue intended to replace lost bone. Various stem cells have been 
studied in vitro such as embryonic stem cells (ESC) and numerous adult MSCs with promising 
results being demonstrated with osteogenic differentiation, enhanced bone healing and 
vascularisation. However, the use of ESCs in vivo is currently forbidden making MSCs the only 
stem cell currently under consideration for therapeutic treatments119. MSCs have shown 
remarkable capacity for osteogenic differentiation making them an ideal candidate for bone 
tissue engineering and regenerative medicine120. It is hoped that orthopaedic defects, such as 
cartilage damage, arthritis, large bone defects or atrophic tendon ruptures, will benefit greatly 
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from the field of regenerative medicine. Because current surgical treatments are insufficient, 
however121–128, novel techniques need exploring. 
2. Bone tissue engineering 
As previously mentioned, tissue engineering, typically but not exclusively, involves the 
combination of specific cells with 3D matrices and particular molecular signals intended to 
replicate tissue-specific cells and ECM101. Engineered bone tissue is considered a plausible 
substitute for the use of standard bone grafts6. Bone tissue has a remarkable capacity for 
regeneration that involves a series of biological events, e.g. cell adhesion, migration, proliferation 
and differentiation, regulated by growth factors secreted by both resident bone cells and reactive 
cells responding at the site of damage129,130. In saying that, however, large bone defects, 
regardless of their origin, congenital disease, trauma etc., might not possess the capacity to 
regenerate or heal instinctively and so may require clinical intervention. Such situations would 
profit from therapeutic strategies that stimulate tissue regeneration or replace lost or damaged 
bone tissue131. This is where bone tissue engineering becomes attractive. Bone tissue engineering 
is simply a division of tissue engineering specifically dedicated to bone. The demand for 
engineered bone tissue within clinical situations is globally widespread and growing. In the United 
States alone, more than 500,000 patients are treated annually for bone defects costing more than 
$2.5 billion. These figures are expected to double by 20206. 
Naturally, the most effective bone regeneration would replicate the in vivo processes known to 
develop bone; therefore, numerous cell types, biomaterials, culture conditions and combinations 
of such, have been rigorously investigated and documented. A critical challenge for in vitro bone 
formation, through a tissue engineering approach for example, is to create a cellular/matrix niche 
for bone cells or stem cells to follow in vivo pathways132. The ultimate goal for bone tissue 
engineering is to generate a construct that closely mimics the physical and biological 
characteristics of natural bone tissue133. 
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2.1 Current bone tissue engineering strategies 
There are several principle components to be considered when discussing tissue engineering. 
These include biomaterials or scaffolds, cell sources, mechanical/chemical stimulation and various 
combinations of such. 
2.1.1 The use of biomaterials/scaffolds 
Scaffolds for bone tissue engineering are typically made from porous degradable biomaterials that 
provide the mechanical support during the repair and regeneration of damaged or diseased 
bone134. In vitro research revolving around bone tissue engineering, in contrast to the majority of 
other tissues, has been mainly focussed on the development of scaffolds that enhance bone 
tissue regeneration through the infiltration of host cells once implanted in vivo, as opposed to the 
in vitro development of actual bone tissue. However, recent years have seen an increase in the 
number of studies being conducted to develop replacement bone tissue in vitro with the aid of 
appropriate cell lines, biomaterial scaffolds, bioactive agents and bioreactors135. 
Biomaterial scaffolds must fulfil a number of prerequisites prior to being used for bone tissue 
engineering. These include biocompatibility, osteoinductive or osteoconductive properties, 
controllable degradation, high levels of porosity enabling mass transport, permeation of cells and 
interstitial fluid flow135. Numerous biomaterials have been developed for use as scaffold matrices 
in tissue engineering and specifically bone tissue engineering. Despite this research and 
development, however, mainly organic biomaterials are employed in scaffold formation. These 
materials can be derived from natural sources, such as collagen, gelatin, agarose, fibrin, alginate, 
silk or hyaluronic acid101. Given its prevalence in native bone tissue, HA is another biomaterial that 
has been investigated thoroughly as a potential candidate for orthopaedic implants136–138. 
Synthetic sources have also been explored with such materials consisting mainly of 
polyhydroxyacids, such as polylactides and polyglycolides101. Despite the advances made in 
23 
 
biomaterial research, bone growth is often limited due to the biomaterial’s lack of osteoinductive 
or osteoconductive properties139. There is currently no scaffold material that fulfils all the 
required necessities131; however, there are options available to enhance the effectiveness of 
these biomaterials. In an attempt to control the rate of biomaterial degradation and matching it 
to that of tissue regeneration for example, recent studies were carried out using hydroxyl acid 
copolymers101. Given that the majority of synthetic polymers are lacking in bioactivity, recent 
studies have also examined various surface modifications in an attempt to influence cell adhesion, 
migration, proliferation and differentiation. This was accomplished by adhering bioactive 
materials or functional groups to the polymer chain prior to scaffold manufacturing140–142. Other 
methods involve the direct adherence of cytokines to the scaffold, such as bone morphogenetic 
protein 2 (BMP-2) bound to keratin sponge143, or coatings of genetic vectors to transfect the 
seeded cells with various growth factors144. 
2.1.2 Cell sources for engineering bone tissue 
Various cell types have been used for tissue engineering bone grafts, such as bone marrow 
aspirates, lineage-specific osteoblasts and differentiated stem cells145,146. 
2.1.2.1 Primary- and cell line-derived bone cells 
The cells used for bone tissue engineering include bone cells derived from a cell line or primary 
culture. It has been noted that the cell types and the characteristics of the substrates used to 
culture them can and do influence the osteoblasts’ ability to maintain their phenotype and level 
of activity which can vary dramatically147. Immortalised cell lines, such as MG-63148, UMR106 and 
Saos-2149, are a popular choice for the study of osteoblast models because of their specific 
characteristics and known differentiation state. The MG-63 cell line for example, which represents 
an immature osteoblast phenotype, was first derived from the left femur of a 14 year male 
diagnosed with juxtacortical osteosarcoma150. The similarities between this osteosarcoma cell line 
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and normal osteoblasts has made them an attractive model for hormonal regulation; however, 
their inconsistent matrix protein expression due to clonal heterogeneity limits their use in 
osteoblast phenotype and mineralisation studies151. MLO-A5, a murine cell line, is another 
popular cell line for investigating potential mechanisms of bone mineralisation. This cell line 
comprises post-osteoblast/pre-osteocyte-like cells derived from 14 day old transgenic mice. The 
cells have very similar Fourier transform infrared (FTIR) spectra to that of normal bone and are 
known to express high levels of ALP, OCN, OPN, periostin, bone sialoprotein, and parathyroid 
hormone receptor in comparison to primary osteoblasts or other osteoblast cell lines. Also, with 
the addition of osteogenic supplements, β-glycerophosphate and ascorbic acid, this cell line was 
seen to spontaneously mineralise after just 3 days making them an ideal candidate for 
mineralisation and mechanical strain studies152. It has been said, however, that no immortalised 
cell line can truly replicate the phenotype of a primary osteoblast making a primary cell culture 
model, although inherently more difficult to accurately replicate, a more truthful model153. 
2.1.2.2 Stem cells 
Stem cells can be defined as pluripotent or multipotent cells displaying two distinctive 
characteristics: self-renewal and the ability to differentiate into any one of several cell lineages. 
Depending upon their source of origin, stem cells can be categorised as ESCs or adult stem cells. 
These adult stem cells can be further subdivided into two primary categories: haematopoietic 
stem cells (HSC) and MSCs154–156. 
2.1.2.3 Mesenchymal stem cells 
MSCs are stem cells that have been isolated from numerous tissues, including bone marrow, 
adipose tissue, the synovial membrane and the periosteum, amongst others157. Given the 
numerous sources and techniques from which MSCs have been isolated, in 2006 the International 
Society of Cellular Therapy (ISCT) suggested minimum criteria for the cells’ characterisation. MSCs 
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should adhere to tissue culture polystyrene (TCP) under standard culture conditions, whilst 
positively expressing CD73, CD90 and CD105, and negatively expressing CD11b, CD14, CD19, 
CD34, CD45, CD79α and HLA-DR. Histological staining should also demonstrate the cells’ ability to 
differentiate into adipocytes, chondrocytes and osteoblasts158. 
The differentiation capacity of MSCs has been studied extensively in vitro demonstrating an ability 
to differentiate into mesenchymal cells, such as bone, tendon, cartilage, fat and fibroblasts128. 
However, as research continues it would appear that MSC differentiation may not be restricted to 
cells of the mesenchymal lineage. Cells of other germinal layers may also be within their reach, 
such as neurons, glia cells, ECs, cardiomyocytes and hepatocytes159–162. Interestingly, MSCs have 
shown differing differentiation potentials dependent upon their tissues of origin163. Although 
similar in many ways, a number of studies have reported differences between MSCs isolated from 
different sources. These differences include proliferation rates, surface markers, multipotency 
and several other markers. This may be an opportunity for regenerative medicine to identify the 
best source of MSCs for specific therapies164,165. When comparing neonatal sourced MSCs to adult 
derived MSCs, MSCs taken from neonatal sources possess an initial advantage over those isolated 
from adult tissues in the respect that their isolation avoids the intrusive procedure which can 
often be associated with infection166 and donor site morbidity167. Those neonatal-sourced MSCs 
have also been reported to possess a higher capacity for expansion and engraftment when 
compared to those isolated from bone marrow168,169. In addition,  contact inhibition was observed 
with bone marrow-derived MSCs but not with umbilical cord blood-derived MSCs170,171. 
Interestingly, not only were differences in population doubling times noted between MSC 
populations derived from different tissues, but also between MSC populations derived from 
different regions of the same tissue172–174. Numerous other differences such as morphology, 
surface markers, cell population and life span, are described in great detail by Zhang and 
colleagues146.  
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MSCs may have characteristics and properties that we do not yet fully understand. Many of the 
studies conducted using MSCs reported the beneficial effects of their presence without any 
detectable engraftment to the damaged tissues. MSCs are also known to encouragingly influence 
cohabiting cells derived from other tissues, such as skin, muscle, endothelial and renal epithelial 
layers175. Tumour growth for example, has been seen to be enhanced by MSCs through an 
increase in the secretion of proangiogenic factors and enhanced blood vessel formation176. In 
addition, protein extracts and conditioned media obtained from MSC cultures resulted in organ 
function improvements for liver disorders and heart ischemia177,178. When investigated further, 
MSCs were seen to release paracrine factors, such as insulin-like growth factor 1 (IGF-1), insulin-
like growth factor 2 (IGF-2), hepatocyte growth factor (HGF), VEGF, basic fibroblast growth factor 
(bFGF) and pre-microRNAs, which are thought to protect the host cells, encourage cell 
proliferation and augment angiogenesis179,180. MSCs have also been shown to secret paracrine 
factors thought to enhance lung function via the regulation of endothelial and epithelial 
permeability, lowering inflammation and enhancing tissue repair, whilst also preventing the 
growth of bacteria in acute lung injury and acute respiratory syndrome181. 
In addition to MSCs remarkable differentiation and cytokine secretion capacity, there is growing 
evidence to suggest that these cells possess a non-immunogenic characteristic that may render 
them transferable from one patient to another without any immune response182. These cells have 
been shown, both in vitro and in vivo, to be capable of curbing an immune response by preventing 
immune cells, such as helper T, cytotoxic T, dendritic, and B cells, from maturing. Cytokines, such 
as transforming growth factor-β1 (TGF-β1), prostaglandin-E2, and IL-10, which are known to be 
responsible for repressing inflammation, have also been shown to be secreted by MSCs163. 
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2.1.2.3.1 Mesenchymal stem cells and osteogenic differentiation 
The potential for MSCs to enhance bone fracture healing has been demonstrated in numerous 
preclinical animal models 183–186 and clinical trials146 meaning the osteogenic differentiation 
pathway of MSCs is well-defined187. A small group of factors are thought to regulate the 
commitment and differentiation of MSCs towards an osteogenic lineage188. The most prevalent of 
these markers appears to be runt-related transcription factor 2 (Runx2). Runx2 is known to 
initiate and regulate osteogenic differentiation via two distinct signalling pathways through TGF-
β1 and BMP-2189,190. Alongside Runx2, BMP-2 and distal-less homeobox 5 (Dlx5) are thought to 
encourage MSCs to commit towards an osteogenic lineage191,192. In addition to this, Runx2 
prevents MSCs from differentiating towards an adipogenic lineage193 (fig. 1.6). 
Once committed, MSCs differentiate to form pre-osteoblasts which are elliptical in shape with an 
elongated nucleus. These cells are capable of proliferation and are known to express Runx2, Dlx5, 
msh homeobox homologue 2 (Msx2), P2Y4 and P2Y14165,194. They are also known to express 
numerous osteoblast markers, such as ALP, COL 1, and OPN, although at weaker levels than 
immature osteoblasts. The differentiation of pre-osteoblasts into immature osteoblasts involves 
β-catenin, Runx2 and osteoblast-specific transcription factor osterix (Osx). These immature 
osteoblasts are spindle-shaped and express BMP, bone sialoprotein and OPN146. Also, the 
expression of Osx is induced by BMP-2 independently from Runx2195. Further down this line, 
Runx2 is thought to obstruct the development of osteoblasts196. Osx induces the terminal 
maturation of osteoblasts and opens the door for OCN expression197 (fig. 1.6). 
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Figure 1.6: MSC differentiation down the osteogenic lineage
146
. 
For some time now, the processes of in vitro osteoblast differentiation have been known and well 
documented. Three distinct phases are known to occur, proliferation, matrix maturation and 
matrix mineralisation. The first, proliferation, occurs at the onset of in vitro differentiation and 
involves the growth of osteoblast numbers forming a dense multi-layered culture. It is at this 
point that the cells undergo morphological changes expressing high levels of COL 1. During the 
onset of the second phase, matrix maturation, a significant increase in ALP activity is noted47. As 
differentiation continues, a balance between cell death and proliferation is reached. It is at this 
point that the cells begin to express non-collagenous ECM proteins, such as OPN198 and OCN199. 
The incorporation of HA crystals within the newly synthesised matrix symbolises the final stages 
of ECM maturation. Mineralised nodules now become apparent in vitro. Osteoblasts have the 
potential to mature further by becoming embedded within the matrix and differentiating into 
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osteocytes153. Fully differentiated osteoblasts are cuboidal in shape and produce a self-
mineralised organic matrix146. Mature osteoblasts have well developed Golgi bodies and rough 
endoplasmic reticula to correspond with an increased demand for protein production. Mature 
osteoblasts also see a reduced OPN expression, whilst experiencing an increase in P2X5165, ALP200, 
COL 1200,201, and OCN201 expression. 
2.1.2.3.2 The use of mesenchymal stem cells in therapy 
Cell therapy, as described earlier, involves the injection of specific cells into the circulation or at 
the site of tissue damage. MSCs are currently one of the most successful examples of such 
therapies in use today. 
For example, when a patient requires a bone marrow transplant, haematopoietic stem cells (HSC) 
are injected into their circulating blood which remarkably then, with the aid of chemokines and 
through a process known as ‘homing’, find their way to the bone marrow202–204. A large number of 
animal models have been used to demonstrate the ability of a number of stem cell types to home 
to the sites of injured or damaged tissues205–207 and in humans, systemically injected MSCs were 
shown to benefit graft-versus-host disease (GVHD) and osteogenesis imperfecta (OI)208,209. MSCs’ 
ability to home has also been demonstrated for fracture healing in a mouse model. In this case, 
the cells migrated to the fracture site after systemic application where they were seen to enrich 
the area and aid regeneration through the paracrine induction of tissue healing, lowering of 
inflammation (both systemic and local) and their differentiation into bone cells210. It was noted, 
however, that the majority of MSCs systemically applied to the mice became trapped in the lungs. 
Therefore, it would appear more logical to practice local application for bone regeneration211. 
These seemingly remarkable traits of MSCs have rendered them a promising candidate for clinical 
trials. Although a number of trials have already been conducted using MSCs with positive results 
and no serious side-effects being reported212, randomised trials are required to confirm these 
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results101. Currently, MSCs are undergoing clinical trials at various stages to investigate their 
potential use as therapies for diseases such as OI, GVHD, and chronic and acute myocardial 
infarction208,213,214. Year 2010 alone saw 123 studies investigating MSCs for a wide range of 
therapeutic applications215. 
2.1.2.4 Mesenchymal stem cell sources 
As mentioned, MSCs have been attained from numerous tissues and below are two such sources. 
2.1.2.4.1 Periosteum 
The periosteum has been seen to play a crucial role during fracture healing216 with the outer 
cambium layer being responsible for initiating angiogenesis and osteogenesis and differentiating 
stem cells down the bone lineage217. The periosteum is a thin but extensively vascularised tissue 
membrane that is attached to the surfaces of bone through a network of collagenous fibre 
bundles known as Sharpey’s fibres. This membrane comprises two layers, the outer of which is 
dense and consists of fibroblasts, the inner of which is the cambium layer comprising of MSCs 
capable of differentiation into bone and cartilage for the regeneration of bone218,219. The inner 
cambium layer is, therefore, believed to play an important role in bone remodelling217,220. The 
osteogenic and angiogenic potential of the periosteum has been investigated in numerous in vitro 
and in vivo studies which have shown a revitalisation of allografts and enhancement of bone 
regeneration217,220–223. 
2.1.2.4.2 Bone marrow aspirate 
Whilst MSCs have been isolated from numerous tissues157, those obtained from bone marrow are 
of particular interest to this study. Studies have shown that bone marrow is a multifarious tissue 
composed of haematopoietic cells, their differentiated offspring and a connective matrix call a 
stroma224,225. This connective tissue or stroma is an assortment of various cell types, such as ECs, 
adipocytes, reticulocytes and fibroblastic cells, which are all in direct contact with the 
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haematopoietic constituents of the marrow. Primary bone marrow cultures have been shown to 
produce an adherent cell layer comprised of at least three distinct cell populations226,227. 
When using bone marrow aspirates, bone regeneration studies have experimented with directly 
implanted aspirate as well as isolated culture-expanded MSCs228. Cultured bone marrow-derived 
MSCs are of interest to regenerative medicine because of their readiness to proliferate and 
produce differentiated progeny but also because they are relatively simple to isolate from bone 
marrow aspirate samples and willingly form single cell-derived colonies227. Their characterisation, 
however, is not so straightforward. Although a number of studies have used stem cell surface 
markers to isolate and characterise human mesenchymal stem cells (hMSC)229, their expression of 
mesenchymal, endothelial, epithelial and muscle surface markers230 and no specific stem cell or 
mesenchymal progenitor antibody profile has impeded their purification through these methods 
alone227. 
Typically, MSCs are isolated from bone marrow aspirate through their selective adherence to 
plastic surfaces. MSCs present in bone marrow will adhere to TCP allowing for their isolation231,232. 
One aspect associated with this method of purification is the haematopoietic cell contamination 
and the cellular heterogeneity of cultures233. Although typical human bone marrow aspirate 
contains a surprisingly low concentration of MSCs, approximately 10 – 100 MSCs/1 x 10⁶ bone 
marrow stromal cells (BMSC)234–236, bone marrow-derived MSC colonies have been shown to be 
capable of approximately 50 population doublings (PD) within 10 weeks of culturing237. Although 
the cells’ differentiation potential may diminish prior to reaching 50 PDs, research has shown that 
when cultured with FGF-2, telomere size is increased, thus maintaining an osteogenic 
differentiation potential over a longer culture period. The cells were seen to reach more than 70 
PDs and maintain an osteogenic differentiation potential up to 50 PDs238. 
The advantages of using bone marrow aspirate as a cell source are numerous. Whilst various 
studies have been carried out using MSCs derived from a host of different tissues, bone marrow-
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derived MSCs in particular, have shown an immense potential in numerous small and large animal 
studies and in a wide range of medical applications concerning fracture repair and bone 
regeneration (see review Asatrian et al.239). Because of their bone formation capabilities, bone 
marrow-derived MSCs are currently thought of as being one of the most important cell sources 
for bone regeneration240. Bone marrow aspirates are so highly used that investigations have been 
carried out to assess the potential of various different donor sites. Traditionally, the iliac crest has 
been the most common source of bone marrow-derived MSCs but several reports have shown 
that these cells are also available within the marrow of the vertebral body, humeral head and 
sternum241–244. An interesting study carried out by Narbona-Carceles and colleagues compared 
bone marrow aspirates from three different sites, i.e. the distal femur, proximal tibia and iliac 
crest245. Whilst MSCs were obtained from all sites tested, higher cell numbers combined with a 
higher success rate in establishing cell cultures from the iliac crest were reported. No differences, 
however, in cell viability, immunophenotype or differentiation potential were observed. 
When compared to cell populations derived from adipose tissue, only 21% of the MSC clones 
obtained from such tissue were tripotent compared with 50% of the clones derived from bone 
marrow-derived MSCs246. Tripotent cells were shown to be highly proliferative, possessed large 
colony-forming efficiencies and accumulated a more highly mineralised ECM than cells from 
unipotent osteogenic clones247.  
Bone marrow-derived MSCs have also been shown to continue expressing Runx2 regardless of 
differentiation suggesting an ability to shift phenotype and redifferentiate into osteoblasts248,249 
making them particularly appealing to the field of bone tissue engineering. Variations between 
samples have been noted, however. There have been a multitude of studies conducted that 
suggest donor-dependent variations of numerous levels exist within MSC populations. Siegel et al. 
for example, noted that phenotype, donor age and gender can all affect the function of bone 
marrow-derived MSCs250. In addition, variations in growth kinetics and gene expression251, 
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variable clonal properties252 and surface markers identifying possible subpopulations253–255 have 
also been identified alongside large donor variations in the concentration of nucleated cells and 
the multi-lineage differentiation potential of bone marrow-derived MSCs251,256. 
2.1.3 Dynamic culturing through mechanical stimulation 
Under physiological conditions, loading placed on the bone through compression and/or tension 
via movement drives interstitial fluid flow through the lacunae of the bone resulting in the 
application of fluid sheer stresses257. This creates hydrostatic and dynamic shear forces detectable 
by the cells258–261. Such mechanical stimuli are known to influence embryonic bone formation262–
264 as well as post-embryonic bone repair265. Therefore, replicating such physiological conditions 
should enhance or encourage bone tissue growth or regeneration. 
Given that dynamic culturing has been demonstrated to improved cell survival and mineralisation 
in both in vitro and in vivo studies266,267, numerous different types of bioreactors have been 
developed for tissue engineering with MSCs, including shear stress bioreactors268, pulsed 
electromagnetic field (PEMF) bioreactors269, hydrostatic pressure bioreactors270, perfusion 
bioreactors271–273, magnetic bioreactors274 and spinner flasks275, all with positive results. Cyclically-
placed hydrostatic pressure in particular, was shown to have a synergistic effect for the 
osteogenic induction of MSCs when combined with biochemical cues270,276. Vascularisation as well 
as bone formation is well documented under such dynamic conditions277–283. 
The use of a hydrostatic bioreactor is particularly appealing because previous studies have shown 
that not only is such a loading mechanism important for influencing the direction of cell fate in 
various tissues, such as the intervertebral disc, vascular system, articular cartilage and 
bone276,284,285, but that it is also thought to enhance the transfer of small molecules, such as O₂ 
and CO₂, into the tissue matrix286. When using hydrostatic loading to pressurise a closed chamber 
containing a gas-liquid interface, the solubility of O₂ and CO₂ is increased resulting in higher 
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concentrations of dissolved gases in the medium284,287. pH levels and dissolved O₂ concentrations 
have been shown to influence cellular mechanisms, such as inter-cellular signalling, cell 
proliferation and differentiation288,289, as well as the cell cycle, apoptosis and protein synthesis290–
295. Culturing osteoblasts in vitro under hyperbaric oxygen conditions has been shown to not only 
boost cell proliferation and differentiation but to also improve ALP activity and COL 1 production 
leading to enhanced osteogenesis296. 
2.1.4 Chemical stimulation via osteoinductive and osteoconductive agents 
Three supplement agents frequently used to influence MSCs down an osteogenic lineage are 
ascorbic acid, a source of phosphate (commonly β-glycerophosphate) and dexamethasone297. 
Ascorbic acid acts as a cofactor for enzymes that hydroxylate proline and lysine in pro-collagen298. 
Its role in osteogenic differentiation is, therefore, mainly attributed to the secretion of COL 1 into 
the ECM297. β-glycerophosphate provides a source of phosphate that is not only needed to 
produce the HA mineral but also operates as an intracellular signalling molecule that regulates the 
expression of numerous osteogenic genes, such as OPN299,300 and BMP-2300. Whilst the precise 
concentration of dexamethasone to be used for optimal differentiation has been a source of 
debate301, its importance is nevertheless undisputed. Dexamethasone is known to induce the 
expression of Runx2, Osx and bone matrix proteins302–304 and when combined with ascorbic acid 
and a source of phosphate, it promotes the osteoblastic differentiation of hMSCs, stimulates the 
expression of ALP, COL 1 and OCN and promotes mineralisation305–309, whilst also inhibiting cell 
proliferation305,307,310. 
There are a number of other drivers being explored for use in bone tissue engineering strategies. 
BMPs for example, are specific bone growth factors known to be heavily involved in in vivo bone 
formation311–314. They are known to be secreted during bone resorption and are actively involved 
in the differentiation of MSCs into osteoblasts, thus stimulating osteogenesis40. Currently, 20 
structurally related BMPs have been identified with two of them, BMP-2 and -7, being highlighted 
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for use in research concerned with the healing of bone defects315,316. There are, however, 
difficulties associated with the clinical use of BMPs. Given the proteins’ high rate of diffusion and 
to avoid excessively high initial doses, a carrier system may be required to allow for their 
prolonged and steady release at a rate that is comparable to that of natural tissue315. Currently, 
those carriers that have been examined still require high initial doses of BMPs and so questions 
have been raised surrounding the safety and costs of such a system131. Other growth factors that 
have been examined for their possible therapeutic uses in bone regeneration include PDGF317, 
VEGF318,319, IGF180, FGF320 and TGF-β321. It is hoped that these factors will aid in the migration, 
differentiation and proliferation of osteoprogenitor cells, as well as vascular ingrowth to the site 
of regeneration130. 
2.2 Limitations to current engineering protocols 
Although small bone-like constructs have been developed using various combinations of MSCs 
and different matrices, several of which have been proven successful by surviving in vivo in animal 
models322, no laboratory has successfully developed these bone constructs in large volumes or as 
whole bones. This may be due to the size of the diffusion tract where 200 μm is thought to be the 
crucial threshold. That is to say, if the bone constructs or nodules have a radius exceeding 200 
μm, the oxygen and nutrients crucial for maintaining cell viability cannot diffuse to the centre of 
the tissue. Thus, functional vascularisation becomes an ever increasing prerequisite for larger 
solid tissue samples. This issue has yet to be resolved and may be the most critical issue inhibiting 
the translation of bone tissue engineering in to the clinic323. 
3. Novel approaches to bone tissue engineering 
Given the aforementioned limitations affiliated with current bone tissue engineering protocols, 
the field of regenerative medicine has been working tirelessly over recent years to both refine 
current techniques and research/explore novel approaches to local and systemic bone tissue 
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regeneration through cell therapies208. Such novel regenerative therapies were so far found to 
improve fracture/osteotomy treatment, remedy pseudoarthrosis, plug bone defects and cysts, 
resolve osteonecrosis and augment spinal fusion101. Further studies are required, however, before 
any significant advances can be made and regenerative medicine becomes a commonly used 
therapeutic solution. 
3.1 Biomaterial surface modification 
Scaffolds are usually required to fulfil at least one of several roles, including delivering cells and/or 
biochemical cues, influencing cell attachment and/or migration, enabling diffusion of nutrients 
and expulsion of waste, and exerting mechanical and/or biological effects324. Whilst numerous 
factors are responsible for determining how cells respond to a scaffold, surface characteristics are 
one criteria being explored as a key component. Surface properties, such as wettability, chemistry 
and topography, hold significant influence over protein interactions which subsequently sway cell 
response325. For the development of scaffolds, a biomaterial should not only be biocompatible, 
but should also actively encourage specific cell responses326.  
There is a multitude of different surface modification techniques, each combining various 
elements for specific reactions. For example, the topography of polyimide was altered using 
reactive ion etching and multibeam laser interference to enhance the osteogenic and adipogenic 
differentiation of MSCs327, the surface chemistry and wettability of polyhedral oligomeric 
silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) was altered using plasma surface 
polymerisation to enhance tissue integration and angiogenesis328 and a reduction in the 
inflammatory response of biomaterials was investigated through the coating of glass with 
polyelectrolyte multilayers (PEM) composed of glycosaminoglycans (GAG) and chitosan329. 
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3.1.1 Enhanced functionality with extracellular matrix proteins 
Cellular adhesion is typically triggered by the adsorption of proteins which influence subsequent 
cellular responses324. Salasznyk and colleagues set out to investigate if and how ECM proteins 
might influence MSC differentiation330. To do this, tissue culture plates were coated with ECM 
proteins found in bone marrow, such as collagen types I and IV, laminin-1 and vitronectin. The 
investigation showed that culturing hMSCs on purified vitronectin and COL 1 coated TCP and 
without the presence of osteogenic-supplemented medium was adequate to induce osteogenic 
differentiation. COL 1 has been proposed to bring about the calcification of the stromal cell 
matrix331, and both COL 1 and vitronectin have been reported as being responsible for the 
differentiation of MSCs down the osteogenic lineage332. 
Matrigel has also been used to coat the substrate surfaces of TCP146. Matrigel is known to be 
comprised of numerous proteins, such as collagen type IV, laminin, heparin sulphate, 
proteoglycan, nidogen and entactin, and growth factors, such as TGF-β, bFGF, EGF, IGF-1 and 
PDGF333. The study conducted by Eslaminejad and associates cultured hMSCs on both matrigel 
coated and non-coated TCP substrates and demonstrated that those cultured on the coated 
substrates experienced significantly enhanced osteogenic differentiation compared to those 
cultured on the non-coated TCP146. 
3.1.2 Impact of surface modifications on suspension/pellet culture models 
Biomaterial surface modifications are not solely used for enhancing cell adhesion, but can also be 
used to prevent adhesion; thus, instigating different cellular responses. To thoroughly appreciate 
and exploit the full potential of MSCs as a source for cell-based therapeutics, it is important to 
understand the factors involved in deciding cell fate so we may control the direction of cell 
differentiation. However, well established conventional monolayer culturing techniques do not 
replicate the formation of complex in vivo tissues. Numerous studies have recently demonstrated 
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that by adopting a micromass or cellular aggregation approach for tissue engineering instead of 
using conventional monolayer cultures, we may be able to utilise a more productive solution for 
bone tissue engineering297,334. The use of micromass culturing or cellular aggregation relies on the 
hypothesis that cellular condensation and aggregate formation can greatly enhance bone tissue 
development by mimicking the intramembranous ossification pathway. Whilst there are two 
principle pathways for bone formation, endochondral ossification and intramembranous 
ossification, the latter bypasses the development of a cartilaginous phase through the 
development of an ossification centre for more rapid bone regeneration24. It is well established 
that cell – cell contact and condensation in the presence of the correct protein-rich ECM are 
essential niches for bone formation335,336 and so the development of cellular aggregate models is 
intended to replicate such in vivo processes for the reduction of mineralisation times. It is thought 
that 3D aggregate cultures better represent the intricacies of tissues with the replication of 
essential bone development processes, such as proliferation arrest, terminal differentiation and 
the formation of osteoid for the deposition of minerals46,337,338. In addition, they may also offer an 
insight into the regulatory signalling cascades induced by particular bioactive elements and 
factors339. 
Wang and co-workers developed a 3D spheroid culture system to investigate and refine the 
differentiation efficiency of MSCs3. The particular culture method utilised throughout that study 
used photolithography and micropatterning techniques to produce uniform MSC spheroids of 
precise dimensions prior to their induction into adipocytes and osteoblasts. The study 
demonstrated that such a culture method could be used to significantly increase the 
differentiation efficiency of MSCs. Those spheroids cultured within that study were shown to not 
only enhance adipogenic and osteogenic specific gene expression levels, but to also down-
regulate the genes specifically associated with sustaining MSCs self-renewal phenotypes, 
mesoderm specific transcript isoform b (MEST) and Thy 1 membrane glycoprotein precursor 
(THY1). 
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Another recent study conducted by Hildebrandt and colleagues aimed to develop a scaffold-free 
3D in vitro model for hMSC osteogenic differentiation4. The study used a number of spheroid 
forming techniques in combination with culture medium supplemented with agents known to 
induce osteogenesis, i.e. ascorbic acid, dexamethasone and β-glycerophosphate. It was only after 
the aggregates were formed that the osteogenic-supplemented medium was added for further 
culturing. Prior to this, basic culture medium was used. The study concluded that the 3D culture 
techniques provided the cells with an environment corresponding to that of in vivo biological 
conditions within which the cells are surrounded by other cells and fibrous layers339. It has been 
reported that engaging the integrins in such a way can and does influence MSC adhesion, 
differentiation and proliferation340,341, and such cultivation practices result in improved 
intercellular and ECM interactions without any influences from a scaffold matrix3. Thus, this 
method of culturing can be said to provide a link between the conventional methods of 
monolayer culturing and whole organs338. 
However, all of the techniques tested were reported to have significant drawbacks. The most 
convenient, effective and efficient method was said to be the suspension cultures within the 96-
well non-adhesive culture plates4. In saying that, the culture period was still quite extensive with 
the first signs of osteogenic differentiation, ALP expression, not being detected until day 18 of 
culturing in osteogenic-supplemented medium. The expression of COL 1 and the deposition of 
mineralised ECM were detected at day 21 and after 25 days of cultivation, an increase in the gene 
expression of collagen types I and III, BMP-2, and OPN were noted4. 
Of course, once osteogenic aggregates or bone nodules have been formed and characterised, an 
injectable carrier system is required for delivery to the patient. This necessity has been tackled by 
Ma and colleagues342 in a study conducted using MSCs cultured under monolayer conditions. 
Previously conducted studies have shown that it is relatively simple and safe to inject autologous 
bone marrow for the treatment of non-unions236. However, given the small percentage of MSCs 
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present in bone marrow, the efficiency of such treatment strategies could be compromised236; 
therefore, it should be assessed for possible refinement. This is where Ma and colleagues342 have 
taken the next step in developing an injectable suspension of in vitro-cultured multicellular 
aggregates. Previously developed carriers have included the use of collagen, fibrin, agarose, 
alginate, hyaluronate, and pluronic343–345, however, each of these products were associated with 
numerous disadvantages, such as heightened inflammatory response, the potential for 
immunogenicity, possible toxicity from degradation products, inconsistent degradation rates, 
unpredictable gelation kinetics and unmanageable cell-biomaterial interactions343,344,346. 
The MSC aggregates for this study were cultured using rabbit BMSCs under monolayer conditions. 
A dense cell sheet was grown on TCP and allowed to culture for 2 weeks without passage. An 
osteogenic-supplemented medium was used from the initial seeding consisting of ascorbic acid, β-
glycerophosphate and dexamethasone. Once ready, the cell sheet was removed in tact using a 
cell scraper instead of enzymatic reactions and cut into sections approximately 1 mm in diameter 
with a scalpel. These aggregates were then resuspended in serum-free DMEM and injected into 
nude mouse models to assess osteogenic potential. 
That study demonstrated that BMSCs can be cultured in vitro and injected in vivo, whilst still 
maintaining their endogenous ECM and cell – cell connections without the need for exogenous 
scaffolding; thus, biocompatibility is maintained because the suspension is entirely derived from 
autologous cells. Higher levels of ALP, OCN, COL 1 and OPN were also noted with such culturing 
techniques when compared to disassociated cells under similar conditions. Six weeks post-
treatment saw a significant improvement in bone healing when compared to the control. 
Although both the aggregated cells and disassociated cells enhanced bone healing, respectively, 
the former was far more impressive. These results would indicate that aggregated cells are more 
efficient in eliciting bone regeneration when compared to their disassociated counterparts. 
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Although promising, these results have their own accompanying limitations. The multicellular 
aggregates obtained from this study were heterogeneous in size and shape and since 
reproducible results are dependent upon uniformity, this is an issue that needs addressing and 
further optimisation. Additionally, size is increasingly important when considering the injectability 
of the aggregates. The aggregates must not only be small enough to fit through a needle and be 
capable of receiving sufficient nutrient supply in vivo, but also big enough so as to be entrapped in 
the tissue interstices, thus, preventing the loss of cells342. 
3.2 Cellular co-culturing 
Large tissue-engineered bone grafts often suffer from poor core cell viability which subsequently 
leads to compromised graft integration and possible graft failure25. Uneven cell integration, 
cellular necrosis and eventual graft failure are often the results of an inadequate supply of oxygen 
and nutrients323,347,348. Such an inhibition to the viability of implants poses a major obstacle to the 
progression and translation of tissue engineering349. In response to this, research is currently 
ongoing to both refine bone tissue engineering techniques and to vascularise the resulting tissue-
engineered constructs323,350. 
The co-culturing of cells is one method being explored for the vascularisation of tissue-engineered 
constructs. ECs for example, are being co-cultured with various other cell types in an attempt to 
achieve in vitro pre-vascularisation within scaffold constructs25,351–354. MSCs and ECs would appear 
to be a sensible combination for co-cultured constructs with the interactions between both cell 
types being a highly regulated process. Paying close attention to and mimicking the in vivo bone 
vascularisation processes where possible is as important as ever when co-culturing. It is thought 
that the most successful microvasculature formation to date was achieved with the delayed 
addition of MSCs to ECs encapsulated in collagen355. Such an experimental procedure was carried 
out because this arrangement was thought to better mimic the natural in vivo environment where 
MSCs are only recruited to the site of vascularisation after ECs have begun vascular 
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construction355. A benefit to in vitro pre-vascularisation is the shortened time required for 
effective vascularisation within tissue-engineered grafts because the host vessels need only grow 
to the outer regions of the construct where they can then anastomose to the existing vessels 
within the construct25. 
3.3 Stem cell subpopulations 
Since their initial isolation from guinea pig bone marrow by Friedenstein et al.356, MSCs have been 
used extensively in research for a number of reasons but what is of particular interest to this 
study is their extraordinary differentiation capacity giving rise to the belief that an MSC 
population may contain numerous subpopulations. Tissue-derived adult stem cells are thought to 
usually only generate cells that are inherent of the tissues within which they reside, as is the case 
for haematopoietic and neural stem cells357,358. MSCs, however, have been shown to possess the 
ability to differentiate into cells of all three germ layers. Whilst belonging to the mesodermal 
lineage, they have been shown to cross from mesodermal to ectodermal and endodermal 
lineages359–361. The precise mechanisms behind this extraordinary triploblastic differentiation 
potential are continuing to elude researchers362. 
One theory for this exceptional differentiation capacity suggests that MSCs may contain a mixture 
of phenotypically, biochemically and functionally different cells comprising 
subpopulations211,363,364. From a population of bone marrow mononuclear cells (MNC) for 
example, a variety of adherent cell types have been shown to exist within an MSC culture. These 
include embryonic-like stem cells, lineage-committed progenitor cells and mature cells, such as 
osteoblasts and fibroblasts365–368. With this in mind, it has been said that bone marrow-derived 
MSC cultures may provide numerous stem cell types with varying differentiation potentials369. 
Interestingly, two theories exist on this subject. In brief, one hypothesis states that MSCs 
comprise a multitude of different stem cells adding up to a ‘pluripotent-like’ cell culture, and the 
second states that amongst this multitude of different stem cells is a small proportion of true 
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pluripotent stem cells. Both of these theories rely on subpopulations. If they do exist, the amount 
of primitive stem cells within such cultures is thought to be rare and varies depending upon donor 
and cell isolation and cultivation methods370,371. 
Numerous attempts have been made to isolate single bone marrow stem cell subpopulations 
using a variety of techniques, such as size sieving372,373, long term culturing under specific 
conditions367,374,375, fluorescence-activated cell sorting (FACS)368,376,377 and counterflow centrifugal 
elutriation (CCE)369, but few have claimed to have actually discovered pluripotent stem cells 
within bone marrow-derived MSCs. Two studies that have claimed to have isolated cells with true 
pluripotent stem cell characteristics, however, are Jiang et al. (multipotent adult progenitor 
(MAP) cells)365 and Kucia et al. (very small embryonic-like (VSEL) stem cells)378,379. Both have since 
been called into question. Kuroda et al. is another who carried out a study to demonstrate that 
bone marrow-derived MSCs and dermal fibroblasts contain pluripotent stem cells capable of self-
renewal and individual differentiation into cells of all three germ layers380. They named these cells 
multilineage-differentiating stress-enduring (MUSE) cells. What is interesting about that particular 
study is that it was carried out using clones of single cells to show that MUSE cells are both 
pluripotent and mesenchymal cell-like. 
With the possibility existing that an MSC population comprises numerous unipotent/bipotent 
stem cells responsible for ectodermal, endodermal and mesodermal lineage differentiation362, 
how such a population is utilised becomes increasingly important. Knowledge of the inner 
workings of such a population would not only offer the prospect for the accurate evaluation of an 
individual’s regenerative capacities prior to treatment but also holds the potential for refined 
donor-specific treatments. 
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4. Aims and objectives of the current research project 
The aims and objectives of this research project were numerous but essentially relied on 
substrate modifications. The initial investigations were focused on the development of a novel 
substrate modification technique to create an MLO-A5 aggregate model for the examination of 
influential parameters in developing mineralisation over time. To do this, two separate culture 
environments were used to form different-sized MLO-A5 aggregates that acted as ossification 
centres replicating natural intramembranous bone formation. The differing-sized aggregates were 
monitored and assessed using several modes of analyses to evaluate and compare the potential 
for bone development. In addition, an 8-week in vivo investigation was carried out with the hope 
of shedding light on the potential for long term bone nodule survival using this model. This project 
also attempted to identify donor-dependent subpopulations within MSCs isolated from human 
bone marrow MNCs that may play a role in determining an individual’s osteogenic capacity. 
Again, using a novel substrate modification technique, denoted as substrate X, cells were 
encouraged to self-sort into identifiable cellular arrangements indicating the presence of 
subpopulations. Quantification of such arrangements found within multiple donor cell 
populations was attempted and their osteogenic potential evaluated alongside the aggregation of 
cells into bone nodules. An in vivo investigation using MSCs was also carried out to confirm the 
data obtained from the MLO-A5 study. The intention was to verify the MLO-A5 aggregate study 
using different-sized aggregates comprised of primary cells. Once again, using a substrate 
modification technique, the simultaneous vascularisation and mineralisation of cellular 
aggregates under mechanical loading was also investigated. The influences imparted by 
mechanical loading on cellular arrangement and mineralisation levels within MSC and human 
umbilical vein endothelial cell (HUVEC) aggregate co-cultures was assessed. Cellular arrangements 
were assessed via monitoring of the inner-aggregate HUVEC arrangements and aggregate 
mineralisation was assessed using microCT. 
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Chapter Two              
Materials and Methods  
46 
 
Overview 
This chapter outlines the general materials and methods used in this thesis. The individual 
experimental chapters will specify parameters and modified procedures for some of the methods 
depicted in this chapter. 
Materials and instruments 
Details of the agents, compounds, cells and materials including the instruments and software 
used in this thesis have been listed in table 2.1. Unless specifically stated, all agents and chemicals 
were used without further purification. 
Table 2.1: Materials list. A complete list of materials and equipment used throughout this research project, their supply 
companies and where possible, their product codes. 
Product Supplier 
0.22 μm filter Sarstedt, UK, 83.1826.001 
24-well cell adhesive plate Greiner, UK, 662160 
24-well cell suspension plate Sarstedt, UK, 83.1836.500 
α-MEM Invitrogen, UK, 11900-016 
β-glycerophosphate Sigma-Aldrich, UK 
A 
Acetic acid Sigma-Aldrich, UK, 320099-500 
Alcian blue Sigma-Aldrich, UK, A5268-10G 
Alexa-fluor 594-conjugated goat anti-mouse 
IgG1 
Life Technologies Ltd., UK, A-11032 
Alizarin red Sigma-Aldrich, UK, A5533 
Alkaline phosphatase (ALP) detection kit Millipore, UK, SCR004 
Antibiotic-antimycotic solution (A + A) Sigma-Aldrich, UK, LZ17-745e 
Ascorbic acid Sigma-Aldrich, UK 
B 
Biopsy punches (ø 8 mm) Williams Medical Supplies, UK, D7480 
Bovine calf serum (BCS) Fisher, UK 
Bovine serum albumin (BSA) Sigma-Aldrich, UK, A7030-50G 
C 
CaF₂ coated windows (ø 13 x 0.5 mm) Crystran, UK, CAFP13-0.5 
Carbon tape Agar Scientific, UK, AGG3939 
CD31 primary antibody, monoclonal mouse 
anti-human 
Dako UK Ltd., UK, M0823 
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CD31 secondary antibody, goat anti-mouse Life Technologies Ltd., UK, A11032 
Cell tracker (cell linker kit) (HUVECs) Sigma-Aldrich, UK, PKH67GL-1KT (FITC) 
Cell tracker (cell linker kit) (MSCs) Sigma-Aldrich, UK, PKH26GL-1KT (TRITC) 
Collagen hydrogel, rat tail type I BD Biosciences, UK, 354236 
Confocal microscope Olympus IX83, Olympus Corp., Japan 
Cryostat-microtome Thermo Shandon, UK 
CXP software Beckman Coulter Inc., USA 
D 
Dako target retrieval solution Dako UK Ltd., UK, S170084 
Dexamethasone Sigma-Aldrich, UK 
Diffusion chamber membrane filters Millipore, UK, HAWP01300 
Diffusion chamber plexiglass ring Millipore, UK, PR0001401 
DMEM w low glucose and w/o l-glutamine Lonza, Belgium, LZBE12-707F 
DSLR camera Nikon D5000, Nikon Corp., Japan 
Durapore membrane filters Millipore, UK, HVLP01300 
E 
E-cadherin primary antibody, goat polyclonal Santa Cruz Biotechnology, Inc., USA, SC31020 
E-cadherin secondary antibody, donkey anti-
goat 
Santa Cruz Biotechnology, Inc., USA, SC-2094 
Epifluorescent microscope Nikon Eclipse Ti, Nikon Corp., Japan 
Ethanol Sigma-Aldrich, UK, E7023-500ML 
F 
Fibronectin Sigma-Aldrich, UK, F1141-1MG 
Flow cytometer Cytomics FC 500, Beckman Coulter Inc., USA 
Flow cytometry antibodies Miltenyi Biotec Ltd., UK 
Flowing Software 2 software Perttu Terho, Finland 
Foetal bovine serum (FBS), ISB020 Lonza, Belgium, DE14-801 
Formalin Sigma-Aldrich, UK, HT501320-9.5L 
G 
Glass slides Menzel-Glaser, Germany, 100857 
H 
Haematoxylin and eosin (H & E) stain Sigma-Aldrich, UK, GHS316/HT110116-500ml 
Hand held digital camera Samsung S3 GT-I8190, Samsung, South Korea 
Histoclear National Diagnostics, UK, HS-200 
Human umbilical vein endothelial cells 
(HUVEC) 
Life Technologies Ltd., UK, C-015-10C 
Hydrostatic chamber Tissue Growth Technologies (TGT), UK 
I 
IBMX bioultra Sigma-Aldrich, UK, I7018 
Image J software Java, USA 
Image-Pro Insight software MediaCybernetics, USA 
Immunocompromised nude mice (MF1-Nu/Nu) Harlan UK Ltd., UK 
Indomethacin Sigma-Aldrich, UK, I7378 
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Insulin Sigma-Aldrich, UK, I9278-5ML 
Inverted optical light microscopy Olympus CKX41, Olympus Corp., Japan 
Isopropanol Sigma-Aldrich, UK, 34965-2.5L 
ITS liquid media supplement Sigma-Aldrich, UK, I3146 
L 
L-glutamine 200 mM Lonza, Belgium, BE17-605E 
Low serum growth supplement (LSGS) Life Technologies Ltd., UK, S-003-10 
L-proline Sigma-Aldrich, UK, P0380 
M 
Medium 200 Life Technologies Ltd., UK, M-200-500 
Mesenchymal stem cells (MSC) Bone marrow MNC, Lonza, Belgium, 2M-125B 
Micro-centrifuge tubes Alpha Laboratories, UK, LW2375 
MicroCT 
Scanco μCT 40, Scanco Medical AG, 
Switzerland 
Microtome Shandon AS325, Thermo Shandon, UK 
MIRIAM beamline B22 Diamond Light Source, Oxfordshire, UK 
MirrIR slides Kevley Technologies, UK, CFR 
MLO-A5 murine cell line 
Prof. Lynda F Bonewald, University of Texas, 
USA 
MxPro software Agilent Technologies, UK 
N 
Neoveil mesh sheet CalMedical Ltd., UK, NV-L-015G 
Non-essential amino acids (NEAA) Sigma-Aldrich, UK, M7145 
O 
OCT compound Tissue-Tek, Sakura Finetek, UK 
Oil red O Sigma-Aldrich, UK, O-0625 
OPUS software Opus Software Solutions, USA 
OriginPro 8 software Originlab, USA 
P 
Phosphate buffered saline solution (PBS) Fisher, UK, BR0014G 
Pluronic F127 solution BASF, USA 
Q 
qPCR genes; 18S, COL 1, ALP, OPN, and OCN TaqMan, Applied Biosystems, UK 
qPCR machine Mx3000P, Agilent Technologies, UK 
Quantax 70 software Bruker, USA 
R 
Reflective microscope Leica S6D, Leica Microsystems, Germany 
Reverse transcription kit Quantitect RT, Qiagen, Netherlands 
RNA Spectrophotometer Nanodrop 2000, Thermoscientific, USA 
S 
SEM-EDX microscope TM-3000, Hitachi, Japan 
Silver nitrate Sigma-Aldrich, UK, 209139 
Sodium bicarbonate (NaHCO₃) Sigma-Aldrich, UK, S5761-500G 
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Sodium carbonate (Na₂CO₃) Sigma-Aldrich, UK, S-6139 
Sodium chloride (NaCl) Sigma-Aldrich, UK, S-7653 
Sodium hydroxide (NaOH) Timstar Lab Supplies, UK, SO5658 
Sodium pyruvate Sigma-Aldrich, UK, S8636 
Standard foetal bovine serum (sFBS) Fisher, UK 
T 
TGF-β3 PeproTech EC Ltd., UK, 100-36E 
Tissue culture polystyrene (TCP) flasks  Greiner, UK, 658175 
Tri reagent lysis buffer Sigma-Aldrich, UK, T-9424 
Tris-HCL Sigma-Aldrich, UK, T-5941 
Triton X-100 Sigma-Aldrich, UK, T8787-250ML 
Trypsin Lonza, Belgium, LZBE02-007E 
Tween-20 BDH Laboratory Supplies, UK, 66368 
V 
vWF, monoclonal mouse anti-human Dako UK Ltd., UK, M0616 
W 
Wax embedder Shandon Histocentre 2, Thermo Shandon, UK 
Wax embedding cassettes Simport, Canada, M491-6 
Whatman paper Sigma-Aldrich, UK, 1001 240 
 
Methods 
1. Cell culturing 
All proliferative culturing was carried out using standard tissue culture polystyrene (TCP) T25 or 
T75 flasks. All of the cells were enzymatically-cleaved with trypsin and passaged once they 
reached 80% confluency. A passage refers to every time a population of cells is enzymatically-
cleaved and transferred to a fresh culture substrate for further culturing or experimentation. 
1.1 MLO-A5 cells 
The late osteoblast/early osteocyte murine cell line, MLO-A5,7 (kindly donated by Professor Lynda 
F Bonewald, University of Texas, USA) was cultured in Modified Essential Medium Eagle Alpha (α-
MEM) supplemented with 5% standard foetal bovine serum (sFBS), 5% bovine calf serum (BCS) 
and 1% antibiotic-antimycotic solution (A + A) (Penicillin-Streptomycin – stock concentration 10 x 
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103 U Penicillin/ml, 10 x 103 ug Streptomycin/ml, 25 ug Amphotericin B/ml) at 37 °C and 5% CO₂ 
(adapted from Kato et al.152). The cells were used between passages 24 and 28. 
1.2 Mesenchymal stem cells 
Human mesenchymal stem cells (MSC) were isolated from donor samples of bone marrow 
mononuclear cells (MNC) purchased from Lonza, Belgium. The cryopreserved bone marrow MNCs 
were isolated by Lonza from whole bone marrow via density gradient separation. The MSCs were 
then further isolated from the MNCs in our laboratory using a conventional attachment isolation 
protocol (adapted from D’Ippolito et al.381). Four x T75 flasks, combined surface area of 300 cm², 
were coated with fibronectin (10 ng/ml phosphate buffered saline (PBS)) for at least one hour 
prior to cell seeding. The fibronectin was then removed from the flasks. One vial of MNCs was 
then thawed and pipetted into a universal tube containing 3 ml proliferative medium. The cells 
were now suspended in 4 ml medium. The 4 ml medium was then separated in to the four x flasks 
at 5 – 6 x 10³ cells/cm². Each of the flasks was then topped up with 12 ml proliferative medium 
bringing the total medium volume in each flask to 13 ml. The cells then received a half medium 
change after 7 days and a full medium change after 14 days. They were optically imaged at both 
time points (section 8.1.1). 
The MSCs were cultured using proliferative/basal medium consisting of low glucose (1 g/l) 
Dulbecco’s Modified Eagle Medium (DMEM), 10% foetal bovine serum (FBS), 1% A + A, 1% non-
essential amino acids (NEAA) and 2 mM l-glutamine. The cells were maintained at 37 °C and 5% 
CO₂. 
1.3 Human umbilical vein endothelial cells 
Human umbilical vein endothelial cells (HUVEC) were purchased from Life Technologies, UK and 
each population was pooled from multiple donors. The HUVECs were cultured using Medium 200 
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combined with 2% low serum growth supplement (LSGS) at 37 °C and 5% CO₂382. The cells were 
used for experiments at passage 4. 
1.4 Differentiation media 
To supplement the proliferative medium further producing a lineage-specific differentiation 
medium, the following supplements were added to the cells’ proliferative medium at specific 
concentrations. 
1.4.1 Adipogenic supplementation 
Dexamethasone (0.5 μM), 3-isobutyl-1-methylxanthine (IBMX) (0.5 mM), insulin (10 μg/ml) and 
indomethacin (100 μM) (adapted from Neuhuber et al.383). 
1.4.2 Chondrogenic supplementation 
1% FBS, insulin-transferrin-selenium (ITS) (1% v/v), dexamethasone (0.1 μM), ascorbic acid (50 
μM), l-proline (40 μg/ml), sodium pyruvate (1% v/v) and TGF-β3 (10 ng/ml) (adapted from 
D’Ippolito et al.381). 
1.4.3 Osteogenic supplementation 
Dexamethasone (10 nM), ascorbic acid (50 µg/ml) and β-glycerophosphate (10 mM) (adapted 
from D’Ippolito et al.381). 
2. Tri-lineage differentiation 
2.1 Differentiation culturing 
Cells from multiple donors were seeded at a density of 2.5 x 10³ cells/cm² in standard TCP 24-well 
plates. The different differentiation media was added immediately upon seeding and the cell 
populations were cultured for 30 days before termination. Six samples were cultured from each 
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donor per lineage, adipogenic, chondrogenic and osteogenic. The specific constituents of the 
media can be found in section 1.4. 
2.2 Differentiation confirmation 
Confirmation of successful differentiation was carried out by optical imaging (section 9.1) and 
histochemical staining (section 12). Adipogenesis was confirmed with Oil red O staining, 
chondrogenesis was confirmed with Alcian blue staining and osteogenesis was confirmed with 
Alizarin red staining. A number of samples were optically imaged prior to staining to monitor cell 
morphologies and all of the samples were imaged post-staining. 
3. Cell tracking 
For general cell membrane labelling, the procedure outlined below followed the manufacturer’s 
protocol supplied with the PKH fluorescent cell linker kit. A cell population of up to 2 x 10⁷ cells 
was washed once in serum-free medium and then centrifuged for 10 minutes at 400 x g to form a 
cell pellet. The majority of the supernatant was removed from the pellet leaving only 25 μl 
approximately. Then, 1 ml of Dilute C was added to the pellet before the cell/Dilute C solution was 
thoroughly mixed. One ml of 4 x 10-6 M working dye solution (4 μl stock dye in 1 ml Dilute C) was 
then added to the cell solution. The cell/dye solution was then incubated at room temperature for 
10 minutes. Two ml of 1% bovine serum albumin (BSA) was added and the solution was again 
incubated for 1 minute at room temperature. The solution was then centrifuged for 10 minutes at 
400 x g. The resulting cell pellet was resuspended and washed 3 times with fully supplemented 
medium, centrifuging and resuspending after each wash. The cells were then ready for use. The 
specific volumes used were adjusted depending on the cell number being labelled, i.e. the 
working dye solution volume would have been halved if working with 1 x 107 cells. 
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4. Modification of cell culture substrates, aggregation and subpopulation identification 
A number of substrates were used/modified throughout this project to achieve particular cellular 
reactions. The first modification was made in order to create a suspension culture for aggregate 
formation (described in section 4.1.1). The second modification was used to induce particular 
cellular attachment arrangements; thus, identifying and separating MSC subpopulations 
(described in section 4.2). 
All monolayer controls were cultured on standard TCP well plates. 
4.1 Substrate modification and aggregate formation 
Aggregates of differing sizes and densities were formed primarily from three different culture 
methods. Two methods used suspension cultures of different wettability properties and the third 
used a pellet culture technique. 
4.1.1 Suspension culture aggregation 
Two different suspension cultures were used throughout this research project. The first was a 
standard commercially available hydrophobic suspension culture plate (denoted as non-coated), 
the second was the same hydrophobic suspension culture plate coated with a Pluronic F127 
solution (denoted as coated). To create the coated suspension culture plate, 500 μl of a sterile 2% 
Pluronic F127 solution (in dH2O) was added to each of the wells of a 24-well suspension culture 
plate and allowed to incubate at room temperature for 24 hours. After such time, the remaining 
solution was removed and the plate was allowed to dry for a short time (1 – 2 hours) before being 
seeded with cells7. Both suspension culture substrates, modified and unmodified, produced 
aggregates of different sizes. Aggregate size and number was dictated by which suspension 
culture was used. MLO-A5, MSC and MSC/HUVEC aggregates were formed using this method. 
Specific seeding protocols are described in the methods sections of the experimental chapters. 
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4.1.2 Pellet culture aggregation 
Up to 1 x 105 cells were added in 1 ml basal medium (those MLO-A5 cells that were aggregated 
using this method were done so in MLO-A5 basal medium (chapter 2, section 1.1), those MSCs 
that were aggregated using this method were done so in MSC basal medium (chapter 2, section 
1.2) and those MSC/HUVEC co-cultures that were aggregated using this method were done so in a 
1:1 ratio of MSC:HUVEC basal medium (chapter 2, sections 1.2 and 1.3, respectively)) to a 1.5 ml 
micro-centrifuge tube. The micro-centrifuge tube was then centrifuged for 4 minutes at 1000 rpm 
before being placed in an incubator at 37 °C and 5% CO₂. The cell pellets were allowed to develop 
into aggregates within the micro-centrifuge tubes for 24 – 48 hours before being used elsewhere. 
Only one aggregate per tube was formed using this method. Aggregate size was dictated by cell 
number. MLO-A5, MSC and MSC/HUVEC aggregates were formed using this method. Specific 
seeding protocols are described in their respective experimental chapters. 
4.2 Substrate modification and subpopulation identification 
MSC subpopulations were identified through particular cellular arrangements using a substrate 
with particular characteristics that cannot be divulged at this time due to pending intellectual 
properties (denoted as substrate X). MSCs were seeded through pipetting onto substrate X at a 
density of 5 x 10⁴ cells/cm² in 1 ml osteogenic-supplemented medium. The medium was not 
changed over the following 7 days. Once seeded, the cells would self-organise and attach to 
substrate X in distinct arrangements, a monolayer arrangement, a ‘sunflower-like’ arrangement 
and an aggregate arrangement (fig. 2.1). Each arrangement is thought to represent a 
subpopulation of cells. The cellular arrangements were then monitored optically for up to 7 days. 
Multiple images were taken at regular time points for subsequent subpopulation quantification 
and donor comparisons. 
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Figure 2.1: Examples of three different cellular arrangements obtained from MSCs cultured on substrate X. A monolayer 
arrangement (A), a sunflower-like arrangement (B) and an aggregate arrangement (C). Scale bar represents 400 µm. 
5. In vivo diffusion chamber construction, seeding, implantation and termination 
5.1 Construction of the diffusion chamber 
The individual components of the diffusion chambers were constructed and sterilised prior to use 
(fig. 2.2). The pre-drilled injection hole of each chamber ring was sealed with the provided nylon 
thread and glue. One Durapore membrane was then used to seal each of the chamber rings on 
one side. A single but constant bead of glue (10 μl) was added to one side of the chamber ring 
before the membrane was dipped in sterile dH₂O to swell them slightly. The excess dH₂O was 
then removed by blotting and the membrane was immediately placed over the glued ring. 
Forceps were then used to gently apply pressure between the membrane and the ring to facilitate 
a water-tight seal. The semi-assembled chambers were allowed to dry completely before being 
sterilised alongside extra Durapore membranes via ultraviolet (UV) light for 15 minutes on both 
sides. Two hundred μl PBS was added to each chamber for 90 minutes to assess water-tightness. 
Two blank chambers were also constructed to act as control blanks during analysis. One chamber 
remained completely empty (a control for the aggregate samples) and the second chamber 
contained a section of Neoveil mesh that was the same size (ø 8 mm) as those used to seed the 
monolayer controls (a control for the monolayer samples). Neoveil mesh is an absorbable 
reinforcement polyglycolic acid (PGA) felt typically used for strengthening tissue defects or, when 
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combined with fibrin glue,  suturing soft tissues384. In this case, however, it was used as a carrier 
to house the monolayer controls (adapted from Komura et al.385). 
 
Figure 2.2: A basic overview of how the diffusion chambers were constructed. 
5.2 Aggregate formation and diffusion chamber seeding 
Both MLO-A5 cells and MSCs (donor D3591A) were used for the in vivo study. The aggregates 
were formed using the pellet culture method described in section 3.1.2. Each of the small 
aggregates was formed using 1 x 10⁵ cells and each of the large aggregates was formed using 3 x 
10⁵ cells. Both MLO-A5 and MSC cellular aggregates were produced in the same way. 
The required number of aggregates, 9 x small or 3 x large per chamber, was added to each semi-
assembled chamber (96 hours prior to implantation for MSCs and 72 hours for MLO-A5 cells) in 
200 μl basal medium (the constituents of the medium depended upon which cells were being 
placed into each chamber). Neoveil mesh was cut in to sheets (ø 8 mm) using a biopsy punch and 
sterilised via UV light for 15 minutes before being seeded directly within the chambers 48 hours 
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prior to implantation. Each mesh sheet received 2 x 10³ cells in 50 µl osteogenic medium. The 
cells were allowed to attach to the mesh for 2 hours before an additional 150 µl osteogenic 
medium was added bringing the total medium volume in the chamber to 200 µl, equal to the 
aggregate samples. Monolayer controls were prepared using both MLO-A5 cells and MSCs. Extra 
Neoveil mesh sheets were seeded with MLO-A5 cells and MSCs to confirm cell attachment. After 
24 hours, the extra mesh sheets were fixed with formalin (a 40% aqueous solution of 
formaldehyde) for 20 minutes. Post-fixing, the mesh sheets were quartered with a fresh scalpel 
and stained with haematoxylin and eosin (H & E) as described in section 12.1. Forty-eight hours 
pre-implantation, osteogenic media was added to each of the aggregate-seeded chambers. 
Twenty-four hours pre-implantation, each of the chambers was placed on a clean/dry surface (a 
sterile square petri dish) and sealed with a second UV-sterilised Durapore membrane. Seventy μl 
supplemented medium was removed from each chamber before being sealed bringing the total 
volume within each chamber to 130 μl. The membranes were glued in place in the same way as 
the initial membranes only using PBS instead of dH₂O to swell the membranes and ensure a 
water-tight seal. 
5.3 Diffusion chamber implantation 
Whilst all of the preparation work for the in vivo experiment was carried out by the author, the 
surgical procedures required for this study were carried out by the University of Leeds Animal 
House. In total, 20 male immunocompromised nude mice (MF1-Nu/Nu, 4 – 5 weeks old, 20 – 24 g) 
and 30 chambers were used throughout this study. Three sample variables, i.e. large aggregates, 
small aggregates and monolayer controls, were assessed using 2 cell types, i.e. MLO-A5 cells and 
MSCs, giving 6 sample variables in total and 5 samples per variable. Ten of the animals were 
implanted with 2 chambers and 10 were implanted with just 1 chamber. The chambers were 
implanted in the intra-peritoneal cavity of each animal with great care being taken not to implant 
a single animal with two of the same experimental variable. This can be seen below in table 2.2. 
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As the chambers were being implanted, each one was thoroughly checked by the surgeon to 
ensure they were all securely sealed. 
 
Figure 2.3: A basic overview of the in vivo experimental plan. 
5.4 Diffusion chamber termination 
After 8 weeks, the animals were culled and chambers removed. As the chambers were being 
removed, they were each checked thoroughly for integrity. Each chamber was logged and imaged 
repeatedly before being opened. The membrane was removed from one side of the chamber and 
the contents were immediately imaged again. The chambers were then fixed in either 100% 
ethanol, formalin or 4% PFA. An equal number of chambers were fixed with each fixative. Each 
chamber was placed into an individual container to avoid any cross-contamination. 
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Table 2.2: In vivo experimental plan. A complete list the animals used, the number of chambers implanted into each 
animal, the cell type used within each animal and the sample type used within each chamber. 
Animal Chambers Cell Type Sample Type 
1 2 MSC Large aggregates and monolayer 
2 1 MSC Small aggregates 
3 1 MSC Large aggregates 
4 1 MSC Large aggregates 
5 2 MLO-A5 Small aggregates and monolayer 
6 2 MLO-A5 Large aggregates and monolayer 
7 1 MLO-A5 Small aggregates 
8 1 MLO-A5 Large aggregates 
9 1 MSC Large aggregates 
10 2 MSC Small aggregates and monolayer 
11 2 MSC Large aggregates and monolayer 
12 2 MSC Small aggregates and monolayer 
13 2 MSC Small aggregates and monolayer 
14 1 MSC Small aggregates 
15 1 MLO-A5 Large aggregates 
16 2 MLO-A5 Small aggregates and monolayer 
17 1 MLO-A5 Large aggregates 
18 2 MLO-A5 Small aggregates and monolayer 
19 2 MLO-A5 Large aggregates and monolayer 
20 1 MLO-A5 Small aggregates 
 
6. Collagen encapsulation  
Collagen gel was prepared using commercially acquired rat tail type I collagen with either 10 x α-
MEM or 10 x PBS depending upon the gels intended use. The procedure outlined below closely 
followed the manufacturer’s protocols. The main applications for the collagen gel were in two 
experiments; the co-culture of MSCs and HUVECs, for which 10 x α-MEM was used, and the 
encapsulation of cellular aggregates for further sample characterisation, for which 10 x PBS was 
used. 
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6.1 Ten x α-MEM preparation 
A full bottle of α-MEM powder (10 g) was added to 50 ml dH₂O. The solution was placed onto a 
magnetic stirrer for several hours for the powder to completely dissolve before 3.7 g sodium 
bicarbonate (NaHCO3) was added to adjust the pH. Another 50 ml dH₂O was added before the 
solution was again placed back onto the magnetic stirrer. The pH was checked and adjusted if 
necessary to 7.0. The solution was then filtered through a 0.22 µm filter to ensure sterility. 
6.2 Ten x phosphate buffered saline preparation 
One x PBS tablet was added to 20 ml dH₂O. This took up to an hour to dissolve fully. Once fully 
dissolved the pH was checked and adjusted (the pH should ideally be neutral). The solution was 
then filtered with a 0.22 μm filter to ensure sterility. 
6.3 Gelation 
The four constituents of the collagen gel were 10 x α-MEM (or 10 x PBS), 1 N sodium hydroxide 
(NaOH), dH₂O and collagen. For a particular final collagen solution conc. (i.e. 3.5 mg/ml) and 
volume (i.e. 500 µl), the following calculations were carried out: 
1. final solution volume / 10 = volume of 10 x α-MEM (or 10 x PBS), 2. (final solution volume x final 
desired concentration of collagen) / original concentration of collagen used = final volume of 
collagen to be used, 3. volume of collagen x 0.023 = volume of 1 N NaOH, 4. final solution volume 
– (volume of 10 x α-MEM + volume of collagen + volume of 1 N NaOH) = volume of dH₂O 
The individual constituents were added to a universal vial in the order of 10 x α-MEM (or 10 x 
PBS), 1 N NaOH, dH₂O and collagen. It was essential to ensure the solution was thoroughly mixed 
but in saying that, care was also taken to slowly pipette the collagen as its increased viscosity 
could have led to inaccurate amounts being pipetted. Creating bubbles in the gel solution was 
also avoided. The individual ingredients and the universal vial containing the final collagen 
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solution were constantly kept on ice throughout this procedure to prevent their temperature 
rising which could have led to premature gelation. After thorough mixing, the final collagen 
solution was transferred to where it was needed. The collagen solution was then placed into an 
incubator (37 °C) for a minimum of 20 minutes to allow the collagen to set into a gel. Once the gel 
had set properly, it was topped up with an appropriate volume of medium or PBS until it was 
completely covered. If the gel was intended to house living cells, it was covered with a specifically 
supplemented medium to supply the required nutrients to the cells; however, if the gel was 
intended to house fixed aggregates for further analyses, it was covered with PBS to prevent the 
samples from drying out. 
7. Hydrostatic loading 
The hydrostatic chamber was sterilised before use via autoclaving. The well plate was placed 
inside the chamber with the plate lid removed (fig. 2.4). The lid of the chamber was then bolted in 
place before the chamber was connected to the pressure generator. The whole chamber was then 
placed inside an incubator set to 37 °C and 5% CO₂ (fig. 2.4). Loading was then carried out for 1 
hour every 24 hours for 7 – 10 days at a pressure of 280 kPa and a frequency of 1 Hz (adapted 
from Henstock et al.386). 
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Figure 2.4: The hydrostatic bioreactor. A diagram outlining the basic structure of the hydrostatic bioreactor (A), a 
common well-plate being prepared for insertion into the bioreactor (B) and the bioreactor connected to the air inlet 
valve and pressure regulator which are maintained at 37 °C and 5% CO2 in an incubator (C). Images were kindly 
provided by Dr Katie Bardsley, Keele University, UK. 
8. Aggregate sectioning 
To facilitate the characterisation and monitoring of the spatial and temporal distribution of 
minerals within the aggregates, they were sectioned into thin slices 3 – 8 μm thick. This was done 
using a microtome on wax-embedded samples or within a cryostat at -25 °C facilitating frozen 
sample sectioning (cryosectioning). Typically, those samples intended for histochemical staining, 
FTIR or SEM were sectioned using a microtome; those intended for immunohistochemical staining 
were sectioned using a cryostat. 
8.1 Paraffin wax embedding 
To section the samples using a benchtop microtome, they were first embedded in wax. To 
facilitate wax embedding, the aggregates were transferred to glass vials and dehydrated in 
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varying ethanol concentrations, i.e. 50%, 70% and 90% ethanol for 45 minutes each, two cycles of 
100% ethanol for 45 minutes each and two cycles of Histoclear for 45 minutes each. The samples 
were then transferred to plastic wax embedding cassettes where they were dipped in 56 – 58 °C 
wax for 2 hours in a wax embedder. The wax embedding cassettes were then inverted with the 
samples still inside and placed into metal chambers. The metal chambers containing both the 
embedding cassettes and samples were then filled with molten wax and left to cool and harden. 
The metal chambers were removed leaving behind the embedding cassettes which each still 
retained a wax block containing the sample inside. The sample was then ready for sectioning with 
a microtome. For improved sectioning, the wax blocks containing the samples were stored in a 4 
°C refrigerator and were only removed immediately prior to sectioning. 
8.2 Microtome sectioning and rehydrating 
The wax embedding cassette with the wax block attached was placed into the microtome. The 
wax block was then sectioned to 3 or 5 μm thick slices. The slices containing sample sections were 
placed into a water bath set to 50 °C to flatten and smoothen out the slices, after which they were 
collected on conventional glass slides. The glass slides were then placed into a 60 °C oven for 40 
minutes. The glass slides were rehydrated to remove all of the remaining wax as follows: 
Histoclear for 2 minutes, twice, 100% ethanol for 2 minutes, twice, 90% ethanol for 2 minutes, 
70% ethanol for 2 minutes, 50% ethanol for 2 minutes and finally, dH₂O. The samples sections 
were then ready for staining and imaging. 
8.3 Cryosectioning 
To accommodate the cryosectioning of samples at -25 °C, they were first prepared and frozen. If 
the samples were not fixed prior to cryosectioning, they were snap-frozen in liquid nitrogen to 
prevent the formation of crystals and damaging of the samples. If the samples were pre-fixed, 
however, they were sectioned without snap-freezing, a process referred to as slow-freezing. Slow-
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freezing simply involved placing the sample into the cryostat for several minutes until it was 
frozen solid. The individual samples, snap- and slow-frozen, were placed on a glass slide and 
covered in an optimal cutting temperature (OCT) compound. The slide/sample/compound set-up 
was then placed inside a cryostat until the OCT had turned completely white, indicating that it 
was suitably frozen solid. The OCT compound, which then contained the sample, was transferred 
to a sample holder. The sample holder was placed back into the cryostat for several minutes to 
ensure the sample was thoroughly frozen solid. The sample was then sectioned to 8 μm thick 
slices. The slices were placed onto glass slides which were then left at room temperature for the 
OCT to melt and ensure the samples were sufficiently adhered to the glass slide. The remaining 
OCT was gently washed off with dH₂O. If the samples were not pre-fixed prior to cryosectioning, 
as was the case for those sections intended for CD31 staining (chapter 5), the glass slides 
containing the sample sections were placed into a cylinder of cold acetone to fix the samples and 
remove the OCT compound. 
9. Imaging 
9.1 Visible light microscopic imaging 
The vast majority of in vitro samples were monitored with an inverted optical microscope 
(Olympus, Japan). Image-Pro Insight software was used to acquire the images. A graticule was 
used to manually calibrate the scale on the microscope and sample images were taken at regular 
intervals to ensure the image scale bars remained accurate. 
The animals and chambers used for the in vivo investigation were optically imaged using a 
number of cameras. The animals and surgical procedures were imaged using a hand held digital 
camera (Samsung, South Korea). Post-termination, the chambers and their contents, including 
Neoveil mesh sheets, were imaged using a reflective dissection microscope (Leica, Germany) with 
an attached digital single-lens reflex (DSLR) (Nikon, Japan) camera. 
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9.2 Epifluorescent microscopic imaging 
All epifluorescent imaging was carried out using a Nikon Eclipse Ti microscope. NIS-Elements Br 
3.2 software was used to adjust the acquisition settings and capture the images. 
Fluorescence intensity was measured using Image J software. Care was taken to ensure all of the 
epifluorescent images from each data set were taken using identical parameters. The images 
were converted to 8 bit in Image J and measured using the developer’s guidelines. 
9.3 Confocal laser scanning microscopy 
All confocal imaging was carried out using an Olympus IX83 microscope. FluoView FV1000 
software was used to adjust the acquisition settings and capture the images. Single images and z-
stacks were acquired using the software developer’s guidelines. Z-stack analysis was carried out 
using Image J software. 
10. Aggregate measurements 
10.1 Aggregate size 
Aggregate size was measured using optical images taken with at least three replicates per 
variable. The length and breadth of the aggregates were measured and an average (mean ± 
standard error of the mean) was taken from both to get the approximate aggregate size. 
Aggregate length was accepted as the longest measurement taken from the aggregate centre, 
whilst breath was taken to be the distance measured perpendicularly to the length from the 
aggregate centre. Image J software was used to obtain each measurement and was calibrated 
separately for each image using the scale bars acquired from the Image-Pro Insight software. 
10.2 Aggregate aspect ratio 
The aspect ratio of each aggregate was acquired from measuring the aggregate length and 
breadth and dividing one onto the other to acquire a ratio. A value of 1 represents a perfect circle. 
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A higher aspect ratio indicates a more elongated or irregularly-shaped aggregate. Image J 
software was calibrated according to the images’ scale bars separately for each image. 
11. Mesenchymal stem cell subpopulation quantification 
Using 85 optical images in total (85 was the total number of available images), the MSC 
populations from multiple donors seeded on substrate X were assessed over two time points: 96 
and 168 hours (table 2.3). The proportions of the cellular arrangements were visually quantified 
using percentages, i.e. 50% monolayer arrangement, 50% sunflower-like arrangement and 0% 
aggregate arrangement. The images were blindly evaluated by three individuals unrelated to the 
study but familiar with the subpopulation arrangements and without influence from the 
investigator. The three individuals assessed each of the 85 images twice to account for any 
possible discrepancies. No discrepancies were noted. 
Table 2.3: MNC donors and the images used for subpopulation quantification. All eight donors who had their MSC 
subpopulations measured using the method outlined above are shown along with the number of images per donor per 
time point that were used for the quantification. 
Donor D3737A D3120B D1908B D3736A D3741A D3433B D3549B D2884D 
96 hours 7 3 10 6 6 3 6 7 
168 hours 10 4 6 3 3 3 4 4 
 
12. Histochemical staining 
Histological analysis involves the fixing, dehydration and embedding, slicing, rehydration and 
histochemical staining of samples for further qualitative analysis387. For the analysis of 3D 
aggregates, the samples can be prepared using histological techniques and histochemically-
stained to show the structural and biochemical make-up of the aggregate centres. Histochemical 
staining can be used as a qualitative analytical tool to observe tissue structure342 and to determine 
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the presence of ALP activity388,389 and minerals associated with bone formation (e.g. Alizarin red 
stain for calcium ions)390. 
12.1 Haematoxylin and eosin staining 
Samples intended for H & E staining were first fixed with formalin for 20 minutes approximately. 
Once the fixative was removed and the samples were washed with PBS, they were covered with 
haematoxylin for approximately 2 minutes (3 minutes maximum) and washed with tap water for 
approximately 5 minutes. They were then covered with eosin for approximately 7 minutes before 
being washed again with tap water for approximately 2 minutes (adapted from the 
manufacturer’s protocols). The samples were then ready for imaging. 
12.2 Alkaline phosphatase staining 
Alkaline phosphatase (ALP) staining was carried using an ALP detection kit. The samples were 
fixed using 4% paraformaldehyde (PFA) for no more than 2 minutes. The PFA was removed and 
the samples were rinsed twice with a tris-buffered saline and Tween 20 (TBST) solution. Fast Red 
Violet solution:Naphthol AS-BI phosphate solution:ddH₂O was mixed in a ratio of 2:1:1 (working 
solution). The samples were covered in working solution and incubated in the dark for 15 minutes 
at room temperature. The remaining working solution was removed and the samples were 
washed 2 – 3 times with dH₂O before imaging (adapted from the manufacturer’s user guide). 
TBST: 20 mM Tris-HCL, pH 7.4, 0.15 M sodium chloride (NaCl), 0.05% Tween-20 
12.3 Alizarin red staining 
Samples intended for Alizarin red staining were first fixed with formalin. Alizarin red staining 
solution was made up to a concentration of 40 mM with dH₂O. The pH was then adjusted to 4.1 
by adding 1 M NaOH dropwise. This pH adjustment created extensive precipitation so filtering 
with Whatmann paper or a 0.22 μm filter was required before use. 
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After removing the fixation solution, the sample was washed twice with dH₂O. Enough Alizarin red 
staining solution was added to completely cover the sample which was then left at room 
temperature and under gentle agitation for 30 minutes. The sample was washed 3 – 5 times with 
dH₂O to remove any unbound stain precipitates before imaging (adapted from Gregory et al.391). 
12.4 von Kossa staining 
Samples intended for von Kossa staining were fixed with formalin. For von Kossa staining, 
solutions were made up fresh every time. The samples were covered with 5% silver nitrate 
solution (in dH₂O) and incubated for 30 minutes at 37 °C without an additional light source. Then 
the samples were thoroughly rinsed with dH₂O and incubated with 5% sodium carbonate (in 25% 
formaldehyde) for 5 minutes at room temperature. The samples were then thoroughly rinsed 
with dH2O and imaged (adapted from Karp et al.
392). 
12.5 Oil red O staining 
Firstly, Oil red O stock solution was made up by adding 0.5 g Oil red O to 100 ml isopropanol. 
Secondly, Oil red O working solution required 30 ml of the stock solution to be added to 20 ml 
dH₂O. This was then left to stand for 10 minutes before filtering with Whatmann paper. The stock 
solution could be stored but the working solution had to be made up fresh for each staining 
session. 
The samples were fixed in formalin to avoid stripping the globules. Once fixed, the formalin was 
removed and the samples were rinsed with tap water for 1 – 10 minutes. The samples were then 
rinsed with 60% isopropanol and enough Oil red O working solution was added to cover the 
samples. The samples were then left to stand for 15 minutes before the remaining working 
solution was removed and the samples were rinsed again with 60% isopropanol (adapted from 
Kinkel et al.393). The samples were then ready for imaging. 
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12.6 Alcian blue staining 
1% Alcian blue stain solution was prepared by adding 1 g Alcian blue to 3 ml acetic acid and 97 ml 
dH₂O. The pH of the solution was then checked and adjusted to 2.5. Samples intended for Alcian 
blue staining were fixed with 100% ethanol or formalin. After the fixation solution was removed, 
the samples were washed several times with dH₂O. Enough Alcian blue solution to completely 
cover the samples was added and they were then left at room temperature for 40 minutes. The 
remaining stain solution was removed and the samples were washed several times with dH₂O 
(adapted from Mowry394). The samples were then ready for imaging. 
13. Immunohistochemical staining 
Immunohistochemistry fundamentally identifies the presence of antigens or proteins in tissue 
sections by means of specific antibodies. Antigen – antibody interactions are seen via a coloured 
histochemical reaction that is visible by light or fluorescent microscopy395. Immunohistochemical 
staining has been used in numerous studies for the identification of osteogenic markers, such as 
bone-specific ALP, COL 1 and OCN396, for EC surface markers (i.e. CD31)397,398 and for E-cadherin 
expression399,400. 
13.1 CD31 staining 
The PFA- (whole aggregates) or acetone- (aggregate sections) fixed samples were incubated for 30 
minutes in 10% FBS (diluted in PBS) to prevent non-specific background staining (blocking). As 
much of the FBS as possible was removed without letting the samples dry. The samples were then 
incubated for 1 hour in the primary antibody, mouse anti-human CD31 (clone: JC70A, isotype: 
IgG1), at a dilution of 1:20 in PBS. The remaining antibody solution was removed and the samples 
were washed 3 times in PBS. The samples were then incubated for 1 hour in the secondary 
antibody, alexa-fluor 594-conjugated goat anti-mouse IgG1, diluted 1:200 in PBS. Again, the 
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remaining antibody solution was removed and the samples were washed 3 times with PBS 
(adapted from Rouwkema et al.401). The samples were then ready to be imaged. 
13.2 E-cadherin staining 
Staining for E-cadherin followed the protocols supplied by Santa Cruz. E-cadherin staining was 
carried out on 96 and 168 hour samples fixed by PFA in situ on substrate X. Samples were washed 
with PBS to remove any remaining fixation solution. They were then permeabilised using 0.3% 
Triton X-100 in PBS (PBS-Tx) for 5 minutes. The samples were then covered in 3% BSA in PBS for 1 
hour to block any non-specific binding sites. The BSA was then removed. The samples were 
covered with the primary antibody E-cadherin (clone: S-17, isotype: IgG-R) (1:100 in PBS-Tx) and 
incubated for 3 hours at room temperature. The samples were washed by PBS-Tx 3 times. The 
secondary antibody (donkey anti-goat) was added (1:100 in PBS-Tx) and incubated for 2 hours at 
room temperature. The samples were then washed 3 times before being imaged. 
14. Real-time polymerase chain reaction 
Measuring specific gene expression levels has been a critical aspect in determining osteogenic 
differentiation in previously conducted studies3,4,342. Real-time quantitative polymerase chain 
reaction (PCR) allows for the quantification of particular nucleic acids402 and can be used to 
measure specific genes associated with osteogenesis, i.e. ALP, osteopontin (OPN), osteocalcin 
(OCN) or collagen type I (COL 1)25,396,403,404. 
The PCR assay and data analysis was carried out by Dr Hu Bin (Keele University, UK). For the 
monolayer samples, Tri Reagent lysis buffer was added to each well and pipetted. The lysed 
solutions were collected and stored at -80 °C until ribonucleic acid (RNA) extraction was to be 
carried out. The aggregate samples were transferred from their wells to micro-centrifuge tubes 
prior to lysing. The supernatant was removed from the aggregates and Tri Reagent lysis buffer 
was then added to each of the micro-centrifuge tubes. The aggregate pellets were thoroughly 
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pipetted and mixed to obtain a complete lysis before being stored in a -80 °C freezer for later RNA 
extraction.  
RNA extraction was carried out using the Tri Reagent protocol and was quantified using 
spectrophotometry, the results of which were then used to establish the required amounts of 
RNA for the next stage of the analysis. Once the quantities of RNA had been calculated, reverse 
transcription (RT) was carried out using an RT kit and complimentary deoxyribonucleic acid 
(cDNA) synthesis followed manufacturer’s protocols. The RT process required several reactions, 2 
minutes at 42 °C followed by ice (genomic deoxyribonucleic acid (gDNA) elimination reaction), 15 
minutes at 42 °C (reverse transcription of template RNA to cDNA) and 3 minutes at 95 °C (reverse 
transcriptase inactivation). 
PCR analysis was carried out using quantitative PCR (qPCR) with MxPro software. Four genes were 
analysed: COL 1, ALP, OPN and OCN. The PCR primers were used following the TaqMan Gene 
Expression Assays protocol. Thermal cycling followed a predetermined regime: 2 minutes at 50 °C 
(AmpErase uracil N-glycosylase (UNG) activation step), 10 minutes at 95 °C (initial denaturing or 
melting step), followed by 40 cycles of 15 seconds at 95 °C (denaturing step) and 1 minute at 60 °C 
(annealing and extending step). The final extending step required 10 minutes at 72 °C. Gene 18S 
was used as the endogenous control for normalisation of expression levels for the genes of 
interest using the delta delta CT (ΔΔ CT) method. Each ΔΔ CT value was used in the formula 2-ΔΔCT 
to give a comparative fold change of gene expression levels relative to that same gene in the 
monolayer sample at 24 hour culture. Each culture condition had a minimum of three samples. 
15. Microcomputerised tomography 
Microcomputerised tomography (microCT/μCT) has quickly become the gold standard for the 
assessment of bone morphology and microarchitecture in mice and other small animal models. 
This technique uses X-ray attenuation data collected from multiple viewing angles to reconstruct 
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a 3D image that highlights the spatial distribution of material density405. Such an analytical tool is 
invaluable to the field of regenerative medicine as it provides an opportunity to examine the 
skeletal system both in vivo and ex vivo406. MicroCT has been used in previous studies for the 
visualisation of bone development and distribution135,407,408 and recent advances in technology 
means microCT is also becoming a frequently used tool for in vivo studies allowing for time-lapse 
microCT analysis of bone formation to be acquired409–411. 
All of the microCT scanning in this study was carried out using a specific protocol comprised of 
predetermined parameters, scanning increments – 157 μm, E (kVp) – 45, I (μm) – 177, resolution 
was set to high, field of view (FOV) diameter – 12.3 mm and 30.1 mm (12.3 mm for the in vitro 
aggregate samples and 30.1 mm for the in vivo chambers), voxel size – 6 μm and 15 μm (again, 
dependent upon which samples were being scanned), integration time – 200 ms. The resultant 
scans were then evaluated using a pre-installed mode of analysis ‘BV/Density only Bone Eval.’. 
15.1 Microcomputerised tomography scanning of in vitro aggregates 
15.1.1 Samples encapsulated in collagen 
Initially, the aggregate samples were encapsulated in 200 µl of 3 mg/ml collagen hydrogel (as 
described in section 5) before conducting microCT to facilitate handling of the small-sized 
specimens. An identical blank hydrogel was used as a control to define the minimum density 
threshold required for analysis. The microCT scanning was carried out at a resolution of 8 μm 
using the provided software and protocols from the manufacturer. A density threshold of 110 was 
set as the minimum threshold for determining the formation of dense collagenous material within 
the aggregates given that the blank collagen gel no longer appeared above a density threshold of 
100. This method did not allow us to analyse any material below a threshold of 110 and simply 
allowed us to visually confirm the presence of dense material at or above a threshold of 110. This 
method was, therefore, considered to need refinement. 
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15.1.2 Samples scanned without collagen encapsulation 
This more refined process did not use a collagen hydrogel to house the samples. All aggregates 
were scanned at a resolution of 8 μm using the Scanco μCT 40 and accompanying software in a 
polystyrene holder designed specifically for this purpose. Given that the smaller MLO-A5 
aggregates of the non-coated suspension culture were so small and numerous, they were 
combined and scanned as a single sample per time point. The larger aggregates, from both MLO-
A5 cells and MSCs, from the coated suspension culture were large enough to be scanned as single 
aggregates. This resulted in vastly different material volumes and so when comparing the levels of 
densification or mineralisation between culture methods over time, the volume of dense material 
was normalised to the total material volume of each sample. Using this method, a density 
threshold of 60 was set as the minimum threshold required to determine the whole sample 
volume because this was the lowest threshold where background noise was eliminated. A 
threshold of 110 was again set as the minimum threshold required to determine dense 
collagenous material volume because this was the lowest threshold where the blank collagen gel 
control was no longer detected. 
15.2 Microcomputerised tomography scanning of the in vivo chambers 
The diffusion chambers from the in vivo experiment were scanned whole at a resolution of 15 μm 
using the Scanco μCT 40 and accompanying software. A density threshold of 110 was set as the 
minimum threshold for determining the formation of dense collagenous material beyond which 
all background material would be removed from the analysis. A threshold of 170 was used to 
quantify the volume of very dense material within the chambers because this was the highest 
threshold where all samples scanned still had a detectable volume. 
Two blank control chambers constructed in the same way as those used in vivo (described in 
section 4.1) were also scanned and used as blank controls. The chambers were then analysed 
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whole for volume and density measurements with the blank chambers subtracted to solely assess 
the chamber contents. The empty control chambers were subtracted from the aggregate sample 
chambers and the Neoveil mesh control chambers were subtracted from the monolayer sample 
chambers. The volume of very dense material was then normalised to the collagenous material 
volume of each sample. 
16. Fourier transform infrared microspectroscopy 
Fourier transform infrared spectroscopy (FTIR) is another common method used to determine the 
molecular structure and chemical composition of given samples7. The entire make-up of a sample 
can be assessed or one could concentrate on a particular area of interest, i.e. inorganic mineral 
composition7. Using a synchrotron source, more powerful Fourier transform infrared 
microspectroscopy (microFTIR) is possible. When combining chemical analysis specificity with 
microbeam accuracy412 in an advanced synchrotron facility for microFTIR, mapping of spatial 
distribution and chemical composition at the micron scale is enabled. This magnifies the 
microstructural details of a biomedical specimen, delivering high quality infrared (IR) 
spectroscopic data on the biochemical fingerprint of the sample. Briefly, this is achieved because 
of the one – one correspondence between chemical bonds and molecular vibration excitation 
induced within the molecular framework by the IR light illumination. In the presence of an 
electrical dipole moment change, the molecule will absorb a specific IR frequency. Such 
absorptions will give a spectrum which will allow for information to be acquired concerning the 
subtle interactions between the surrounding groups of a molecule413. Thus, the presence of 
proteins, lipids, cell nuclei and minerals within a sample will have separate absorption peaks, the 
so-called IR fingerprint, in a single FTIR spectrum. In the past, a number of studies have used 
microFTIR to track mineralisation during animal bone development414. 
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16.1 Sample preparation 
After fixing with 100% ethanol, the aggregate specimens were encapsulated in 200 μl of 3 mg/ml 
collagen hydrogel (section 5) and wax embedded prior to sectioning (section 7.1). The wax-
embedded samples were sectioned into 3 and/or 5 μm thick slices (section 7.2) and placed on 
MirrIR slides and/or CaF₂-coated windows. The MirrIR slides received both 3 and 5 μm thick 
sections, whilst the CaF₂-coated windows received only 3 μm thick sections (for comparative 
purposes only). The sections were then rehydrated using multiple alcohol dilutions (section 7.2) to 
remove any remaining wax415. 
16.2 Microspectroscopy analysis 
MicroFTIR spectral acquisition and analysis were carried out using the MIRIAM beamline B22 at 
Diamond. Spectra were collected using an aperture size of 10 x 10 μm². To compare culture 
duration and aggregate size effects, 3 μm thick sections of small and large aggregates cultured for 
24 and 72 hours were scanned (128 scans per point with a resolution of 8 cm-1) on MirrIR slides 
using a grid mapping sequence in reflection mode. Thirty points were chosen at random for 
spectral comparison and 15 points were chosen at random for quantitative analysis. The grid 
mapping sequence allowed for whole aggregate mapping and spatial distribution of calcification 
to be visually compared. At least two aggregates per experimental group (aggregate size and 
culture duration) have been mapped.  
From the spectra, protein (amide I region, 1625 – 1694 cm-1) and phosphate (PO₄ region, 960 – 
1143 cm-1) ratios416,417 from 15 spectra were used to quantify and differentiate the levels of 
mineralisation between culture duration and aggregate size since the relative intensity of the 
mineral and protein bands have been accepted as accurate measures of the mineral-to-protein 
ratio of the samples416,417. 
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To compare sample thickness effects, 3 and 5 μm thick sections of aggregates cultured for 24 and 
72 hours on coated and non-coated suspension culture substrates were scanned (128 scans per 
point on 3 μm sections, 256 scans per point on 5 μm thick sections, both at a resolution of 8 cm-1) 
on MirrIR slides in reflection mode. Ten points were chosen at random for spectral comparison 
and quantitative analysis. Amide I and PO₄ ratios were again acquired. 
All spectra were baseline corrected through OPUS software using the concave rubber band 
correction with 10 iterations and 64 baseline points excluding the CO₂ region. 
17. Scanning electron microscopy – energy-dispersive X-ray 
Scanning electron microscopy (SEM) uses a fine probe of electrons focused on a specimen and 
scanned in parallel lines. Numerous signals are generated as a result of the impact of the 
electrons which are then collected to form a sample surface image or analysis. These collected 
electrons are primarily secondary electrons, high-energy electrons back-scattered from the 
primary beam and characteristic X-rays418. SEM allows for detailed images to be taken of materials 
and structures at magnifications that would be difficult to obtain under normal optical 
microscopic conditions.  
Energy-dispersive X-ray (EDX) is used primarily to identify or measure inorganic elements, i.e. the 
detection of inorganic graphene419, the monitoring of sulphur speciation in Li-S batteries420 and 
the observation of the crystallisation of the porous zirconium terephthalate UiO-66421, but it can 
also be used to detect heavier inorganic elements in biological samples, such as those minerals 
associated with bone formation, calcium and phosphorus. When combined with SEM, SEM-EDX 
offers enhanced imaging capabilities combined with an insight into the elemental makeup of 
materials and structures. 
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17.1 Sample preparation 
Aggregate samples intended for SEM imaging and EDX analysis were prepared in the same way as 
those used for microFTIR analysis. The aggregates were dehydrated and wax-embedded (section 
7.1), sectioned into 5 μm thick sections and placed onto MirrIR slides before being rehydrated 
(section 7.3). Prior to SEM imaging, a ring of carbon tape was placed around the sample that was 
also in contact with the metal stand onto which the sample slide was placed to dissipate the 
build-up of static charge during imaging and analysis. 
17.2 Scanning electron microscopy – energy-dispersive X-ray analysis 
SEM images and EDX mineral analyses of the aggregates were taken and evaluated (15 kV for 5 
minutes per sample) using an SEM microscope. The elemental distribution of calcium and 
phosphorus within the aggregates was mapped and analysed. Three replicates have been taken 
for all of the analysis representing the average (mean) value and standard error of the mean. 
Analysis was carried out using Quantax 70 software. 
18. Flow cytometry 
Flow cytometry provides a method to rapidly and accurately measure the physical and chemical 
attributes of individual cells422. It has become a commonly used analytical technique for various 
applications, such as a screening method for urinary tract infections423, murine HSC analysis424 and 
cell cycle analysis422. Given that the presence, or lack thereof, of certain cell surface markers has 
been outlined as one of the minimum criteria for MSC verification158, it is central to almost all 
MSC-based research. 
18.1 Antibody staining 
Twelve cell samples were prepared from each donor for flow cytometry analysis, one blank, three 
positive (CD73, CD90, and CD105), five negative (CD14, CD19, CD34, CD45, and HLA), one 
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additional antibody (CD324) for donor comparisons and two isotype controls (IgG1 and IgG2). The 
eleven samples that required antibody tagging followed the same Miltenyi Biotec protocols as 
supplied by the company. Given the small number of cells being analysed, 1 – 3 x 10⁴ 
approximately, the manufacturer’s recommended antibody volumes were reduced by a factor of 
10. The volumes used in the manufacturer’s protocols were designed for cell counts of 1 x 10⁷. 
18.2 Flow cytometry protocol 
Flow cytometry was carried out using the Beckman Coulter Cytomics FC 500 and CXP software. 
Before any analyses were carried out, a series of checks were performed to ensure the equipment 
was working correctly. Once satisfied, the antibody-stained cell samples were prepared. Each of 
the cell samples were filtered immediately prior to use in the flow cytometer to ensure that no 
cell aggregates or debris greater than 40 µm would block the fluidics. These preparation steps 
made approximately 1 – 3 x 10⁴ events available for assessment. To ensure consistency between 
individual donor data sets, the first cell population to be assessed was used to establish a protocol 
on the software specific to this study. The antibodies used to stain the cells were conjugated to a 
PE dye, so FS linear, SS linear and FL2 log were selected as the protocol parameters. The 
acquisition limits were set to 40,000 events or 300 seconds. Colour Dot Plots, Density Plots and 
Histogram Plots were selected for the protocol using the parameters mentioned above. For each 
donor assessed, the blank cell sample was run through the flow cytometer first with the Quick Set 
option selected to fine tune the slider bars and calibrate the specific population location on the 
Histogram Plot. The stained cell samples then followed one at a time. 
18.3 Data analysis 
Flow cytometry data analysis was carried out using Flowing Software 2. The isotype controls, IgG1 
and IgG2, were used to establish positive and negative events for each of the nine antibodies 
measured. A Density Plot, two Histogram plots (one for the isotype control and one for the 
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specific antibody being measured) and an Overlay Histogram Plot were used to acquire the 
quantitative data from each antibody for each donor. A marker was used on the negative control 
Histogram Plot to include 95% of the cells and to record any stain greater than this as being 
positive. 
19. Statistical analysis 
A minimum of three specimens per variable were tested. Recorded data was initially sorted using 
Microsoft Office Excel software before being transferred to GraphPad Prism for statistical analysis 
and graphing. Data was averaged and represented as a mean value ± standard error of the mean. 
Groups were compared using independent t-tests, f-tests and one-way or two-way analysis of 
variance (ANOVA). A p-value below p = 0.05 was denoted to indicate statistical significance. In 
graphs, statistical significance is indicated at four levels: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and 
****p ≤ 0.0001. 
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Overview 
This study used a novel substrate modification technique to create an MLO-A5 aggregate model 
for the examination of developing mineralisation over time. The model comprised a commercially 
available hydrophobic substrate and a Pluronic coating to create two culture environments, one 
hydrophobic and one extremely hydrophilic, to form differing-sized MLO-A5 aggregates that acted 
as ossification centres replicating natural intramembranous bone formation. The differing-sized 
aggregates were monitored and assessed over 72 hours, whilst being compared with a 
conventional monolayer control. 
Several modes of analyses were used to evaluate and compare the potential for bone 
development, such as histochemical staining, real-time polymerase chain reaction (PCR), 
microcomputerised tomography (microCT/μCT), synchrotron-sourced Fourier transform infrared 
microspectroscopy (microFTIR) and scanning electron microscopy (SEM) combined with energy-
dispersive X-ray (EDX). The data obtained from each mode of analysis is discussed with the aim of 
understanding the underlying mechanisms of aggregate mineralisation. In addition, an 8-week in 
vivo investigation was carried out with the hope of shedding light on the potential for long term 
aggregate survival and potential bone formation using this model. 
1. Introduction 
Numerous studies have recently demonstrated that by adopting a micromass or cellular 
aggregation approach for tissue engineering instead of using conventional monolayer cultures, we 
may be able to utilise a more productive solution for bone tissue engineering297,334. The use of 
micromass culturing or cellular aggregation relies on the hypothesis that cellular condensation 
and aggregate formation can greatly enhance bone tissue development by mimicking the 
intramembranous ossification pathway. Whilst there are two principle pathways for bone 
formation, endochondral ossification and intramembranous ossification, the latter bypasses the 
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development of a cartilaginous phase through the development of an ossification centre for more 
rapid bone regeneration24. It is well established that cell – cell contact and condensation in the 
presence of the correct protein-rich extracellular matrix (ECM) are essential niches for bone 
formation335,336 and so the development of a cellular aggregate model is intended to replicate 
such in vivo processes so that we can greatly reduce the time required for mineralisation. It is 
thought that three-dimensional (3D) aggregate cultures better represent the intricacy of tissues 
with the replication of essential bone development processes, such as proliferation arrest, 
terminal differentiation and the formation of osteoid for the deposition of minerals46,337,338. In 
addition, they may also offer an insight into the regulatory signalling cascades induced by 
particular bioactive elements and factors339. 
Each of the studies centred around cellular aggregation have developed or refined a number of 
aggregation techniques, such as shaker flasks, hanging drop cultures, 3D rotary wall vessels and 
agarose coated multiple well plates4,425–427. Whilst effective in establishing reliable cellular 
aggregate models, these studies have used techniques that retain numerous disadvantages that 
have restricted their ability to answer some key questions regarding bone formation and how we 
might best mimic in vivo processes in vitro. For this reason, our study has developed a novel yet 
simple aggregation technique that will allow for the rapid and replicable development of 
aggregates of varying sizes. This model is intended to not only confirm the bone formation 
accelerating effects of aggregation but to also investigate how aggregate size might influence the 
rate and quality of mineralisation. 
To do this, we have developed a simple yet effective substrate modification technique to alter 
surface chemistry and create aggregates of varying sizes. Such a technique takes a previously 
established hydrophobic substrate (denoted as non-coated) used for culturing cells in suspension 
and coating it with a Pluronic solution (F127) (denoted as coated) to create an extremely 
hydrophilic substrate. Each substrate, coated and non-coated, discourages cell attachment and so 
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maintains a cell population in suspension. In doing so, the cells will attach to one another, rather 
than the substrate, creating cellular aggregates. How the coated and non-coated substrates differ 
from one another is in the magnitude by which they deter cell attachment. The coated substrate, 
being extremely hydrophilic, has a higher repulsive force compared to the non-coated substrate, 
being hydrophobic, deterring cell attachment to a higher degree. This results in the formation of 
small aggregates on the non-coated substrate and large aggregates on the coated substrate. 
With the model developed, the next step was deciding how best to analyse the aggregates to 
extrapolate as much information as possible. One of the most interesting challenges associated 
with aggregate culturing is uncovering how the close cell – cell/cell – matrix interactions lead to 
mature bone tissue through bone nodule progenies. Various qualitative and quantitative 
techniques have been used by previous cellular aggregate studies, such as histochemical staining 
for the presence of mineralised matrix, e.g. Alizarin red and von Kossa staining387, computerised 
tomography for the visualisation of bone formation in a mouse model387, the use of various 
protein assay kits (ELISA) and quantitative PCR (qPCR) for the measurement of specific genes342. 
However, it is difficult to accurately measure the concentration of matrix and mineral phases 
simultaneously with spatial and temporal distribution using a single aforementioned technique. 
Therefore, a combination of analytical techniques may be required. With that in mind, numerous 
qualitative and quantitative techniques have been adopted in this study, such as optical imaging, 
histochemical staining, real-time PCR and microCT. In addition, a number of off-site facilities have 
been utilised, such as synchrotron-sourced microFTIR for molecular fingerprinting and spatial 
mapping and SEM-EDX analysis for high resolution imaging combined with elemental analysis and 
quantification. Despite the use of numerous modes of investigation, however, a key question 
remained. How does aggregate size affect actual bone formation in vivo? Therefore, in 
conjunction with various in vitro assessments, an in vivo experiment was also carried out. 
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In this study we aimed to further the aggregate culture principle by using substrate chemistry 
modifications to induce bone aggregate formation in large quantities and with variable sizes. We 
intended to develop a facile model enabling us to identify the variables that control the 
mineralisation process and the quality and distribution of minerals formed in in vitro 3D 
aggregates. This was done by examining gene expression profiles and mineral production rates, 
whilst also evaluating mineral properties and spatial distributions over time. We postulated that 
the outcome of the quantitative examination comparing culture environments over time may 
help to establish distinct models which are in different formation stages. Such models will allow 
for the investigation of parameters that dictate the quality and quantity of mineralisation, 
important for generating implantable bone for clinical applications. 
2. Materials and Methods 
The MLO-A5 in vitro aggregation study was carried out on three separate occasions with a 
minimum of three samples per variable. The MLO-A5 in vivo aggregation study was carried out on 
one occasion with five samples per variable. MLO-A5 cells were the only cell type used 
throughout this chapter. 
2.1 Cell culture 
A late osteoblast murine cell line, MLO-A5 (kindly donated by Professor Lynda F Bonewald152) was 
used for the development of this model. A comprehensive cell culture protocol can be found in 
chapter 2, section 1. The supplemented medium used prior to aggregation (basal media) is 
described in chapter 2, section 1.1. 
2.2 Modification of cell culture substrates and aggregate formation 
A full description of the substrates used and a detailed explanation of how they were modified to 
form aggregates of different sizes is available in chapter 2, section 4. Suspension aggregation is 
described in chapter 2, section 4.1.1. Both suspension culture aggregation techniques described in 
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chapter 2, section 4.1.1 were used in this study. The process of aggregation used an osteogenic-
supplemented medium as described in chapter 2, section 1.4. The aggregate samples and 
monolayer controls were cultured for up to 72 hours in osteogenic medium with samples being 
collected after 24 hours, 48 hours, and 72 hours. Given the high proliferation rate of the cells, the 
monolayer controls were seeded with different initial densities depending upon when they were 
intended for termination to avoid them becoming over confluent. The controls were seeded with 
1.2 x 10⁵ cells for samples intended for collection after 24 hours, 1 x 10⁵ cells for samples intended 
for collection after 48 hours and 0.8 x 10⁵ cells for samples intended for collection after 72 hours. 
Both suspension cultures were seeded with 3 x 10⁵ cells regardless of time point collection. 
2.3 In vivo diffusion chamber construction and seeding 
Diffusion chambers were used to house the aggregated cell samples and monolayer controls 
during the in vivo experiment. Details of how the diffusion chambers were constructed, seeded, 
implanted and terminated can be found in chapter 2, section 5. 
2.4 Optical microscopic imaging 
Optical imaging was carried out on all variables within three separate MLO-A5 in vitro aggregation 
studies and one MLO-A5 in vivo aggregation study. 
2.4.1 In vitro samples 
Optical microscopy was used to monitor cellular morphology and aggregation. Images were taken 
using the equipment and software outlined in chapter 2, section 9.1. All samples were imaged 
using at least three replicates per variable. 
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2.4.2 In vivo chambers 
Optical imaging was used to monitor surgical procedures, chamber integrity post-implantation, 
possible engraftment and contents immediately following the in vivo experiment termination and 
sample fixation. Equipment and software used are outlined in chapter 2, section 9.1. 
2.5 Aggregate size measurement 
Aggregate size was measured using a minimum of three images per variable from separate 
samples collected over three separate MLO-A5 in vitro aggregation studies and one in vivo 
aggregation study. Aggregate size was determined using the software described in chapter 2, 
section 10.1. All measurements were made using a minimum of three images per variable. 
2.6 Histology 
Histochemical staining was carried out on a minimum of three samples per variable collected 
from two separate MLO-A5 in vitro aggregation studies. Staining was conducted using an ALP 
detection kit, Alizarin red stain and von Kossa on all aggregate and monolayer control samples 
cultured for 24, 48 and 72 hours. The monolayer control samples were stained in situ for each 
stain mentioned. The aggregate samples, however, required additional preparation. Those 
aggregates stained with the ALP detection kit were stained whole and immediately post-fixation 
due to the rapid decline in ALP activity post-fixation using the protocol described in chapter 2, 
section 12.2. The aggregates intended for Alizarin red and von Kossa staining were fixed in 
formalin for 20 minutes, collagen encapsulated, wax embedded and sectioned prior to staining. 
The small size of the aggregates required them to be encapsulated in collagen prior to any further 
analyses to facilitate their handling. The collagen encapsulation process is described in chapter 2, 
section 6. The wax embedding and sectioning protocols can be found in chapter 2, sections 8.1 
and 8.2, respectively. Detailed protocols for ALP, Alizarin red and von Kossa staining can be found 
in chapter 2, sections 12.2 – 12.4, respectively. 
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2.7 Real-time polymerase chain reaction 
PCR was conducted on one MLO-A5 in vitro aggregation study with a minimum of three samples 
per variable. A detailed protocol outlining how PCR was conducted can be found in chapter 2, 
section 14. Details of data analysis are also described. 
2.8 Microcomputerised tomography 
MicroCT scanning was conducted on a minimum of three samples from each variable over two 
separate MLO-A5 in vitro aggregation studies. Scanning of collagen-encapsulated MLO-A5 
aggregates was conducted on samples acquired from the first of two in vitro aggregation studies, 
whilst scanning of non-encapsulated aggregates was carried out using samples acquired from the 
second of two in vitro aggregation studies. Scanning was also carried out on five samples for each 
variable within one MLO-A5 in vivo aggregation study. 
2.8.1 Aggregate size effect 
To measure aggregate density and mineralisation over time, microCT scanning was carried out. 
Given the small size and integrity of the aggregate samples to be scanned, two methods of sample 
preparation were tried and tested. The first was with collagen gel encapsulation (as described in 
chapter 2, section 15.1.1) and the second was with aggregate samples alone (as described in 
chapter 2, section 15.1.2). Although the collagen gel encapsulation made handling of the samples 
easier, it lessened the level of detail that could be acquired from the microCT, especially from the 
samples with lower densities. The second method made handling of the samples more difficult 
but ultimately more successful given that more accurate results could be obtained from all 
samples regardless of density. The monolayer controls could not be analysed via microCT. The 
microCT data described in the results section of this chapter is taken from scans carried out using 
the second method of preparation described above, aggregate samples without collagen gel 
encapsulation. Thresholds of 60 and 120 were used to quantify the total aggregate volumes and 
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dense material volumes, respectively. A normalised value was then acquired using both volume 
measurements giving a dense material volume normalised to total material volume. 
The total aggregate volume represents all of the material that was present at a threshold of 60. 
The threshold of 60 was chosen because at this threshold the microCT imaging did not show any 
background interference yet the whole aggregates were visible suggesting that any material that 
remained at this threshold was solely aggregate. The dense material volume represents all of the 
material remaining at a threshold of 120. The threshold of 120 was chosen because previously 
conducted microCT scans of collagen hydrogel of a known concentration suggested that only 
dense extracellular material remained at a threshold of 110 or above. 
2.8.2 In vivo chambers 
MicroCT was the primary mode of analysis for evaluating levels of mineralisation within the in vivo 
samples. To avoid any sample contamination or loss of material during scanning, each diffusion 
chamber was microCT scanned and analysed in its entirety, as described in chapter 2, section 
15.2. Because of the lengthy duration of the in vivo experiment and the subsequent increase in 
material density compared to the in vitro samples, the density thresholds had to be increased for 
the quantitative analysis. Therefore, a threshold of 110 was used to show the total volume of 
material within each of the chambers and a threshold of 170 was used to show the volume of 
dense material within each of the chambers. 
2.9 Fourier transform infrared microspectroscopy 
MicroFTIR spectra acquisition was carried out at MIRIAM beamline B22, Diamond Light Source, on 
two separate occasions using a minimum of three samples per variable from two separateMLO-A5 
in vitro aggregation studies. Mapping images were taken of two samples per variable acquired 
from one MLO-A5 in vitro aggregation study. Aggregate samples were sectioned and prepared for 
microFTIR scanning following the protocols outlined in chapter 2, section 16.1. 
89 
 
Analysis protocols are described in full in chapter 2, section 16.2. Initially, analysis was carried out 
solely on 5 μm thick sections that were placed on MirrIR slides and scanned in reflection mode. 
Typical sample sections scanned in this way were reported to be 5 – 30 μm thick with the majority 
of polymers, non-mineralised biological tissues and organic materials being 10 – 15 μm thick. Fully 
mineralised bone is typically tested using 3 – 5 μm sections412. The intention was simply to assess 
and compare aggregate size and culture duration. However, due to higher-than-expected 
variances in sample thickness between proteinaceous regions and regions of mineralisation (later 
confirmed by atomic force microscopy (AFM) analysis, data not included) and the resulting 
decreased signal-to-noise ratio (S:N), fresh 3 μm thick sections were prepared and placed on 
MirrIR slides. A comparison could now be made between sample thicknesses for the purposes of 
preparation refinement. During this preparation phase, the decision was made to also use CaF₂ 
slides. This was due to literature suggesting the use of such slides for measuring biological tissues 
in transmission mode412. Three μm thick sections of large aggregates from both 24 and 72 hour 
culture durations were then placed on CaF₂ slides so that we could confirm the observations 
noted from MirrIR slides in reflection mode with CaF₂ slides in transmission mode. 
The use of paraffin wax as an embedding tool and the possible effect it might have on infrared (IR) 
spectra was also considered and believed to be irrelevant. Before any analyses were carried out, 
each specimen was dewaxed, rehydrated and cleaned to ensure there was no wax present. 
However, should any residues have remained they would not have had any effect on our areas of 
interest within the spectra. The most intense absorbance features of paraffin wax are limited to 
2800 – 3000 cm-1, the C – H stretch region, with weaker features occurring around 1465 cm-1, the 
C – C stretch region412. These qualities could not affect our data. 
MicroFTIR analysis was carried out using the specifics discussed in chapter 2, section 16.2. The 
decision to use peak ratios as opposed to absolute values for specific peak quantification was 
taken with the intention of negating any possible data discrepancies caused as a result of peak 
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oscillations from variations in sample thickness413. In the case of mineralised tissue, the ratio of 
the phosphate (PO₄) band to any of the amide bands is considered an accurate representation of 
the amount of mineral present normalised to the amount of collagen present428. 
2.10 Scanning electron microscopy – energy-dispersive X-ray 
SEM-EDX imagining and analysis was carried out a minimum of three samples per variable 
acquired from two separate MLO-A5 in vitro aggregation studies. SEM-EDX analysis was used to 
confirm elemental observations and quantities. How the samples were prepared for SEM-EDX 
analysis is explained in full in chapter 2, section 17.1. SEM-EDX scanning and analysis is described 
in chapter 2, section 17.2. 
2.11 Statistical analysis 
Sample groups were compared using independent t-tests or one-way analysis of variance 
(ANOVA). A p-value below 0.05 was taken to indicate statistical significance. Graphically, 
statistical significance is indicated at four levels: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p 
≤ 0.0001. 
3. Results 
3.1 Aggregate morphology and size 
MLO-A5 cellular aggregation on both coated and non-coated culture substrates was observed to 
occur within just 8 hours of seeding. The size and shape of the aggregates formed showed a large 
variation between both suspension cultures, coated and non-coated, with considerable 
differences in aggregate size already evident after just 24 hours of culturing (t-test, p = 0.0255). 
The aggregates formed after 24 hours on the coated substrates appeared to clump together over 
the following 24 hours creating larger irregular-shaped aggregates. In contrast, the smaller 
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aggregates formed on the non-coated substrates did not clump together and remained separate 
and more uniformly spherical in shape (fig. 3.1). 
 
Figure 3.1: MLO-A5 cell aggregates and the monolayer control. Optical images of MLO-A5 cell aggregates formed on 
both coated and non-coated suspension culture substrates over three time points: 24 hours, 48 hours and 72 hours. 
Also shown are the monolayer controls over the same three time points. Red scale bar represents 150 μm and black 
scale bar represents 400 μm. 
After 48 hours in culture, the average (mean ± standard error of the mean) size of the non-coated 
suspension aggregates had ceased to increase and by 72 hours had started to condense and 
shrink in size (fig. 3.1 and 3.2). Contrastingly, continuous growth was noted for the aggregates 
cultured on the coated substrates up to the 72 hour time point. This increase in aggregate size is 
thought to be caused by smaller, earlier-formed aggregates joining together and forming large, 
ellipse-shaped aggregates (fig. 3.1). After 72 hours in culture, the average (mean ± standard error 
of the mean) size of the aggregates was 79 μm for those formed on non-coated substrates and 
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607 μm for those formed on coated substrates (fig. 3.2). After 72 hours, the number of aggregates 
obtained also varied between suspension cultures with approximately 20 – 30 per well for the 
non-coated substrates and between 2 and 3 per well for the coated substrates. The monolayer 
control cells attached within 2 hours of seeding and their morphology remained unchanged 
throughout the 72 hour culture period. 
 
Figure 3.2:  The average size of the MLO-A5 aggregates. Quantitative measurements showing the average (mean) size 
of the MLO-A5 cell aggregates from both suspension cultures over three time points. 24 denotes 24 hours, 48 denotes 
48 hours and 72 denotes 72 hours. CS denotes coated suspension culture and NCS denotes non-coated suspension 
culture. Error bar represents standard error of the mean.   * signifies p < 0.05, *** signifies p < 0.001 and **** signifies 
p < 0.0001. 
3.2 Histochemical staining 
At all three time points, the monolayer culture specimens showed only marginal ALP staining. At 
24 hours, the aggregates from both suspension cultures, coated and non-coated, showed very 
faint staining. At 48 hours, both the large and small aggregates showed improved staining but this 
failed to be captured on the images of the large aggregates. At 72 hours, both large and small 
aggregates were positively stained for the presence of ALP but again, this was difficult to see in 
the images of the large aggregates (fig. 3.3). The increased size and density of the large 
aggregates is responsible for the poor image quality. 
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Figure 3.3: ALP staining carried out on MLO-A5 cell aggregates. The aggregates were formed using both suspension 
cultures over three time points: 24 hours, 48 hours and 72 hours. Also shown are the monolayer controls over the same 
three time points. Cell aggregate staining was carried out on whole aggregate samples. Red colouration indicates 
positive staining. Black arrows highlight the areas where positive staining can be seen. Red scale bar represents 150 μm 
and black scale bar represents 400 μm. 
Similar staining results were noted with Alizarin red staining which identified the presence of 
calcium deposits (fig. 3.4). Calcium deposits were identified within both aggregates, small and 
large, after just 24 hours in culture. Calcium was not detected in the monolayer controls after 72 
hours in culture. The encapsulating collagen surrounding the aggregate sections was not stained 
by Alizarin red indicating that physical entrapment of the reagents was not an issue and so did not 
result in any false positive staining. 
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Figure 3.4: Alizarin red staining carried out on MLO-A5 cell aggregates. The aggregates were formed using both 
suspension cultures over three time points: 24 hours, 48 hours and 72 hours. Also shown are the monolayer controls 
over the same three time points. Aggregate staining was carried out on 5 μm thick sections. Red colouration indicates 
positive staining. Black arrows highlight the areas where positive staining can be seen. Blue scale bar represents 80 μm 
and red scale bar represents 150 μm. 
Similar staining results were again noted with von Kossa staining which highlighted the presence 
of phosphate deposits (fig. 3.5). Phosphate was detected in both small and large aggregate 
samples after 24 hours in culture; whereas, monolayer controls did not stain positively for 
phosphate after 72 hours in culture. 
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Figure 3.5: von Kossa staining carried out on MLO-A5 cell aggregates. The aggregates were formed using both 
suspension cultures over three time points: 24 hours, 48 hours and 72 hours. Also shown are the monolayer controls 
over the same three time points. Aggregate staining was carried out on 5 μm thick sections. Brown to black colouration 
indicates positive staining. Black arrows highlight the areas where positive staining can be seen. Blue scale bar 
represents 80 μm and red scale bar represents 150 μm. 
3.3 Osteogenic gene expression 
The four genes, i.e. collagen type I (COL 1), ALP, OPN and osteocalcin (OCN), were expressed 
under all three culture conditions but the expression patterns varied depending upon culture 
substrate and culture duration. Except for COL 1, the smaller aggregates from the non-coated 
substrates had higher gene expression levels when compared to the other two groups, monolayer 
and coated substrate cultures (fig. 3.6). 
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Figure 3.6: Gene analysis comparing MLO-A5 cell aggregates to a monolayer control. Real time-PCR analysis comparing 
the fold increase of specific genes associated with bone development across three sample variables, i.e. two MLO-A5 
aggregate cultures and one ML0-A5 monolayer control, over three time points: 24 hours, 48 hours and 72 hours. Error 
bar represents standard error of the mean. * signifies p < 0.05, ** signifies p < 0.01, *** signifies p < 0.001 and **** 
signifies p < 0.0001. 
3.3.1 Collagen type I 
At 24 and 48 hours, mean collagen expression levels in the monolayer and non-coated substrate 
specimens were higher than in the coated substrate specimens. At 24 hours, the monolayer 
culture had a 4.5 fold increase (95% confidence interval (CI) 3.04 – 7.19) over the coated substrate 
specimens, whilst the non-coated substrate specimens had a 2.7 fold increase (95% CI 0.21 – 6.02) 
over the coated substrate specimens. At 48 hours, the monolayer culture had a 7.8 fold increase 
(95% CI 4.76 – 11.26) in COL 1 expression over the coated substrate specimens, whilst the non-
coated substrate specimens had a 7.3 fold increase (95% CI 5.72 – 9.33) over their coated 
substrate counterparts. At 72 hours, the mean expression level in the non-coated substrate 
24 Hours 
48 Hours 
72 Hours 
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specimens had dropped to that of the coated substrate specimens, whereas mean expression 
levels remained relatively high in the monolayer culture specimens with a 5.8 fold increase (95% 
CI N/A) over the non-coated substrate specimens and 3.2 fold increase (95% CI 1.63 – 6.78) over 
the coated substrate specimens (fig. 3.6). 
3.3.2 Alkaline phosphatase 
At 24 and 48 hours, aggregates formed on the non-coated substrate expressed the highest levels 
of ALP compared to the other two culture groups with a 2.2 fold increase (95% CI 0.75 – 3.1.74) at 
24 hours and a 1.6 fold increase (95% CI 1.02 – 2.57) at 48 hours. Whilst the monolayer and non-
coated substrate specimens had their peak ALP expressions at 48 hours, the coated substrate 
specimens had their ALP peak expression at 24 hours which continually decreased thereafter (fig. 
3.6). 
3.3.3 Osteopontin 
The three culture conditions exhibited dramatically different OPN expression patterns. The large 
aggregates of the coated substrate maintained a relatively constant expression for all three time 
points, whilst the monolayer culture specimens and the non-coated substrate aggregates 
experienced changes in expression throughout the culture period. At 24 and 48 hours, the non-
coated substrate specimens expressed a 6 fold increase (95% CI 1.63 – 13.21) and a 2 fold 
increase (95% CI 1.54 – 2.73), respectively, over the monolayer specimens, which in turn 
expressed a 2.35 fold increase (95% CI 1.52 – 4.71) and a 4 fold increase (95% CI 2.68 – 6.5) over 
the coated substrate specimens at 48 and 72 hours, respectively. The peak expression along the 
culture time points was different for all three culture type specimens. The peak expression in both 
aggregate culture specimens was at 48 hours, whereas that in the monolayer culture specimen 
was at 72 hours (fig. 3.6). 
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3.3.4 Osteocalcin 
The mean expression levels of OCN were similar in the three culture groups, with the highest 
mean expression seen at 48 hours. At 72 hours the non-coated substrate specimens exhibited the 
lowest mean expression levels amongst the three culture groups with a 0.5 fold increase (95% CI 
0.09 – 1.25) when compared to both the monolayer and the coated substrate specimens. The 
coated substrate specimens showed quite similar levels throughout the three culture time points 
(fig. 3.6). 
3.4 Observations noted during in vivo sample termination 
All of the diffusion chambers used to house the aggregate and monolayer samples were checked 
and confirmed to have remained sealed throughout the 8-week culture duration. Increased 
vascularisation was noted covering some of the chambers but no correlation could be made 
between a particular sample type, i.e. aggregates of a particular size or the monolayer samples, 
and the varied vascularisation (fig. 3.7). The monolayer samples had in several cases developed 
extracellular material within the sealed chambers confirming the presence of cellular activity (fig. 
3.7). With regards to the aggregates, the small aggregates (those produced on the non-coated 
suspension substrate) appeared to better maintain their structure over the course of the 
experiment when compared to the large aggregates. A large number of small aggregates were 
found in each of their chambers, whilst many of the large aggregates (those produced on the 
coated suspension substrate) appeared to have disintegrated in vivo (fig. 3.7). The surgeon also 
noted at the time of termination that the small aggregates felt more solid when being examined. 
The small aggregates too appeared to have created more extracellular material over the course of 
the experiment that often had stronger colouration when compared to the large aggregates (fig. 
3.7). 
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Figure 3.7: In vivo chambers post-termination. Optical images showing the initial in vivo chamber terminations and the 
varied chamber vasculature followed by the condition of the chamber contents. Scale bar represents 500 μm. 
3.5 Microcomputerised tomography 
3.5.1 MLO-A5 in vitro aggregates 
fig. 3.8 shows the coated and non-coated suspension aggregates over the three culture time 
points, 24 hours, 48 hours and 72 hours, and fig. 3.9 shows the quantitative measurements 
acquired from such scans. The total volume of material within each of the samples at a density 
threshold of 60 (provided by the software mode of analysis ‘BV/Density only Bone Eval.’) after 24 
hours were 0.219 and 2.189 mm³ for the coated and non-coated culture specimens, respectively. 
After 48 hours, the volumes were 0.458 and 2.288 mm³ for the coated and non-coated culture 
specimens, respectively. After 72 hours, the volumes were 0.379 and 0.414 mm³ for the coated 
and non-coated culture specimens, respectively. The volumes of dense material within these 
samples at a density threshold of 120 after 24 hours were 0.002 mm³ and 0.035 mm³ for the 
coated and non-coated culture specimens, respectively. After 48 hours, the volumes of dense 
material were 0.020 mm³ and 0.139 mm³ for the coated and non-coated samples, respectively. 
After 72 hours, the volumes were 0.078 mm³ and 0.078 mm³ for the coated and non-coated 
culture specimens, respectively. Given the way in which the aggregate samples were scanned, the 
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volume of dense material within the aggregates at a density threshold of 120 was normalised to 
the total volume of the aggregate samples at a density threshold of 60. This gave normalised 
figures of 0.01 mm³ and 0.016 mm³ for the coated and non-coated culture specimens, 
respectively, after 24 hours. After 48 hours, the normalised figures were 0.042 mm³ and 0.060 
mm³ for the coated and non-coated culture specimens, respectively. After 72 hours, the 
normalised figures were 0.218 mm³ and 0.190 mm³ for the coated and non-coated culture 
specimens, respectively (fig. 3.9). 
 
Figure 3.8: MicroCT scan images of both MLO-A5 cell aggregate cultures. Shown are the coated and non-coated culture 
aggregates over three time points, 24 hours, 48 hours and 72 hours, at a density threshold of 60. The three scan images 
representing the non-coated suspension culture specimens comprise multiple small aggregates combined into one; 
whereas, the three scan images representing the coated suspension culture specimens are of single aggregates. 
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Figure 3.9: MLO-A5 cell aggregate volume measurements. Values were acquired from two thresholds: 60 (A) (total 
aggregate volume) and 120 (B) (dense material volume). Also shown is the ratio of both volume measurements (C) 
giving a dense material volume normalised to total material volume. Error bar represents standard error of the mean. * 
signifies p < 0.05, ** signifies p < 0.01 and **** signifies p < 0.0001. 
3.5.2 MLO-A5 in vivo samples 
Fig. 3.10 shows whole chamber scan images for the small and large MLO-A5 aggregate samples at 
a threshold of 130 alongside the average (mean ± standard error of the mean) density 
measurements for each variable. Fig. 3.11 shows the quantitative measurements acquired from 
the whole chamber scans. The volume of material found in each of the samples tested at a 
density threshold of 110 averaged (mean ± standard error of the mean) values of 0.426, 5.698 and 
2.222 mm³ for the monolayer, small aggregate and large aggregate samples, respectively (one-
way ANOVA, p = 0.0391). The volume of dense material found in the diffusion chambers at a 
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density threshold of 170 was 0.036, 1.165 and 0.623 mm³ for the monolayer, small aggregate and 
large aggregate samples, respectively. The volume of dense material was then normalised to the 
total volume of material found in the chambers giving values of 0.047, 0.197 and 0.088 mm³ for 
the monolayer, small aggregate and large aggregate sample chambers, respectively (fig. 3.11). 
Also shown is a comparison between the normalised dense material values from each chamber 
variable and their equivalent values acquired from rat femur samples of various ages. 
 
Figure 3.10: MicroCT scan images of whole MLO-A5 in vivo chambers. The chambers were fixed in formalin and contain 
both small and large MLO-A5 aggregate samples. No material was visible in the monolayer control chambers. The 
chamber contents are shown at a threshold of 130. Also shown is a graph displaying the density measurements of the 
chambers containing all three sample variables, small and large aggregates and the monolayer controls, at a threshold 
of 110. Error bar represents standard error of the mean. * signifies p < 0.05, ** signifies p < 0.01 and *** signifies p < 
0.001. 
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Figure 3.11: MLO-A5 in vivo chamber volume measurements. Values were acquired from two thresholds: 110 (A) (total 
material volume) and 170 (B) (dense material volume). Also shown is the ratio of both volume measurements (C) giving 
a dense material volume normalised to total material volume. In addition, the normalised material volume has also 
been compared to that of rat femur samples over three different ages: 4 days, 35 days and 5 months (D). Error bar 
represents standard error of the mean. * signifies p < 0.05, ** signifies p < 0.01 and **** signifies p < 0.0001. 
3.6 Fourier transform infrared microspectroscopy 
3.6.1 The effect of culture duration and aggregate size 
MicroFTIR analysis of the in vitro aggregates has shown that culture duration has a substantial 
effect on mineralisation. Aggregates cultured over 24 and 72 hours have exhibited significant 
differences in spectral regions associated with mineralisation. Those aggregates cultured over 72 
hours displayed considerably higher PO₄ peaks (960 – 1143 cm¯1)429 when compared to the 
aggregates cultured over just 24 hours (fig. 3.12). Considerable differences within particular 
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spectral regions have also been observed between substrate types (aggregate size). The large 
aggregates have shown higher levels of mineralisation when compared to the small aggregates 
over the same 72 hour culture period (fig. 3.12).  
 
Figure 3.12: MicroFTIR spectra of MLO-A5 aggregates. Shown are the 24 hour and 72 hour coated suspension culture 
MLO-A5 aggregates (A) alongside microFTIR spectra of 72 hour non-coated suspension and coated suspension culture 
aggregates (B). Also shown is the PO₄:amide I ratios (C) of 24 hour and 72 hour coated and non-coated suspension 
culture aggregates. The MLO-A5 aggregate samples were prepared on MirrIR slides using 3 μm thick sections. Analysis 
was carried out in reflection mode using 128 scans per point at a resolution of 8 cm
-1
. 24 and 72 denote hours in 
culture; CS and NCS denote coated suspension culture and non-coated suspension culture, respectively. Error bar 
represents standard error of the mean. ** signifies p < 0.01 and **** signifies p < 0.0001. 
Taking PO₄:amide I ratios into account, the large and small aggregates displayed mineralisation 
levels of 0.48 and 0.55, respectively, after 24 hours in culture. After 72 hours in culture, these 
levels increased to 5.73 and 1.51, respectively (fig. 3.12) (t-test, p = 0.0054). After 72 hours of 
culturing, the levels of mineralisation within both types of aggregates increased significantly (one-
way ANOVA, p < 0.0001) with the largest increase noted within the large aggregates compared to 
the small aggregates (t-test, p = 0.001 compared with p = 0.0199).  
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Scanning images and mapping analysis of both MLO-A5 aggregate sizes over 24 and 72 hours not 
only visually confirmed the presence of phosphate within the aggregates, but also offered an 
insight into the mineralisation development pattern (fig. 3.13). The concentrations of amide I 
(1625 – 1694 cm¯1) and PO₄ (960 – 1143 cm¯1) groups for the aggregates were mapped. After 24 
hours in culture, the large aggregates displayed developing mineralisation that was more 
peripheral within the aggregates, whilst the initial areas of mineralisation within the small 
aggregates appeared to be more central. After 72 hours, mineralisation within both aggregate 
cultures, small and large, appeared to be more uniform and widespread throughout the 
aggregates. 
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Figure 3.13: MicroFTIR mapping images of the MLO-A5 aggregates. I) Top: PO₄ and amide I regions of a 24 hour non-
coated suspension MLO-A5 aggregate. Bottom: PO₄ and amide I regions of a 24 hour coated suspension MLO-A5 
aggregate. II) Top: PO₄ and amide I regions of a 72 hour non-coated suspension MLO-A5 aggregate. Bottom: PO₄ and 
amide I regions of a 72 hour coated suspension MLO-A5 aggregate. The black and white images are corresponding 
visible images and the colour scale indicates spectral intensity. The PO₄ region of the 72 hour coated suspension 
aggregate was so intense (see insert in lower left image), the arbitrary unit (au) scale was heightened to lessen the 
intensity. The samples were prepared on MirrIR slides using 3 μm thick sections. Analysis was carried out in reflection 
mode with an 8 cm
-1
 resolution and 128 scans per point. 
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3.6.2 The effect of sample preparation 
Analyses were carried out on 24 hour and 72 hour coated suspension aggregate sections cut to 
thicknesses of 3 and 5 μm using a synchrotron source in reflective mode. Visually, differences 
between the PO₄ regions of the spectra of the 24 hour aggregate sections were not overly 
impressive. The spectra of the 72 hour aggregates, however, clearly show considerable 
differences in PO₄ peak height (fig. 3.14). The 3 μm thick samples showed far higher PO₄ peaks 
indicating a higher sensitivity within that particular range. 
 
Figure 3.14: MicroFTIR spectra of MLO-A5 aggregates. Shown are the 24 hour (A) and 72 hour (B) coated suspension 
culture MLO-A5 aggregates. Also shown is the PO₄:amide I ratios (C) of 24 hour and 72 hour coated suspension MLO-A5 
aggregates. Samples were prepared on MirrIR slides using 3 μm and 5 μm thick sections. Analysis was carried out in 
reflection mode with an 8 cm
-1
 resolution. The 3 μm thick sections used 128 scans per point and the 5 μm thick sections 
used 256 scans per point. 24 denotes 24 hours and 72 denotes 72 hours. Error bar represents standard error of the 
mean. ** signifies p < 0.01 and **** signifies p < 0.0001. 
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Using PO₄:amide I ratios has given a more in-depth look at how section thickness affects the 
obtained data. Even after just 24 hours in culture, significant differences were noted between the 
PO₄:amide I ratios of the 3 and 5 μm thick sections, 0.48 and 0.13, respectively (t-test, p < 0.0001) 
(fig. 3.14). Significant differences were again noted between the 72 hour aggregate sections, 
5.732 and 1.062 for the 3 and 5 μm thick sections, respectively (t-test, p = 0.0033). 
3.7 Scanning electron microscopy – energy-dispersive X-ray 
The SEM imaging and EDX analysis was carried out for large and small MLO-A5 aggregates 
cultured over 24 and 72 hours. The spatial distribution of mineralised regions has clearly been 
identified within the aggregates with calcium and phosphorus regions also being shown to overlap 
for both time points, 24 and 72 hours (fig. 3.15). After 24 hours in culture, the only apparent 
difference between aggregate samples is in aggregate size; no significant differences can be 
identified in calcium and/or phosphorus levels between the two different-sized aggregates. After 
72 hours, clear differences can be seen in both calcium and phosphorus levels between the 
aggregates of the coated and non-coated substrates (fig. 3.15). 
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Figure 3.15: SEM images with combined EDX analysis of MLO-A5 aggregates. Shown is the calcium (green) and 
phosphorus (red) element distributions in MLO-A5 aggregates from both coated and non-coated suspension cultures 
after 24 hours (I) and 72 hours (II). BSE denotes base, Ca denotes calcium and P denotes phosphorus. Scale bar 
represents 80 µm. 
Quantitatively, the total calcium levels from both MLO-A5 aggregate sizes at 72 hours increased 
from their 24 hour levels; however, only the increase in the large aggregates was significant (t-
test, p = 0.0023) (fig. 3.16). The larger aggregates showed a 2.93 fold increase (95% CI 2.19 – 3.93) 
in calcium levels compared to their smaller aggregate counterparts at the same time point. The 
calcium-to-phosphorus ratio (Ca:P) is also represented (fig. 3.16). At 24 hours, the large and small 
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aggregates had Ca:P ratios of 1.43 and 1.66, respectively. At 72 hours, the ratios had risen to 3.11 
and 3.10 for the large and small aggregates, respectively. The large aggregates saw the most 
significant increase in ratio value, t-test, p = 0.0008 compared to 0.0361. 
 
Figure 3.16: SEM-EDX measurements of MLO-A5 aggregates. Shown is the analysis of 24 hour and 72 hour coated and 
non-coated suspension MLO-A5 aggregates showing the total calcium content represented as a percentage (A). Also 
shown is the SEM-EDX analysis of 24 hour and 72 hour coated and non-coated suspension MLO-A5 aggregates showing 
the calcium and phosphorus contents represented as a ratio (B). 24 denotes 24 hours, 72 denotes 72 hours, CS denotes 
coated suspension culture and NCS denotes non-coated suspension culture. Error bar represents standard error of the 
mean. * signifies p < 0.05, ** signifies p < 0.01, *** signifies p < 0.001 and **** signifies p < 0.0001. 
4. Discussion 
In this study, we established a facile bone cell aggregation model by using a simple and 
convenient surface modification technique to promote the production of different-sized bone cell 
aggregates. We confirmed the acceleration effect of mineral formation in aggregates compared to 
a monolayer culture. Consistent with reports from other groups153,415, our data demonstrated that 
culturing osteoblasts in an aggregate culture generates far more mineralised matrix under 
identical culture conditions, medium and duration, when compared to culturing them in a 
conventional monolayer culture, where little or no mineralised matrix was generated. The 
experimental results revealed that the gene expression of important ECM molecules for bone 
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formation, COL 1, ALP, OPN and OCN, was temporally and spatially regulated, most likely 
influenced by cell – cell/cell – ECM interactions. In addition, the mineral content, composition and 
distribution within the bone cell aggregates depends on the culture substrate used (large 
aggregates formed on the coated substrate versus small aggregates formed on the non-coated 
substrate), evidenced by the histochemical staining, microCT analysis for both in vitro and in vivo 
components of the study, elemental quantification provided by microFTIR and SEM-EDX analyses, 
and phosphate distribution mapping, again provided by microFTIR. We postulate that aggregate 
culturing mimics the endogenous microenvironment, thus supporting osteoblast survival and full 
osteogenic differentiation416. An important effect of the culture substrate was on aggregate size. 
Aggregation pushes osteoblasts from a proliferation phase to a matrix synthesis, or maturation 
and mineralisation phase, whilst aggregate size determines how fast and how far these cells can 
be driven toward matrix mineralisation. Our data suggest that the large aggregates accelerate the 
onset and rate of mineralisation; most likely as a response to the more intense cell – cell contact 
experienced by those cells in the large aggregates compared to those in the small aggregates. 
4.1 Substrate chemistry modification 
Our study shows that altering the chemistry of cell culture substrates is a convenient and efficient 
technique to promote cell aggregation. Multiple aggregates can be formed within just a few hours 
without the requirement of a complicated mould or hanging drop culture. We used two different 
substrates to control aggregate size, i.e. a non-coated polystyrene surface and a Pluronic F127-
coated polystyrene surface7. Pluronic F127 is polypropylene oxide (PPO) – polyethylene oxide 
(PEO) tri-block copolymer with two hydrophilic PEO side chains and a hydrophobic PPO chain in 
the centre417, which endows Pluronic F127 with extremely flexible molecular chains and a high 
capacity to hydration. Coating substrates with F127 greatly suppresses protein adhesion416,417, 
preventing seeded cells from adhering to the substrate and inducing them to form aggregates 
which then remain in suspension. The large aggregates found in the F127-coated plates were 
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ascribed to the higher expulsion forces of F127 for proteins430,431. Our data reveal that aggregate 
size, controlled by substrate chemistry, affected the mineralisation rate. This finding is consistent 
with an earlier study on a spheroid culture system with different cell numbers in each 
aggregate432. In that study, higher cell numbers resulted in larger aggregates that produced higher 
calcium contents, a similar tendency to our results. Our microCT and SEM-EDX data indicate that 
the size of the aggregates may be a critical parameter in controlling mineralisation rate and mass. 
By tailoring the substrate composition, we can generate different-sized aggregates, enabling the 
study of different mineralisation stages. 
4.2 Gene expression 
In vivo bone formation is a prolonged process characterised by a series of reactions with 
osteoblasts playing a pivotal role in all stages. Osteoblasts are derived from osteoprogenitor cells, 
frequently from pluripotent mesenchymal stem cells (MSCs)433. The major role of osteoblasts is to 
produce ECM proteins and to regulate the mineralisation of the matrix. Gene expression patterns 
for these ECM proteins are similar between the in vivo developmental sequence and in vitro 
culture systems9 except for one minor difference. It has been reported that OPN expression is 
slightly different in vivo when compared to in vitro; in vivo levels continue to increase after animal 
birth, whilst in vitro levels decrease when reaching the calcification stage. Nevertheless, 
osteoblast differentiation takes place in sequential steps. The rapid expression of ALP and COL 1 is 
followed by mineralisation9,434 and fibronectin and COL 1 levels are high during proliferation but 
decline during the differentiation stage.  
Lian and Stein434 have depicted the temporal expression of cell growth and osteoblast phenotype 
related genes during a series of monolayer culture experiments and used them to define three 
distinct phases of osteoblast phenotype development eventually leading to bone formation, 
namely: I) proliferation and matrix synthesis, II) matrix development, maturation and 
organisation, and III) matrix mineralisation (fig. 3.17)337,434,435. Interestingly, when we plot the 
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gene expression data from our three cell cultures under different culture durations on the same 
figure, a distinct separation between the aggregates and the monolayer culture method is 
suggested. The monolayer culture specimens appeared to stay in the late proliferation/early 
matrix maturation phase for the first time point tested and for the last two time points remained 
in matrix maturation, not mineralisation. The small aggregates seemed to be in the maturation 
phase for the first two time points and only moved to the mineralisation phase during the third 
time point. In contrast, the large aggregates seemed to be in the mineralisation phase for all three 
time points (fig. 3.17). 
 
Figure 3.17: Prediction of the osteoblast development stages in MLO-A5 aggregates. Shown is the function of culture 
conditions and duration through depicting the temporal gene expression data (fig. 3.6) into the profile of marker gene 
expression produced by Lian and Stein
434
, modification of fig. 4. Three symbols are used for each culture condition to 
represent three time points: 24 hours, 48 hours and 72 hours. 
In this study, the monolayer culture exhibited the highest COL 1 expression for all three time 
points. A high COL 1 gene expression suggests that the monolayer culture specimens were in a 
late proliferation/matrix maturation phase (fig. 3.6)45,434–438. There are two peaks across the two 
phases implying that collagen production lasts for a prolonged period in the development 
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pathway. The large aggregates demonstrated a low expression of COL 1 and ALP suggesting that 
they had left the maturation phase within just 24 hours of culturing and started transferring to 
the mineralisation phase (fig. 3.6). OPN expression in the monolayer culture continuously 
increased, further suggesting that they were in a late proliferation/maturation phase, whilst in 
both aggregate cultures, OPN expression was down-regulated by the 72 hour time point, 
reinforcing the suggestion that these cultures had entered the mineralisation stage (fig. 3.6). OCN 
has been classified as the last of the expression markers to be upregulated in mature 
osteoblasts439. Our OCN expression was similar in all culture specimens, suggesting all had at least 
reached a late osteoblast stage. From our study and those reported by other groups440, it 
becomes clear that monolayer culture of even late osteoblasts under conditions of non-
confluency maintains them in a proliferative state and could not drive them into matrix 
mineralisation for the duration of our experiments (3 days, see also Kato et al.152), whilst 
aggregate culturing can decisively drive this later proliferation/early maturation phase into the 
subsequent mineralisation phase. 
A unique aspect of our study is the ability to finely control the stage of the osteoblast population 
along the osteoblast developmental sequence. If osteoblasts are cultured into aggregates of a 
large size by using a coated substrate, e.g. 500 – 100 µm, they have a high probability of quickly 
passing the late proliferation and maturation phase and entering the matrix mineralisation phase. 
Within such a culture environment, a large portion of the cell population has intense cell – cell 
contact, inhibiting further proliferation and causing a jump to the subsequent phase. In the 
smaller aggregates produced using a non-coated substrate, e.g. 80 – 300 µm, a large proportion of 
the cell population is lacking this intense cell – cell contact, particularly the cells on the periphery 
of the aggregates. These cells, therefore, remain in the matrix maturation phase for a longer 
period before eventually entering the matrix mineralisation phase at 72 hours. Further 
investigation is needed to define more accurately the aggregate size regions and determine which 
developmental phase is reached within a 72 hour culture period. 
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4.3 Mineralisation 
Other outcomes of this study, including protein and mineral productions, support the above 
discussed phase mapping (proliferation, maturation and mineralisation). The histochemical 
staining, SEM-EDX and microFTIR all indicate that the large aggregates contained a higher quantity 
of minerals compared to the small aggregates. 
4.3.1 Histochemical staining 
The presence of minerals associated with bone formation, i.e. calcium and phosphate, was 
confirmed in both aggregate samples, i.e. small and large, after just 24 hours in culture, but not in 
the monolayer culture. This suggests that both aggregate types experienced enhanced 
mineralisation rates compared to their monolayer counterparts, whilst using the same 
supplemented medium and over the same culture period. Numerous previous studies have also 
used similar histochemical stains to confirm the onset of osteogenesis, i.e. ALP staining4, and the 
presence of particular osteogenic-related minerals, i.e. calcium ions (through Alizarin red 
staining)153,386 and phosphate salts (through von Kossa staining)4,152, with the intention of showing 
enhanced osteogenesis and/or mineralisation rates. 
4.3.2 Scanning electron microscopy – energy-dispersive X-ray 
The combination of SEM imaging and EDX analysis accurately displayed the spatial distribution of 
developing calcification evidenced by the regions of calcium and phosphorus deposition which are 
believed to highlight regions of mineralisation. It is the quantitative elemental analysis that 
provided the most interesting data with this technique in the form of Ca:P ratios. In terms of what 
these ratios mean for bone nodule quality, some points of discussion can be raised. On one hand, 
one might consider higher ratios as being beneficial in terms of bone quality given that lower 
bone Ca:P ratios have been associated with bone loss441 and a correlation has also been made 
between collagen fibril diameter and Ca:P ratios; in that, a decreased Ca:P ratio is an indication of 
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a decreased collagen fibril diameter as well as bone loss442. Another aspect to be taken into 
account is that a ratio of 2.19 is typically used as a median reference value443. This value, however, 
is lower than those obtained from a study which found human ribs to contain ratios of 2.31 and 
2.36 for women and men, respectively444. A ratio of < 2 is indicative of a hydroxyapatite (HA) 
dominant environment where bone hardening is occurring, whereas a ratio of > 2 is considered to 
be a calcium oxide (CaO) dominant phase which is indicative of bone formation due to osteoblast 
adhesion445. Whatever the true meaning of these ratios, the levels of calcium and phosphorus 
within both aggregate sizes, which are not evident in the monolayer culture, are promising 
indicators for developing bone but it is noted that further investigation is needed to evaluate the 
true significance of the figures discussed here. 
4.3.3 Fourier transform infrared microspectroscopy 
4.3.3.1 Temporal and spatial mineral distributions 
The data obtained from the microFTIR not only corroborates with the data discussed above but 
also demonstrates that synchrotron-sourced microFTIR is advantageous in revealing dynamic 
mineralisation within immature tissue-engineered bone specimens. It would appear that the PO₄ 
region is very sensitive to the infrared source7. Our data has shown that both culture duration and 
aggregate size can affect the level and spatial distribution of minerals associated with bone 
formation.  Mineral levels increased in conjunction with aggregate size and culture duration. This 
is most likely due to the larger aggregates entering the matrix mineralisation phase earlier and 
staying there for longer during the 72 hour culture period, compared to the smaller aggregates. 
 Interestingly, the mapping images have revealed different mineralisation patterns in the small 
and large aggregates. After 24 hours in culture, the large aggregates showed PO₄ regions 
developing around the outer edges of the aggregate, whilst the small aggregates showed signs of 
mineralisation centred within the aggregate. After 72 hours in culture, both the large and small 
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aggregates displayed substantially increased and uniformly widespread PO₄ distributions. This 
suggests that the large aggregates mineralised from the periphery, whereas the small aggregates 
mineralised from the centre. Peripheral mineralisation was also observed by Schneider and 
colleagues446. These differing regions of initial mineral deposition could possibly be an indication 
of a region within the aggregates where an optimum balance exists between cell – cell and cell – 
matrix interactions and oxygen and nutrient diffusion. Given the size difference between the 
aggregates, these regions of optimum activity are located in different areas of the large and small 
aggregates. 
4.3.3.2 Sample preparation and analysis 
Another benefit to this study was the opportunity to refine sample preparation for use with 
microFTIR. Biological materials are predominantly probed in transmission- or reflection-mode; 
however, sample preparation becomes increasingly important when reflection mode is used 
because the incidence flux is reduced by almost 50%. This is so because the one objective has to 
both direct the beam onto the sample and also collect the reflected beam. Importantly, any 
inhomogeneities within the sample can cause oscillations in the IR spectra which can alter peak 
shapes, intensities, and frequencies412. In the case of this current study, those samples 
microtomed to 5 μm thick sections showed vastly differing inner-specimen thicknesses between 
the more dense mineralised regions and the thinner, non-mineralised regions. In a separate study, 
AFM analysis  showed that even after just 24 hours of culturing, a 5 μm thick section of a large 
aggregate had a thickness range of 0 – 11.8 μm. Over the same culture period, a 5 μm thick 
section of a small aggregate had a thickness range of 0 – 6.7 μm. These data support the belief 
that considerable differences exist between culture method techniques. Given that the S:N ratio 
relies strongly on the collection of the reflected light back to the IR objective, the topography of 
the sample needs to be as smooth as possible. 
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4.4 MLO-A5 aggregate density and material volume 
4.4.1 In vitro aggregates 
Using two different thresholds to calculate material volumes of different densities derived from 
microCT analysis has been used with success in previous studies285,386. Therefore, the current 
study used two thresholds to determine total aggregate volume (lower threshold) and dense 
material volume within the aggregates (higher threshold) for mineralisation analysis (adapted 
from Henstock et al.386). In addition, the volume of dense material was normalised to the total 
material volume in the hope of eliminating any data misinterpretations as a result of scanning the 
non-coated suspension culture aggregates together. Whilst statistical analysis could not be carried 
out for the non-coated suspension samples, the coated suspension samples showed significantly 
increasing levels of dense material as culturing continued. The 72 hour samples had significantly 
higher volumes of dense material per unit volume of total material compared with the 24 and 48 
hour samples, especially the 24 hour samples. The trend for the non-coated suspension aggregate 
samples followed that of the coated suspension culture but without statistical analysis it is 
difficult to determine how relevant this observation actually is. These data correlate with the 
above mentioned data sets confirming that aggregate mineralisation (dense material volume in 
this case) increases as culturing continues over the 72 hour period. 
4.4.2 In vivo aggregates 
 Taking the material volume measurements into account, particularly the normalised volume 
measurements (fig. 3.11), it would appear as though the monolayer samples are not too dissimilar 
from the large aggregate samples. This may be for a number of reasons. Firstly, the monolayer 
samples are considerably more proliferative compared with the aggregate samples. It is, 
therefore, speculated that the control samples proliferated throughout the Neoveil mesh using it 
as a scaffold. Over the duration of the experiment, the once monolayer of cells created a self-
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assembled 3D structure of ECM. It is thought that, whilst very little of this material was actually 
formed, a similar proportion of normalised dense material to that of the large aggregates was 
developed. Secondly, a considerable proportion of the large aggregates disintegrated in vivo; 
thus, significantly reducing the amount of productive samples from this variable. Combined, these 
circumstances are believed to have significantly reduced the gap between the tissue formation 
potential of the monolayer control samples and the large aggregate samples. 
With the initial in vitro investigation concentrating on aggregates being cultured over 72 hours, 
necrosis is not believed to be an issue. Although cell viability is a critical issue in aggregate culture, 
it is difficult to accurately evaluate cell viability within the aggregate centres. However, the 
histochemical staining, SEM analysis and outgrowth capacity (explained in further chapters) of the 
aggregates within this study, both large and small, showed no signs of necrosis or diminished 
osteogenic development within the aggregate centres after 72 hours which would suggest that 
high cell viability was maintained. Differences in cell – cell interactions are, thus, more likely to 
explain the differences in mineralisation levels between the different-sized aggregates of this 
short duration in vitro study447. However, over an 8-week period necrosis may become more of an 
influential factor given the findings of Rouwkema and colleagues who reported that necrosis is 
more prevalent in large aggregates exceeding 200 μm in diameter and who have been cultured 
for more than 7 days323. The small aggregates of both in vitro and in vivo experiments never 
exceeded this critical diameter size; however, the large aggregates of both the in vitro and in vivo 
experiments, in particular the in vitro experiments, did. It could therefore be argued that initial 
bone nodule development or osteoid mineralisation is largely dependent on cell – cell and cell – 
ECM contact but as development continues, oxygen and nutrient deficiency leading to necrosis 
could play a more influential role in determining a critical aggregate size limit. 
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5. Conclusions 
In conclusion, by modifying culture substrates, this study generated a convenient and effective 
model to delineate some of the influential factors leading to mineralisation. Although aggregation 
is accepted to accelerate mineralisation, this study offers an insight into how aggregate size and 
culture duration affect mineralisation and the variation of mineral composition. The findings of 
this study have shown that the small aggregates are significantly more active for matrix synthesis, 
remaining in the early matrix formation phase for longer compared to the large aggregates. In 
comparison, the large aggregates mineralised earlier and became denser than their small 
aggregate counterparts. Additionally, the large aggregates also appeared to mineralise from the 
periphery, whilst the small aggregates mineralised from their centres. Interestingly, this study 
revealed that the effect of aggregate size and culture duration on the concentration of 
mineralising matrix within both in vitro- and in vivo-cultured bone tissue was different. When 
combined with the findings of other studies, it could be suggested that an aggregate size of 200 
µm would offer the optimum level of cell – cell interaction, whilst also maintaining a diffusible 
construct for improved bone formation. 
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Chapter Four       
Identification of 
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Overview 
This study investigated the heterogeneity of mesenchymal stem cells (MSC) isolated from human 
bone marrow mononuclear cells (MNC) and the possibility of donor-dependent heterogeneity 
(subpopulations) that may play a role in determining an individual’s osteogenic capacity. 
Using a substrate with particular characteristics that cannot be divulged at this time due to 
pending intellectual properties, substrate X, a new protocol was developed for the identification 
and isolation of possible subpopulations which encompasses a simple technique allowing the cells 
to self-sort and self-separate into identifiable cellular arrangements. The proportions of these 
specific cellular assemblies are thought to be donor specific and may correspond with an 
individual’s bone formation potential. To investigate this, the quantification of such arrangements 
found within multiple cell populations provided by individual donors was attempted. The 
aggregation potential of several individual MSC populations was also evaluated using the 
aggregation of such cells into bone nodules. An aggregation model developed in a previous 
chapter (chapter 3) was used to assess this aggregation capacity. An in vivo investigation using 
MSCs was also carried out to investigate how aggregate size might influence eventual bone 
formation. The intention was to verify the MLO-A5 aggregate study using different-sized 
aggregates comprised of primary cells. 
1. Introduction 
MSCs possess a number of characteristics that render them a popular choice for research into 
tissue engineering and regenerative medicine, such as their homing ability following systemic 
injection208,209, their non-immunogenic characteristics182 and their ability to release paracrine 
factors thought to protect host cells, encourage cell proliferation and augment angiogenesis179,180. 
It is their extraordinary differentiation capacity that is of particular interest to this study, however. 
It is this capacity that has given rise to the belief that MSCs may contain numerous 
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subpopulations. Unlike haematopoietic and neural stem cells, which typically only generate cells 
of the tissues from which they reside357,358, MSCs have been shown to differentiate into cells of all 
three germ layers, mesodermal, ectodermal and endodermal359–361. It is not entirely clear how 
they perform this feat, however362. 
In an effort to explain this differentiation capacity, it has been suggested that MSCs may contain a 
mixture of phenotypically, biochemically and functionally different cells comprising 
subpopulations211,363,364. A number of adherent cell types have already been shown to exist within 
a population of bone marrow MNCs, i.e. embryonic-like stem cells, lineage-committed progenitor 
cells and mature cells, such as osteoblasts and fibroblasts365–368; so, the prospect that bone 
marrow-derived MSC cultures may contain numerous stem cell types with varying differentiation 
potentials has been put forward369. There are currently two theories on the subject. One 
hypothesis states that MSCs comprise a multitude of different stem cells making up a 
‘pluripotent-like’ cell culture and the other suggests that amongst this multitude of different stem 
cells is a small proportion of true pluripotent stem cells. If a population of true pluripotent stem 
cells does exist within an MSC culture, it has been suggested that their numbers would be very 
small and dependent upon donor, and cell isolation and cultivation methods370,371. Numerous 
attempts have been made to isolate single bone marrow stem cell subpopulations using a variety 
of techniques, such as size sieving372,373, long term culturing under specific conditions367,374,375, 
fluorescence-activated cell sorting (FACS)368,376,377 and counterflow centrifugal elutriation (CCE)369, 
but few have claimed to have actually discovered pluripotent stem cells within bone marrow-
derived MSCs. This study offers an alternate route for the identification of donor-dependent 
subpopulations through specific cellular arrangements alongside the ability to assess an 
individual’s osteogenic potential. MSC subpopulation characterisation and differentiation 
potential has been the focus of numerous studies in the past377,448–450 but none have used the 
specific strategy outlined in this study. This investigation is carried out with specific substrates, i.e. 
a substrate for subpopulation identification (denoted as substrate X) and a Pluronic F127-coated 
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substrate (denoted simply as coated) used to create cellular aggregates. Both substrates are used 
alongside conventional monolayer controls. 
2. Materials and Methods 
Various tables have been used throughout this methods section to highlight the number of MNC 
donors used for MSC isolation, the age and gender information for donors and the various 
analyses each MSC population was subjected to. MSCs isolated from MNCs were the only cells 
used throughout this chapter; however, comparisons are made to data collected using the MLO-
A5 cell line that was presented in the previous chapter, chapter 3, in sections 3.5.1.1 and 3.6.4.1. 
2.1 Mesenchymal stem cell culturing and growth profile monitoring 
Below is a table outlining the age and gender information for eight of the nine MNC donors used 
throughout this study (table 4.1). Additionally, table 4.2 highlights the nine MNC donors and the 
initial analyses carried out on each of their MSC populations. 
Table 4.1: The age and gender of eight of the nine MNC donors used for MSC isolation. Information on the remaining 
donor, D3433B, was not available from the supply company. 
Donor Age Gender 
D3737A 30 M 
D1908B 22 F 
D3741A 37 M 
D3120B 25 F 
D3736A 23 M 
D3549B 29 M 
D3246B 23 M 
D2884D 24 F 
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Table 4.2: MNC donors and initial analyses. Shown is each of the nine MNC donors used for MSC isolation and which of 
them were used for growth profile measurements, substrate X sample counts, subpopulation identification and 
proportion measurements and E-cadherin immunohistochemical staining. Two time points are represented for the 
latter two analyses: 96 and 168 hours. 
MSC Culturing Staining 
Donor Growth Profiles Sample Counts Time Subpopulations E-Cadherin 
D3737A X X 
96 hrs X - 
168 hrs X X 
D1908B X X 
96 hrs X X 
168 hrs X X 
D3741A X X 
96 hrs X X 
168 hrs X - 
D3120B X X 
96 hrs X X 
168 hrs X X 
D3433B X - 
96 hrs X - 
168 hrs X X 
D3736A X X 
96 hrs X - 
168 hrs X - 
D3549B X X 
96 hrs X X 
168 hrs X X 
D3246B X X 
96 hrs X X 
168 hrs - - 
D2884D X X 
96 hrs X X 
168 hrs X X 
 
MSCs were isolated from populations of commercially acquired MNCs (Lonza, Belgium) which 
were acquired from the bone marrow of nine individual human donors (table 4.1). Only donor 
number was recorded and used to identify and track the evaluation of different MSC populations. 
The MSCs were isolated and cultured using protocols described in chapter 2, section 1.2. Both 
culturing and experimental media are described in full. During cell expansion, a basal medium was 
used, chapter 2, section 1.2. The cells were passage three when used for experimenting, passage 
four for tri-lineage differentiation and passage five for flow cytometry analysis.  
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Detailed records were kept during the culturing phase of this study taking into account the 
number of days between each time a cell population reached 80% confluency. This gave rise to 
growth profiles which could then be used to compare growth rates between each donor. 
2.2 Subpopulation identification and quantification 
Possible subpopulations were identified for each MSC population obtained from the donors 
outlined in table 4.1 using a minimum of three samples per time point. During the subpopulation 
identification process, an osteogenic-supplemented medium was used, chapter 2, section 1.4.3. 
MSCs were seeded onto substrate X as described in chapter 2, section 4.2. They were then 
allowed to self-sort and form specific cellular arrangements for up to 7 days. These cellular 
arrangements were optically imaged using software and equipment outlined in chapter 2, section 
9.1. Identification and quantification of the cellular arrangements was made from optical images 
as explained in chapter 2, section 11. Quantification was carried out using a minimum of three 
images per MSC population per time point. The substrate X samples were terminated after 4 (96 
hours) and 7 days (168 hours). Termination involved fixing in situ with an appropriate fixative. 
Those samples intended for alkaline phosphatase (ALP) staining were fixed with 4% 
paraformaldehyde (PFA) for 2 minutes, those intended for all other histochemical and 
immunohistochemical staining were fixed with formalin for 20 minutes. 
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2.3 Aggregate formation 
Table 4.3: MNC donors and MSC aggregation assessment. A table showing each of the MNC donors used for MSC 
isolation and which were then used for aggregation. Also shown are those samples that were used for aggregate size 
and aspect ratio measurements alongside those that were used for microCT scanning. Two culture durations are 
represented: 96 and 168 hours. 
MSC Aggregation 
Donor Time Size Aspect Ratio MicroCT 
D3737A 
96 hrs X X - 
168 hrs X X X 
D1908B 
96 hrs X X - 
168 hrs X X X 
D3741A 168 hrs - - X 
D3120B 
96 hrs X X - 
168 hrs X X X 
D3433B 
96 hrs X X - 
168 hrs X X X 
D3736A 
96 hrs X X - 
168 hrs X X X 
D3549B 
96 hrs X X - 
168 hrs X X X 
D3246B 168 hrs - - X 
D2884D 
96 hrs X X - 
168 hrs X X X 
 
A minimum of three aggregates were formed from each MSC population outlined in table 4.2, per 
time point. During the MSC aggregation process, an osteogenic-supplemented medium was used, 
chapter 2, section 1.4.3. Aggregation was used to evaluate donor-dependent variabilities and 
followed the same principals outlined in the MLO-A5 study (chapter 3). The technique used for 
aggregate formation, the F127-coated suspension culture, is explained in detail in chapter 2, 
section 4.1.1. Cells were seeded at a density of 3 x 105 cells per well in 1 ml osteogenic-
supplemented medium and were cultured for 4 days (96 hours) and 7 days (168 hours). Culture 
medium was not changed throughout this culture period. The samples were terminated in the 
128 
 
same way as the substrate X samples described in the previous section. The only difference being, 
the aggregates were not fixed in situ but were first transferred to micro-centrifuge tubes. Once 
fixed, the aggregate samples were stored in phosphate buffer saline (PBS) at 4 °C (except for 
those intended for ALP staining which were processed immediately). 
2.4 Aggregate measurements 
The aggregates were imaged via optical microscopy (chapter 2, section 9.1). Measurements were 
taken from a minimum of three separate samples per variable to give aggregate size and aspect 
ratio values as discussed in chapter 2, section 10. 
2.5 Histology 
Table 4.4: MNC donors and aggregate analyses. A table showing each of the MNC donors used for MSC isolation and 
which MSC populations were then subjected to histochemical staining. Both subpopulation and aggregate section 
staining are represented with two time points: 96 and 168 hours. 
Subpopulation Staining Aggregate Staining 
Donor Time ALP Alizarin Red von Kossa ALP Alizarin Red von Kossa 
D3737A 
96 hrs X X X - X - 
168 hrs X X X - X X 
D1908B 
96 hrs X X X X X - 
168 hrs X X X X X X 
D3120B 
96 hrs - - - - X X 
168 hrs - - - - X X 
D3736A 
96 hrs X X X X X X 
168 hrs X X X X X X 
D3549B 
96 hrs X X X X X - 
168 hrs X X X X X X 
D3246B 
96 hrs - - - X X X 
168 hrs - - - X X - 
D2884D 
96 hrs X X X X X X 
168 hrs X X X X X X 
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Histochemical staining was carried out on a minimum of two separate samples per variable. 
Staining was carried out for the identification of markers associated with osteogenic 
differentiation and mineralisation. All samples used for subpopulation evaluation were stained in 
situ, whilst most, but not all, aggregate samples used for osteogenic evaluation were 
cryosectioned prior to staining. Those aggregates intended for ALP staining were not 
cryosectioned prior to staining. 
2.5.1 Alkaline phosphatase staining 
ALP staining for subpopulation evaluation was carried out in situ at the time of termination 
because ALP activity is very sensitive and diminishes quickly after fixation. The aggregates stained 
for ALP activity too were stained immediately upon fixation and so were stained whole (without 
sectioning) in micro-centrifuge tubes. A full protocol outlining the procedures used is described in 
chapter 2, section 12.2. The stained aggregates were placed onto standard glass slides and 
imaged immediately post-staining. 
2.5.2 Alizarin red staining 
Alizarin red staining was used for the identification of calcium, thus, indicating the presence of 
minerals. This staining, for subpopulation evaluation, was carried out in situ following the 
protocol outlined in chapter 2, section 12.3. Aggregate samples stained for Alizarin red were 
cryosectioned prior to staining following the protocol outlined in chapter 2, section 8.3. Staining 
of the aggregate sections then followed the protocol outlined in chapter 2, section 12.3. 
2.5.3 von Kossa staining 
von Kossa staining was used to identify the presence of phosphate salts, again indicating the 
presence of minerals. For subpopulation evaluation, staining was carried out in situ following the 
protocol outlined in chapter 2, section 12.4. Aggregate samples stained for von Kossa were 
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cryosectioned prior to staining following the protocol outlined in chapter 2, section 8.3. Staining 
of the aggregate sections then followed the protocol outlined in chapter 2, section 12.4. 
2.6 E-cadherin staining 
E-cadherin staining was used to evaluate the cadherin levels of the cellular subpopulations and to 
compare them between multiple donors. The staining was carried out using the manufacturer’s 
protocols outlined in chapter 2, section 13.2. Samples from multiple donors over two culture time 
points, 96 hours and 168 hours, were selected. Epifluorescent imaging and the quantification of 
fluorescence intensity followed the protocols described in chapter 2, section 9.2. 
2.7 Flow cytometry 
Table 4.5: MNC donors and MSC validation. A table showing each of the MNC donors used for MSC isolation and which 
donors were subjected for flow cytometry and tri-lineage differentiation. 
Flow cytometry Tri-Lineage 
Donor All Antibodies CD324 Alizarin Red Alcian Blue Oil Red O 
D3737A X X X X X 
D1908B X X X X X 
D3741A X X X X X 
D3120B X - X X X 
D3433B X X X X X 
D3736A X X X X X 
D3549B X X X X X 
D3246B X X X X X 
D2884D X X X X X 
 
Flow cytometry was used to test for the presence of multiple surface markers to confirm the use 
of MSCs. Three positive markers (CD73, CD90 and CD105) and five negative markers (CD14, CD19, 
CD34, CD45 and HLA) were evaluated. An additional surface marker (CD324) was used with the 
intention of quantifying the levels of E-cadherin within multiple donor samples. Flow cytometry 
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was carried out on nine donors (passage five) and analysed using the protocols outlined in 
chapter 2, section 18. 
2.8 Tri-lineage differentiation 
Tri-lineage differentiation was intended to confirm the use of MSCs through positive 
differentiation down multiple lineages: adipogenic, chondrogenic and osteogenic. A minimum of 
three separate samples were used per variable. The MSCs used were passage four. Each lineage 
required particular supplementation; therefore, all three media are described in chapter 2, 
section 1.4. MSC culturing for differentiation is explained in chapter 2, section 2.1. The same 
methods were used for all three lineages and all donors tested. To confirm positive 
differentiation, the cells were optically imaged, histochemically-stained and imaged again, as 
described in chapter 2, section 2.2. Each differentiation required a different stain, the protocols 
for which can be found in chapter 2, section 12. 
2.9 Microcomputerised tomography of in vitro aggregates 
Microcomputerised tomography (microCT/μCT) was intended to compare the aggregate volumes 
and densities of multiple donor samples. A minimum of three samples per variable were scanned. 
Scanning was carried out on the aggregates of numerous donors after 168 hours in culture (table 
4.2) using the protocol discussed in chapter 2, section 15.1.2. Two thresholds were used for the 
analysis, 110 and 130. The first, 110, was chosen to represent the volume of dense collagenous 
material within the aggregates; the second, 130, was chosen because this was the highest 
threshold where all of the samples scanned still registered a volume measurement. 
2.10 In vivo investigation 
An in vivo study was carried out to demonstrate how different-sized aggregates from a single 
donor (D3591A – selected at random) react to long term in vivo culturing. A monolayer control 
seeded on a Neoveil mesh was used as a control for comparative purposes. The intention of this 
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element of the study was to confirm the observations made during the MLO-A5 in vivo study 
(chapter 3). 
2.10.1 Diffusion chamber construction, seeding, implantation and termination 
A complete protocol for the in vivo experiment is described in chapter 2, section 5. Five separate 
samples were used per variable. 
2.10.2 Optical imaging 
Optical imaging was used to monitor chamber integrity post-implantation, possible engraftment 
and contents immediately following in vivo experiment termination and sample fixation. 
Equipment and software used are outlined in chapter 2, section 9.1. 
2.10.3 Microcomputerised tomography of the in vivo diffusion chambers 
MicroCT scanning followed the protocols outlined in chapter 2, section 15.2. The samples were 
scanned whilst still in their chambers so as not to disturb any of the material that had formed 
over the course of the experiment. All five samples per variable were scanned in this way. To 
maintain consistency with the MLO-A5 in vivo study, a threshold of 110 was used to show the 
total volume of material within each of the chambers and a threshold of 170 was used to show 
the volume of dense material within each of the chambers. 
2.11 Statistical analysis 
Sample groups were compared using independent t-tests alongside one-way and two-way 
analysis of variance (ANOVA). A p-value below 0.05 was taken to indicate statistical significance. 
Graphically, statistical significance is indicated at four levels: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
and **** p ≤ 0.0001. 
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3. Results 
The MNCs from the bone marrow of nine individual donors were used for various experiments 
throughout this study. The cells were commercially acquired and labelled with donor numbers for 
identification (e.g. D1908B) prior to our procurement. Those same donor numbers were used 
throughout this study to track the specific MSC populations as investigations continued. 
3.1 Stemness verification 
The cell populations of nine donors were evaluated for stemness verification through the use of 
flow cytometry and tri-lineage differentiation. 
3.1.1 Flow cytometry 
Nine surface markers were measured in each of the nine donor cell populations evaluated for 
stemness using flow cytometry: three positive (CD73, CD90 and CD105), five negative (CD14, 
CD19, CD34, CD45 and HLA) and one additional marker explained later (CD324) (table 4.4 and 
4.5). 
Table 4.6: MSC flow cytometry data. Shown is the percentage of positive events from nine MSC populations. Eight 
markers are represented: three positive (the first three rows) and five negative (the remaining five rows). 
Marker D3737A D1908B D3741A D3120B D3433B D3736A D3549B D3246B D2884D 
CD73 89.31 86.36 92.17 96.59 52.05 46.03 60.53 75.35 62.55 
CD90 9.86 8.65 51.24 16.99 44.36 3.71 9.72 7.52 9.38 
CD105 17.92 35.85 18.15 70.49 15.22 17.16 39.73 13.69 9.57 
CD14 6.16 3.32 13.22 5.96 7.68 5.9 63.44 5.33 6.47 
CD19 7.5 9.07 5.01 5.12 5.24 5.67 3.18 5.02 3.94 
CD34 5.21 4.5 5.97 4.8 5.71 4.74 19.14 4.13 3.85 
CD45 6.23 3.46 5.03 4.19 5.28 4.72 5.61 4.34 3.97 
HLA 5.79 4.67 5.55 13.85 5.6 8.37 61.41 4.45 5.25 
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Fig. 4.1 shows the flow cytometry Overlay Histogram Plots of each surface marker with their 
particular isotype control. Each donor cell population depicted in this figure was selected to 
represent a particular marker because it most closely represents the average (mean ± standard 
error of the mean) percentage of positive events amongst all cell populations evaluated. 
 
Figure 4.1: MSC flow cytometry Histograms. Shown are the Overlay Histograms of eight surface markers and their 
respective isotype controls: CD73, CD90, CD105, CD14, CD19, CD34, CD45 and HLA, alongside IgG1 and IgG2. 
3.1.2 Tri-lineage differentiation 
Nine separate cell populations were evaluated for stemness capacity through their ability to 
differentiate down three separate lineages, i.e. adipogenesis, chondrogenesis and osteogenesis. 
All nine cell populations were positively confirmed as having differentiated down all three 
lineages. Fig. 4.2 shows examples of the different cellular morphologies resulting from the 
differentiation processes alongside examples of positive staining used to confirm differentiation. 
Oil red O staining was used to confirm adipogenesis, Alcian blue staining was used to confirm 
chondrogenesis and Alizarin red staining was used to confirm osteogenesis. 
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Figure 4.2: MSC tri-lineage differentiation. Optical images showing three different MSC morphologies following 30 days 
of culturing under three different differentiation conditions: adipogenesis (A), chondrogenesis (B) and osteogenesis (C). 
Also shown are the stains used to confirm differentiation: Oil red O to confirm adipogenesis (D), Alcian blue to confirm 
chondrogenesis (E) and Alizarin red to confirm osteogenesis (F). Scale bar represents 400 μm. 
3.1.2.1 Adipogenesis 
Morphologically, those cells encouraged down an adipogenic lineage now comprised clearly 
visible globules. The presence of such globules was confirmed with the use of Oil red O staining 
(fig. 4.2). Subsequently, the presence of such globules confirms differentiation down the 
adipogenic lineage. 
3.1.2.2 Chondrogenesis 
Fig. 4.2 shows the MSCs with a more fibroblastic morphology and increased extracellular matrix 
(ECM) production post-chondrogenic differentiation. Alcian blue staining confirmed the presence 
of ECM proteins associated with cartilage (fig. 4.2), thus, confirming differentiation down the 
chondrogenic lineage. 
  
A B C 
F E D 
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3.1.2.3 Osteogenesis 
Osteogenic differentiation was apparent because the presence of dark mineral deposits post-
differentiation (fig. 4.2). Alizarin red staining confirmed the presence of calcium ions which in turn 
confirmed the onset of mineralisation and, thus, differentiation down the osteogenic lineage (fig. 
4.2). 
3.2 Cell population heterogeneity 
3.2.1 Mesenchymal stem cell isolation and expansion 
Prior to any subpopulation experimentation being carried out, a sufficient cell number/population 
had to be acquired. This resulted in the cells being expanded to 16 x T75 flasks at passage two. 
Additionally, this expansion stage allowed for further cell heterogeneity assessment through the 
monitoring of proliferation profiles and cell morphologies. 
3.2.1.1 Initial mesenchymal stem cell attachment and culturing 
An example of the initial MSC isolation through attachment of two donor cell populations is 
documented showing differences in terms of cell number relative to culture duration (fig. 4.3). At 
given time points, i.e. 7 or 14 days, the faster proliferating cells resulted in higher cell numbers 
which subsequently led to the formation of larger colonies at said time points.  It was also noted 
immediately prior to the use of each MSC population that cellular morphology and size differed 
considerably between each population. Those cells that were slower to proliferate remained in 
culture for longer and so were larger and more fibroblastic in shape compared to the faster 
proliferating cells which were smaller and more elongated in shape. These differences did not 
become apparent until the cells were in their second passage. Fig. 4.4 shows cells from two 
donors, one fast proliferating and one slow proliferating, over three time points, 7 days, 14 days 
and 21 days, at passage three. 
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Figure 4.3: Initial MSC attachment. Optical images showing initial MSC attachment from two donors, D3737A and 
D2884D, after 14 days in culture. Scale bar represents 400 μm. 
 
Figure 4.4: MSC culturing over time. Optical images showing MSCs from two donors covering three time points, 7 days, 
14 days and 21 days, at passage three. The images show different cell morphologies, with D3246B (the slower 
proliferating cell population) having a larger and more fibroblastic cell size and shape. Scale bar represents 400 μm. 
3.2.1.2 Growth profiles 
The growth profiles of the MSCs over three passages (0 – 2) are shown in fig. 4.5. The total culture 
time in days ranged from 33 to 64 days. Whilst differences could be seen over the three passages, 
the largest culture time gap was between passages one and two where culture duration ranged 
from 5 to 35 days (fig. 4.5). 
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In addition, the growth profiles affected the number of available cells for use in each experiment 
(fig. 4.5). As noted, a decreased growth rate was observed to correspond with an increase in cell 
size. This subsequently meant that, whilst all of the MSC populations were cultured to 80% 
confluency, passage two, before being used in each experiment, available cell numbers differed 
between each population. The faster proliferating cells produced approximately 16 x 10⁶ cells in 
total, whilst the slower proliferating cells produced approximately 12 x 10⁶ cells in total, a 25% 
decrease. This decrease in cell numbers resulted in a subsequent decrease in substrate X sample 
numbers (fig. 4.5). 
 
Figure 4.5:  Quantitative growth profile data from MSC culturing. Growth profiles (A) of individual donors from initial 
MNC seeding and MSC isolation (revival) through to use in subpopulation experiments (passage three). Also shown is 
the total culture duration correlating to the total substrate X sample number acquired (B). Growth profile refers to the 
time required by each cell population to reach 80% confluency following each treatment/passage (passage 0 covers 
culture duration from MSC isolation through to 80% confluency, passage 1 covers first passage to 80% confluency and 
passage 2 covers second passage to 80% confluency). Total culture duration refers to the length of time (in days) 
required to culture an MSC population from initial isolation to 16 x T75 flasks at 80% confluency. Substrate X sample 
number refers to the number of samples acquired from each donor using substrate X and is used to convey cell 
numbers. 
 
 
139 
 
 
3.2.2 Subpopulation separation and identification 
Once the appropriate cell number/population had been acquired (16 x T75 flasks at 80% 
confluency), the next phase was to seed the cells on substrate X for subpopulation separation and 
identification. Tissue culture polystyrene (TCP) was also used alongside substrate X for control 
purposes. The cells were cultured on both substrates, substrate X and TCP, and terminated after 
96 hours and 168 hours. 
3.2.2.1 Attachment arrangements 
Nine donor cell populations were identified as having multiple subpopulations through differing 
attachment arrangements (fig. 4.6). Under TCP control culture conditions, little difference could 
be seen in terms of cellular arrangements between any of the cell populations examined over 
both time points. A considerable difference, however, could be seen with cellular arrangements 
between each of the donors after just hours under substrate X culture conditions. Three distinct 
cellular arrangements became apparent within each donor MSC population examined under the 
same culture conditions: a monolayer arrangement, a sunflower-like arrangement and an 
aggregate-like arrangement (fig. 4.6). 
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Figure 4.6:  MSC attachment arrangements on substrate X. Optical images showing how the MSCs from each donor 
reacted to substrate X. The images were taken after 96 hours in culture with osteogenic-supplemented medium. Scale 
bar represents 400 µm. The three images on the bottom row labelled 1 – 3 represent magnified examples of three 
subpopulations highlighted by black squares in the upper three rows of images: a sunflower-like arrangement (1), an 
aggregate-like arrangement (2) and a monolayer arrangement (3). 
In addition, the proportions of each subpopulation were measured within each of the MSC 
populations assessed (fig. 4.7). An aggregate-like arrangement was the rarest with only three of 
the eight populations showing this arrangement. The donors are also arranged in order of 
ascending growth profiles, i.e. the fastest proliferating population to the front and slowest to the 
back. 
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Figure 4.7:  Quantitative data showing donor variations in subpopulation proportions. The subpopulation proportions of 
each donor are represented as a percentage of total cell population. Three subpopulations correspond to three cellular 
arrangements: sunflower, monolayer and aggregate. 
3.2.2.2 E-cadherin 
In addition to the morphological assessment identifying three distinct subpopulations, E-cadherin 
was measured from two different angles to confirm the presence of subpopulations and to 
explain why the subpopulations are identifiable on substrate X. E-cadherin staining was carried 
out on multiple substrate X cell samples after 96 hours and 168 hours in culture (fig. 4.8 and 4.9, 
respectively). After just 96 hours, clear differences could be seen with the stain intensity 
depending upon the arrangement of the cells. Those cells with a more monolayer or featureless 
cellular arrangement were poorly stained (D2884D for example), whilst those with a more 
sunflower-like or aggregated arrangement were stained more positively (D3120B for example). 
Fluorescence intensity was also measured giving figures of 9.101 and 21.412 for D2884D and 
D3120B, respectively (fig. 4.10). This trend continued for those samples stained after 168 hours in 
culture albeit with slightly less dramatic differences between donors. Fluorescence intensity 
ranged from 9.101 – 21.412 at 96 hours and 23.12 – 36.849 at 168 hours. That is a 235% 
difference in comparison to a 159% difference, respectively. 
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Figure 4.8: Subpopulations immunohistochemically stained for E-cadherin. Epifluorescent images showing E-cadherin 
staining carried out on MSCs which were cultured on substrate X for 96 hours. Red colouration indicates positive 
staining for E-cadherin. Scale bar represents 250 μm. 
 
Figure 4.9: Subpopulations immunohistochemically stained for E-cadherin. Brightfield and corresponding epifluorescent 
images showing E-cadherin staining carried out on MSCs which were cultured on substrate X for 168 hours. Red 
colouration indicates positive staining for E-cadherin. Brightfield images scale bar represents 400 μm, fluorescent 
images scale bar represents 250 μm. 
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Figure 4.10: Quantitative data derived from E-cadherin staining. Fluorescence intensity of E-cadherin staining carried 
out on MSCs cultured on substrate X. Samples were culture for 96 hours (A) and 168 hours (B). Error bar represents 
standard error of the mean. * signifies p < 0.05, ** signifies p < 0.01 and *** signifies p < 0.001. 
In addition to fluorescently staining and measuring the intensity of such fluorescence on cell 
samples cultured on substrate X, donor cells were assessed for E-cadherin using flow cytometry 
(fig. 4.11). In conjunction with the eight markers being assessed for stemness verification, one 
additional marker was also measured, CD324 (E-cadherin). CD324 levels were evaluated for eight 
cell populations and with levels of positive events ranging from 0.69% to 10.29% (fig. 4.11); this 
corroborates previous findings suggesting the populations of MSCs have measurable levels of 
heterogeneity. 
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Figure 4.11: Flow cytometry data showing CD324 (E-cadherin) analysis on multiple MSC populations. Represented are 
the IgG1 control and CD324 antibody Histograms alongside an Overlay Histogram. Also shown is a chart demonstrating 
the percentage of CD324 positive events within MSC populations acquired from multiple donors. 
3.3 Subpopulation osteogenic capacity evaluation 
Alongside identifying possible subpopulations, the osteogenic capacity of such was also assessed. 
This was carried out through the histochemical staining of cell samples cultured on substrate X in 
the hope of identifying differing levels of markers associated with osteogenic potential. 
3.3.1 Histology 
Histochemical staining has shown that all three subpopulations achieved different osteogenic and 
mineralisation levels under the same culture conditions and over the same culture period (fig. 
4.12 and 4.13). 
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3.3.1.1 Alkaline phosphatase staining 
After just 96 hours in culture, ALP staining was strongest in the samples with more self-organising 
cellular arrangements, i.e. sunflower-like or aggregate-like arranged cells (fig. 4.12). Whilst 
positive staining was seen in a number of control and monolayer dominant cultures, it is the 
substrate X cultures containing obvious sunflower-like or aggregate-like cellular arrangements 
that were stained most vividly.  
After 168 hours in culture, the same trait was observed as with the 96 hour samples (fig. 4.13). 
Also, after 168 hours, those samples with the highest cellular mass appeared to become loosened 
and/or lift from substrate X during the fixing and staining process. These more organised cellular 
arrangements stained more positively than their monolayer-arranged and/or control 
counterparts. 
3.3.1.2 Alizarin red staining 
As was the case with the ALP staining, substrate X cultures with a higher degree of cellular 
arrangement stained more positively for Alizarin red compared to their monolayer counterparts 
at both 96 and 168 hours culturing (fig. 4.12 and 4.13, respectively). 
3.3.1.3 von Kossa staining 
von Kossa staining correlates well with the observations noted during Alizarin red staining (fig. 
4.12 and 4.13, respectively). The more organised cellular arrangements again stained more 
positively compared to their monolayer-like or monolayer control counterparts for both time 
points tested. 
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Figure 4.12:  Histochemical staining of MSCs seeded on substrate X. Optical images of ALP, Alizarin red and von Kossa 
staining carried out on MSCs acquired from multiple donors cultured on substrate X for 96 hours. Positive staining for 
ALP and Alizarin red is indicated with red colouration and positive staining for von Kossa is indicated with brown to 
black colouration. Red scale bar represents 150 μm, black scale bar represents 400 μm. 
 
Figure 4.13: Histochemical staining of MSCs seeded on substrate X. Optical images of ALP, Alizarin red and von Kossa 
staining carried out on MSCs acquired from multiple donors cultured on substrate X for 168 hours. Positive staining for 
ALP and Alizarin red is indicated with red colouration and positive staining for von Kossa is indicated with brown to 
black colouration. Red scale bar represents 150 μm, black scale bar represents 400 μm. 
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3.4 Donor-dependent variability 
Given that multiple subpopulations have been identified from individual MSC donors 
corroborating the long-held theory that MSC populations are heterogeneous and that each of the 
three subpopulations have been shown to hold differing osteogenic potentials, logic would 
dictate that varying subpopulation proportions between the MSC populations of different donors 
would result in varying osteogenic capacities between those different donors. Of the nine MSC 
populations (donors) cultured, four underwent sufficient analyses allowing for growth profile 
assessment, subpopulation separation and identification, and subsequent subpopulation 
osteogenic assessment. These four MSC populations all came from individual donors allowing for 
the assessment of possible donor-dependent variabilities. The four donors were not purposefully 
selected. Additional donors would have been used ideally but time and sample constraints have 
restricted our comparisons to four. 
3.4.1 Culture duration, osteogenic markers, cell size and E-cadherin levels 
Each of the donors had different proliferation rates and subsequent culture durations. This 
resulted in a cell culture duration ranging from 36 to 64 days, a 78% difference between the 
slowest (D2884D) and fastest (D3737A) proliferating cells. 
In terms of osteogenic markers, the faster proliferating cell population provided by D3737A 
displayed a higher affinity to histochemical staining when compared to the slower proliferating 
cell population provided by D2884D (fig. 4.12 and 4.13). D3737A exhibited more positive staining 
for all three markers assessed, i.e. ALP, calcium ions (Alizarin red) and phosphate (von Kossa), 
when compared to D2884D. This suggests that D3737A had a higher capacity for osteogenic 
differentiation compared with D2884D. Both cell populations provided by D1908B and D3549B 
again provided similar histochemical staining results for all three markers. 
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These differing proliferation rates also resulted in varying sample number availability as a result of 
differing cell sizes. D2884D for example, provided 33 samples cultured on substrate X, whilst 
D3737A provided 74; that is more than a 120% increase, indicating a considerable difference in 
cell size resulting from expansion duration. The other two cell populations provided by D1908B 
and D3549B, which have fast and moderate cell growth profiles, respectively, provided similar 
substrate X sample numbers, 48 and 53, respectively, indicating a similar cell size post-expansion 
(fig. 4.14). 
The proportions of the subpopulations within each cell population cultured on substrate X has 
also been quantified for each of the four donors (fig. 4.14). The fastest proliferating cell 
population (D3737A) displayed the highest proportion of self-organising cellular arrangements, 
most notably the aggregate-like-arranged cells, whilst the slowest proliferating cell population 
(D2884D) displayed the lowest proportion of self-organising cellular arrangements with no 
aggregate-like cellular arrangements at all. D2884D consisted mainly of monolayer-arranged cells. 
The cells provided by D1908B had the highest proportion of sunflower-like-arranged cells with a 
small fraction of aggregate-like-arranged cells, whilst the cells provided by D3549B had no 
aggregate-like-arranged cells but an almost even mix of sunflower-like-arranged cells and 
monolayer-arranged cells. 
In parallel, E-cadherin levels determined via fluorescence intensity post-substrate X culturing was 
also used to compare all four donors (fig. 4.14). After 168 hours in culture, the cells provided by 
D3737A displayed the highest fluorescence intensity, 36.849, indicating the highest presence of E-
cadherin, whilst the cells provided by D2884D displayed the lowest fluorescence intensity, 23.115, 
indicating the lowest E-cadherin levels amongst the four donors evaluated. Both cell populations 
provided by D1908B and D3549B again displayed very similar levels of fluorescence intensity, 
26.525 and 26.675, respectively. These data strongly corroborate previously noted observations 
suggesting that the faster proliferating cells, D3737A for example, contained a higher proportion 
149 
 
of subpopulations with a higher degree of self-organising once cultured on substrate X when 
compared to the slower proliferating cells, D2884D for example. 
 
Figure 4.14: Various correlations derived from MSC culturing, substrate X seeding and immunohistochemical staining. 
Shown are the correlations between MSC culture duration and substrate X sample number (A), culture duration and 
subpopulation proportions (B) and culture duration and E-cadherin fluorescence intensity levels from substrate X 
samples cultured for 168 hours (C). MSC populations from four individual donors contributed to these data sets. Error 
bar represents standard error of the mean. 
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3.5 Cellular aggregation and osteogenic potential 
Using a previously developed aggregation technique, an F127-coated suspension culture 
substrate, the MSCs from multiple individual donors were aggregated and assessed for donor-
dependent variabilities. This phase of the study intended to show that individual donors possess 
different aggregation capabilities. 
3.5.1 Aggregate size and morphology 
 
Figure 4.15: MSC aggregates from numerous donors. Optical images showing the aggregates formed using MSCs from 
multiple donors over two time points: 96 and 168 hours. Scale bar represents 400 μm. 
The aggregates were optically imaged (fig. 4.15) and dimensions measured over two time points, 
96 and 168 hours (fig. 4.16 and 4.17, respectively). Significant differences could be seen between 
aggregate sizes over both time points between multiple donors especially after just 96 hours in 
culture. After 96 hours of culturing, the aggregates ranged from 370 μm to 820 μm 
151 
 
approximately, a 120% difference. After 168 hours of culturing, the aggregates ranged from 465 
μm to 985 μm approximately, a 112% difference (fig. 4.16). The aspect ratios of the aggregates 
are also shown in fig. 4.17. After 96 hours in culture, the aspect ratios ranged from 1.08 – 2.14 
and after 168 hours, the aspect ratios dropped to a range of 1.02 – 2.02. 
 
Figure 4.16: MSC aggregate size measurements. Values cover two time points, 96 hours (A) and 168 hours (B), and the 
average (mean) aggregate size from both time points (C). Error bar represents standard error of the mean.        * 
signifies p < 0.05, ** signifies p < 0.01 and *** signifies p < 0.001. 
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Figure 4.17: MSC aggregate aspect ratio measurements. Shown are the aspect ratios of multiple MSC aggregates over 
two time points: 96 hours (A) and 168 hours (B). Also shown are the average (mean) aggregate aspect ratio 
measurements from both time points (C). A value of 1 represents a perfect circle with circularity decreasing with 
increasing values. Error bar represents standard error of the mean. * signifies p < 0.05 and ** signifies p < 0.01. 
In addition, aggregate size has been correlated with E-cadherin fluorescence intensity levels (fig. 
4.18). Whilst just five donor cell populations underwent both aggregation and E-cadherin 
immunohistochemical staining, a strong correlation appears to exist between both data sets with 
the smaller aggregates having the highest E-cadherin levels and the larger aggregates having the 
lowest E-cadherin levels (two-way ANOVA, p < 0.0001). 
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Figure 4.18: E-cadherin fluorescence intensity levels compared with aggregate size. Samples were cultured for 168 
hours (two-way ANOVA, p < 0.0001). Error bar represents standard error of the mean. 
3.5.1.1 Aggregate circularity and cell source 
As an interesting observation, comparisons between cell sources can be made at this point. In 
terms of  the average (mean ± standard error of the mean) aggregate circularity, as determined by 
aspect ratio measurements, the fastest proliferating MSC population, D3737A, the slowest 
proliferating MSC population, D2884D, and the MLO-A5 cell line were compared (fig. 4.19 and 
4.20). Neither of the MSC aggregates differed significantly from one another; however, the faster 
proliferating MSC population, D3737A, did differ from the MLO-A5 cell line (t-test, p = 0.0441). 
The slower proliferating MSC population, D2884D, did not (fig. 4.20). 
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Figure 4.19: Comparisons between MSC and MLO-A5 aggregates. Optical images showing cellular aggregates formed on 
the F127-coated suspension substrate. The left and centre images show aggregates produced from two MSC 
populations acquired from two different donors: one fast proliferating (D3737A) and one slow proliferating (D2884D). 
The image on the right shows an aggregate produced from the MLO-A5 cell line. Both MSC aggregates were imaged 
after 96 hours in culture and the MLO-A5 aggregate was imaged after 72 hours in culture. Scale bar represents 400 μm. 
 
Figure 4.20: Aggregate measurements comparing MSC and MLO-A5 aggregates. A graph showing the average (mean) 
aspect ratios of the aggregates formed from both MSC populations and the MLO-A5 cell line. The measurements were 
taken from the MSC aggregates after 96 hours in culture and the MLO-A5 aggregates after 72 hours in culture. Error bar 
represents standard error of the mean. * signifies p < 0.05. 
In addition, the standard error of the mean aggregate aspect ratio also differed in areas. If we 
take the standard error of the mean as being an indication of the variation from average (mean), 
the slower proliferating MSCs, D2884D, had a significantly higher variation compared to the faster 
proliferating MSCs, D3737A, (f-test, p = 0.0008) but did not differ from the MLO-A5 cell line. The 
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MLO-A5 cell line was also seen to have a significantly higher standard error of the mean 
compared to the faster proliferating MSCs, D3737A, (f-test, p = 0.0082). These observations are 
discussed in chapter 6. 
3.5.2 Histology 
Histochemical staining was also carried out on the aggregates obtained from multiple donors to 
assess possible osteogenic potential. The aggregates were sectioned prior to staining. Both 
Alizarin red and von Kossa stains confirmed the presence of minerals associated with bone 
formation after just 96 hours of culturing.  
In addition, the levels of such minerals differed between donors. After 168 hours of culturing, 
both Alizarin red and von Kossa staining was stronger than that noted in the 96 hour samples. 
Aggregate integrity was also noted to differ between donors during histological processing. Those 
aggregates that stained more positively for Alizarin red and von Kossa appeared to better 
maintain their aggregate structures whilst being sectioned. This meant that after 96 hours, the 
majority of the aggregates sectioned lost their aggregate shape and structure, whereas after 168 
hours, the majority of the aggregates sectioned maintained their aggregate shape and structure. 
3.5.2.1 Alizarin red staining 
Aggregate sections stained for Alizarin red showed differences between donor aggregates after 
just 96 hours (fig. 4.21). Clear differences can be seen between aggregate samples in terms of the 
number of small pockets of positively-stained minerals. Fig. 4.21 shows the 96 hour aggregates of 
seven donors that were stained for Alizarin red. One of the seven donors stained positively for 
Alizarin red indicating the presence of calcium ions at this early time point. 
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Figure 4.21: Alizarin red staining of MSC aggregate sections. Optical images of Alizarin red staining carried out on MSC 
aggregate sections after 96 hours in culture. Scale bar represents 80 μm. Images are arranged in no particular order. 
After 168 hours in culture, differences in stain intensity are more apparent between donor 
aggregates (fig. 4.22). Four of the seven donors assessed with Alizarin red stained positively. A 
significant increase in mineral quantity when compared to the 96 hour samples was evident. 
Additionally, the differences between donor samples are more apparent when compared to the 
96 hour samples indicating that certain donor samples progressed further along the osteogenic 
lineage when compared to the others. 
 
Figure 4.22: Alizarin red staining of MSC aggregate sections. Optical images of Alizarin red staining carried out on 
sections of MSC aggregates after 168 hours in culture. The MSCs were obtained from multiple donors. Scale bar 
represents 80 μm. 
 
157 
 
3.5.2.2 von Kossa staining 
Again, aggregate sections were stained for von Kossa with differences being visible between 
donor aggregates after just 96 hours (fig. 4.23). von Kossa staining highlighted the presence of 
small phosphate deposits within one of the donors after 96 hours. After 168 hours in culture, 
differences in stain intensity are again more apparent between donor samples further suggesting 
that certain donors progressed further down the osteogenic lineage when compared to others 
(fig. 4.24). Three of the six donors assessed with von Kossa stained positively. 
 
Figure 4.23: von Kossa staining of MSC aggregate sections. Optical images of von Kossa staining carried out on sections 
of MSC aggregates after 96 hours in culture. Scale bar represents 80 μm. 
 
Figure 4.24: von Kossa staining of MSC aggregate sections. Optical images of von Kossa staining carried out on sections 
of MSC aggregates cultured for 168 hours. Scale bar represents 80 μm. 
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3.5.3 Microcomputerised tomography 
MicroCT scanning and analysis was carried out on aggregate samples acquired from multiple MSC 
populations, each provided by individual donors. Fig. 4.25 shows a number of microCT scan 
images of several aggregates from different donors at a threshold of 110 after 168 hours in 
culture. The difference in aggregate density has been quantified and shows significant differences 
between a number of the donor aggregates. The average (mean ± standard error of the mean) 
aggregate density obtained from multiple donors ranged from 1.093 to 1.805 at a threshold of 
110. Interestingly, these data appeared to produce a trend, albeit a surprising one. That is to say, 
the 3 smallest aggregates mentioned previously (fig. 4.16) appeared the least dense, whilst the 
largest aggregates previously mentioned (fig. 4.16) appeared to have the highest densities at a 
threshold of 110. 
The volume of the aggregates was also measured at a number of thresholds (fig. 4.26). At a 
threshold of 110, significant differences in aggregate volume could already be seen between 
several of the aggregate samples, values ranged from 0.013 mm³ to 0.068 mm³. At a threshold of 
130, the same trend was noted and volume measurements ranged from 0.001 mm³ to 0.056 mm³. 
With volume measurements taken from two thresholds, a ratio was obtained to determine the 
volume of dense material per unit total aggregate volume. Using this method of analysis, only one 
donor differed significantly from the remaining donors assessed. The volume of dense material 
per unit total aggregate volume of the different aggregates was also compared with those same 
measurements taken from rat femurs of different ages with the majority of the donor samples 
appearing to fall directly between 4 day old femurs and 35 day old femurs. 
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Figure 4.25: MicroCT scan images and density measurements of MSC aggregates. The aggregates were obtained from 
multiple donor cell populations after 168 hours in culture at a threshold of 110. Also shown are the aggregate density 
measurements at a threshold of 110. Error bar represents standard error of the mean. * signifies p < 0.05 and ** 
signifies p < 0.01. 
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Figure 4.26: MSC aggregate material volume measurements. The average (mean) volume of MSC aggregates obtained 
from multiple donors after 168 hours in culture at a threshold of 110 (A). Also, the average (mean) dense material 
volumes from the same aggregates at a threshold of 130 (B) are shown. Both volumes were used to give normalised 
dense material volumes to total aggregate volumes (C). In addition, normalised dense material volumes were compared 
to those of rat femurs from three different ages: 4 days, 35 days and 5 months (D). Error bar represents standard error 
of the mean. * signifies p < 0.05, ** signifies p < 0.01 and **** signifies p < 0.0001. 
3.6 In vivo study 
3.6.1 Monolayer controls 
Alongside the contents of a monolayer control sample chamber, fig. 4.27 shows H & E staining 
carried out on Neoveil mesh sections post-termination. The presence of cells was confirmed by 
dark speckled colouration. 
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Figure 4.27: MSC monolayer samples pre and post-in vivo termination. Optical images showing a monolayer sample of 
MSCs within its chamber (left). Also shown is H & E staining carried out on a section of Neoveil mesh taken from a fixed 
monolayer sample pre-implantation (right). Scale bar represents 200 μm. 
3.6.2 Aggregate size post-termination 
Post-termination, the small MSC aggregates had an average (mean ± standard error of the mean) 
diameter of 81 μm (± 5 µm), whilst the large MSC aggregates had an average (mean ± standard 
error of the mean) diameter of 218 μm (± 18 µm). No pre-experiment aggregate measurements 
were taken. 
3.6.3 Termination observations 
Whilst removing the chambers it was noted that each one had remained sealed throughout the 
course of the experiment thus preventing the unwanted infiltration of any host cells and/or 
materials. The level at which the chambers were enveloped within the body and their subsequent 
vascularisation varied from sample to sample with no obvious pattern being noted. The 
monolayer samples had in several cases developed extracellular material further confirming the 
presence of cellular activity within the chambers (fig. 4.28). 
In terms of the aggregates, many of the large aggregates appeared to disintegrate over the course 
of the experiment, whilst many of the small aggregates remained intact and in many cases 
appeared to have created more extracellular material in vivo which often also had stronger 
colouration compared to the material found in the large aggregate chambers. Fig. 4.28 shows 
optical images taken of the contents of both small and large aggregate sample chambers. Each of 
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the small aggregate chambers show intact aggregates surrounded by considerable extracellular 
material growth. The large aggregate chambers, however, show very few intact aggregates, a 
large amount of debris and little extracellular material. 
 
Figure 4.28: MSC sample chambers post-in vivo termination. Optical images showing the contents of the chambers with 
small aggregates (left) and large aggregates (right). Scale bar represents 200 μm. 
3.6.4 Chamber content assessment 
MicroCT analysis was carried out in such a way so as to evaluate the contents of the whole 
chamber and also the individual aggregates themselves. Fig. 4.29 shows the microCT scan images 
of both small and large aggregates. The small aggregates appear more uniform in size and shape, 
whilst the large aggregates appear to be more irregularly-shaped. Fig. 4.30 shows microCT density 
gradient map images of both small and large aggregates. The small aggregates again appeared 
more regular in size and shape and although the level of dense material varied from aggregate to 
aggregate, they all had their most dense material located around their peripheries. The large 
aggregates were again more irregular in size and shape making the spatial distribution of dense 
material more difficult to determine. 
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Figure 4.29: MicroCT scan images of MSC aggregates post-in vivo termination. Shown are small MSC aggregates (left) 
and large MSC aggregates (right) at a threshold of 130. 
 
Figure 4.30: MicroCT density gradient map images of MSC aggregates post-in vivo termination. Shown are small MSC 
aggregate (left) and large MSC aggregates (right) at a threshold of 110. Density gradient ranges from 0.9 – 1.2 1/cm with 
the red end of the spectrum indicating areas of higher densities and the blue end of the spectrum indicating areas of 
lower densities. 
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The microCT scans of the chambers containing the MSCs showed total material volumes of 1.963 
mm³, 4.832 mm³ and 10.187 mm³ for the monolayer, large aggregate and small aggregate 
samples, respectively, at a threshold of 110 (fig. 4.31). 
 
Figure 4.31: MSC in vivo chamber material volume measurements. Graphs showing the total material volume within the 
chambers at a threshold of 110 (A), the volume of dense material per chamber at a threshold of 170 (B) and the volume 
of dense material normalised to the total volume per chamber (C). Also shown is the normalised dense material volume 
compared to the equivalent values derived from rat femur samples of various ages (D). Error bar represents standard 
error of the mean. * signifies p < 0.05, ** signifies p < 0.01 and *** signifies p < 0.001. 
The small aggregate samples had significantly higher volumes at this threshold compared to both 
the monolayer and large aggregate samples. Using a threshold of 170, the volume of dense 
material per sample was also measured giving values of 0.45 mm³, 1.179 mm³ and 3.902 mm³ for 
the monolayer, large aggregate and small aggregate samples, respectively. 
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The small aggregate samples again had significantly higher volumes at this threshold compared to 
both the monolayer and large aggregate samples. Using the 110 and 170 thresholds, a volume of 
dense material normalised to unit total chamber material volume was obtained. Figures of 0.205, 
0.234 and 0.381 were obtained for the monolayer, large aggregate and small aggregate samples, 
respectively. The volume of dense material normalised to unit total chamber material volume was 
also compared with the equivalent measurements taken from rat femurs of different ages. All 
three in vivo samples showed similar values to that of 4 day old femur samples but were 
significantly lower than both the 35 day old and 5 month old femur samples. 
When assessing the total volume of the individual samples rather than the whole chambers, the 
monolayer samples and individual aggregates for instance, significant differences can be seen (fig. 
4.32). At the lowest threshold used for assessment, 110, the monolayer samples did not register a 
volume, whilst both large and small aggregate samples had average (mean ± standard error of the 
mean) individual aggregate volumes of 1.716 mm³ and 0.516 mm³, respectively. The average 
(mean ± standard error of the mean) volume of the large aggregate samples was significantly 
higher than those of the small aggregate samples. Given the nil value acquired from the individual 
sample analysis for the monolayer samples, all continued measurements refer to the large 
aggregates and small aggregates only. Using a threshold of 170 a volume of dense material per 
aggregate was obtained and averaged (mean ± standard error of the mean) giving values of 0.18 
mm³ and 0.063 mm³ for the large and small aggregate samples, respectively. Using both data sets, 
the volume of dense material was normalised to the total aggregate volumes giving figures of 
0.104 and 0.114 for the large and small aggregate samples, respectively. The normalised dense 
material volumes were again compared to those of rat femur samples of differing ages. Both the 
large and small aggregate samples were significantly lower than the femurs of all ages. 
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Figure 4.32: MSC in vivo chamber aggregate volume measurements. Graphs showing the total material volume per MSC 
aggregate at a threshold of 110 (A), the volume of dense material per aggregate at a threshold of 170 (B) and the 
volume of dense material normalised to the total material volume (C). Also shown is the normalised dense material 
volume compared to the equivalent values derived from rat femur samples of various ages (D). Error bar represents 
standard error of the mean. * signifies p < 0.05, *** signifies p < 0.001 and **** signifies p < 0.0001. 
3.6.4.1 In vivo sample observations and cell source 
If we take the in vivo data obtained from the MLO-A5 cell line and compared it to that of the MSC 
data, some interesting additional observations can be made from the in vivo study. Whilst 
significant differences cannot be seen directly between either of the monolayer samples or either 
of the large aggregate samples, significant differences can be seen between the small aggregate 
samples of both cell types. The small aggregates formed using MSCs produced a significantly 
higher volume of dense material normalised to total sample volume (t-test, p = 0.002). 
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Additionally, both data sets were compared to their equivalent data set obtained from rat femur 
samples of various ages (fig. 4.33). Whilst none of the MSC samples differed significantly from the 
youngest of the rat femur samples, all of the MLO-A5 samples did (t-test, p = 0.0011, 0.0128, and 
0.0036 for the monolayer, large aggregate and small aggregate samples, respectively). Whilst 
there were no direct significant differences between the first two of the three sample variables 
from either cell type; indirectly, differences can be seen with the MSCs producing more similar 
levels of dense material to natural bone compared to the MLO-A5 cell line. 
 
Figure 4.33: MicroCT material measurements comparing MLO-A5 and MSC in vivo chambers. Shown are the normalised 
dense material volumes acquired from whole chamber scans of both MLO-A5 (A) and MSC (B) in vivo samples post-
termination. Also shown is a comparison between both cell types and rat femur samples of various ages (C). Error bar 
represents standard error of the mean. * signifies p < 0.05 and ** signifies p < 0.01. 
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4. Discussion 
This study used a newly developed substrate, substrate X, to identify, quantify and assess the 
bone formation potential of donor-dependent MSC subpopulations. MSCs were isolated from 
MNC populations obtained from nine individual donors and cultured under previously established 
proliferative conditions until a sufficient cell number was acquired, 16 x 80% confluent T75 flasks 
at passage two. Monitoring growth profiles afforded us the opportunity to compare this new 
subpopulation identification technique with previously established growth rate studies. Once a 
specific culture point was reached and using substrate X, three subpopulations were identified 
based on their cellular attachment arrangements, a monolayer arrangement, a sunflower-like 
arrangement and an aggregate-like arrangement. Each subpopulation was subsequently assessed 
for osteogenic potential using a well-established osteogenic assay, histochemical staining, under 
the speculation that each subpopulation will hold a different capacity for osteogenic 
differentiation. The varying subpopulation-dependent osteogenic potentials are thought to ally 
with varying donor-dependent subpopulation proportions which could aid in assessing an 
individual’s osteogenic capacity. 
4.1 Mesenchymal stem cell verification 
There are a minimum of three validation techniques required to confirm the use of MSCs in any 
study: isolation through plastic adherence, flow cytometry measurements of at least eight surface 
markers and tri-lineage differentiation down three lineages, i.e. adipogenic, chondrogenic and 
osteogenic158. Whilst two techniques have been successfully completed throughout this study, i.e. 
isolation through plastic adherence and tri-lineage differentiation, the third requirement, i.e. flow 
cytometry analysis of eight surface markers, did not provide evidence to a satisfactory degree to 
conclude that MSCs were used here. This is thought to be due, in part, to the way in which the 
flow cytometry assessment was carried out. The manufacturer’s protocol recommended a specific 
volume of antibody to be used, 10 μl; however, this was for a far greater cell number, 1 x 10⁷, 
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than those intended for use in this element of this study, 1 – 3 x 10⁴ approximately. Therefore, 
the volume used was reduced to one tenth of that recommended. Whilst the supply company 
assured that this was perfectly safe and would not affect the results, it is the opinion of the author 
that this may have hindered the acquisition of reliable data. Given the limited availability of cells 
and in the interest of maintaining consistency throughout the study, the true impact of the 
volume reduction on the results was not thoroughly investigated and the volume used was not 
altered by the author. The author is of the belief, however, that should repeated flow cytometry 
analyses be possible, the use of MSCs would be satisfactorily verified. 
4.2 Mesenchymal stem cell heterogeneity 
MSC heterogeneity was investigated and evaluated from two primary points, differences in 
growth profile characteristics during initial cellular expansion and the identification and 
quantification of multiple subpopulations. 
4.2.1 Mesenchymal stem cell isolation and expansion 
Using common isolation techniques, MSCs were isolated from MNC cultures taken from multiple 
donors. The growth profile of each MSC population differed considerably once the cells had been 
cultured beyond their second passage. This is thought to be the earliest point at which one can 
start to identify possible bone formation potential as growth rate has been linked with osteogenic 
capacity in previous studies451. It is thought that the quicker the growth rate, the higher the 
potential for bone formation. Morphologically speaking, the MSCs within our study that were 
cultured for longer periods, the slower proliferating cells, demonstrated different cell shapes and 
sizes to those MSCs with shorter culture periods, the faster proliferating cells. The faster 
proliferating cells were smaller overall than their slower proliferating counterparts. The evidence 
for this is, whilst at 80% confluency and passage two, the acquired cell numbers differed between 
MSC populations indicating cells of differing sizes and/or qualities. The faster proliferating cells 
170 
 
had approximately 1 x 10⁶ cells per T75 culture flask, whilst the slower proliferating cells had 
approximately 0.75 x 10⁶ cells per T75 culture flask. The lowering of the cell counts with 
increasing culture duration was also observed through sample number records (fig. 4.5). 
Additionally, previous studies have suggested that subpopulations of different sizes, proliferation 
rates and differentiation capacities may exist368,376. Majore and colleagues attempted to isolate 
two MSC subpopulations from human umbilical cord using CCE369. Their results demonstrated that 
the smaller cells (11 μm) had a higher proliferative capacity compared to the larger cells (19 μm) 
which correlates with the data presented in this study. Interestingly, a flattened and enlarged cell 
shape similar to that noted for the slower proliferating cells in this study is also characteristic of 
MSC senescence452. Taken together, these data would suggest that an increased proliferation 
duration or decreased growth rate correlates with an increased level of possible senescence 
within an MSC population which results in an altered fibroblastic morphology and a subsequent 
reduction in bone formation potential. 
Whilst age and gender are two commonly used parameters for donor-dependent comparisons, 
they were not included in this study. The age range of the cohort used in this study is fairly narrow 
(age range of 22 – 30 with one outlier of 37) (table 4.1). Several other groups have examined age-
related donor differences in bone marrow-derived MSCs with much wider age ranges than that 
noted here, as reviewed by Stolzing et al.453. Furthermore, a cohort of nine with information for 
eight, five males and three females, is thought to be too small a sample size to be further divided 
into gender subcategories. For example, Leonardi et al. used 20 donors and reported cell recovery 
and osteogenic potential to be independent of donor gender454, Yoo et al. used 72 donors and 
again reported no significant differences dependent upon donor age or gender455, Payne et al. 
used 41 donors with no gender-related differences in cumulative population doublings being 
reported456 and Siegel et al. used 53 donors250. With a larger cohort and wider age range, such 
donor comparisons could have been possible within the current study. 
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4.2.2 Subpopulation identification 
Subpopulation identification has been achieved on two levels, initial identification and 
quantification through a cellular arrangement study followed by verification and possible 
reasoning via immunostaining. 
4.2.2.1 Cell attachment arrangements 
During each of the donor-dependent experiments, the MSCs were seeded on both TCP and 
substrate X, for monolayer/control culturing and subpopulation identification, respectively. When 
the MSCs were seeded onto substrate X, they attached and formed three specific cellular 
arrangements, i.e. a monolayer arrangement, a sunflower-like arrangement and an aggregate-like 
arrangement. Using multiple optical images of each MSC population from multiple donors over 
two time points, 96 and 168 hours, the proportions of these cellular arrangements have been 
quantified (fig. 4.7) with each donor being seen to produce differing proportions of these 
supposed subpopulations. Interestingly, for the donors that completed the full array of 
assessments, the proportions of the three subpopulations appeared to correlate with growth 
rates (fig. 4.14). Those cell populations with faster proliferation rates subsequently produced 
more organising cellular arrangements, i.e. sunflower-like- and/or aggregate-like-arranged cells, 
when cultured on substrate X compared to the cell populations with slower proliferation rates. 
4.2.2.2 E-cadherin levels 
In an effort to ascertain if E-cadherin expression might be the reason behind these apparent 
cellular arrangements, E-cadherin staining was carried out on the MSC samples cultured on 
substrate X (fig. 4.8 and 4.9) in the hope of identifying and quantifying cadherin expression levels 
within each of the subpopulations. The colony-like arrangements observed on substrate X are 
thought to be more indicative of embryonic stem cell (ESC) cultures, rather than MSC cultures. 
Whilst typical in vitro cultures grow in a two-dimensional (2D) -monolayered fashion, ESC cultures 
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have been shown to be morphologically distinct from such cultures whilst being grown on the 
same substrate. Such cells have been seen to form three-dimensional (3D) colonies under 
standard tissue culture conditions155,457. The distinct cellular arrangements observed with the MSC 
cultures grown on substrate X are thought to possibly represent varying degrees of ESC-like 
subpopulations within the MSC population. 
Much of the self-organising carried out by cells is mediated through the expression of particular 
surface molecules called cadherins458. Cadherins are of interest to this study because they 
encompass a group of transmembrane or membrane-associated glycoproteins responsible for 
mediating specific cell – cell adhesions. These molecules function in a calcium-dependent manner 
controlling the morphogenesis of a number of tissues and organs459–461. Whilst there have been 
many different cadherins identified, E-cadherin-mediated cell – cell contact is particularly relevant 
because it maintains colony formation within ESC cultures462 and is, therefore, thought to also be 
responsible for the cellular arrangements noted in this study. 
During the early stages of mammalian development, cell – cell contact mediated by E-cadherin is 
required for embryonic blastocyst integrity463 and has also been shown to control the processes of 
early differentiation464. Whilst E-cadherin is expressed in all cell types during early mouse 
embryonic development, its inactivation first becomes apparent in mesodermal cells during the 
gastrulation phase465–467. Those mesodermal cells then express mesoderm-specific genes468. 
Interestingly, cadherin-11 is initially detected in mesodermal cells at the gastrulation phase with a 
particularly high expression being noted in MSCs surrounding developing organs469. It has been 
suggested that E-cadherin expression during early embryonic development is essential for the 
further development of tissue-specific structures during the gastrulation phase. As E-cadherin 
expression decreases, the expression of other cadherins increases. 
The expression of other cadherins and subsequent tissue formation is dependent upon the initial 
foundations laid down by the expression of E-cadherin. E-cadherin is required for early cell 
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condensation which might be a prerequisite for subsequent inductive events leading to controlled 
cell patterning and the generation of differentiated structures464. The expression patterns of 
cadherins have been shown to correlate with distinct morphogenetic events. For example, E-
cadherin is expressed during mouse gastrulation and in epithelial tissues465,467, N-cadherin is 
expressed in neuroepithelium, myocardium and osteoblasts470,471, and R-cadherin displays a clear 
expression pattern in the developing nervous system472. 
The varied fluorescence intensities measured in this study suggest that the more organisation-
capable the cellular arrangement, i.e. the higher the proportion of sunflower-like and aggregate-
like cells, the higher the degree of E-cadherin expression. These data not only confirm the 
presence of distinguishable subpopulations but also suggests that E-cadherin plays a part in the 
subpopulations’ self-organising properties, if not controlling them entirely. 
When comparing E-cadherin levels between the individual MSC populations that were subjected 
to the complete series of analyses, a correlation appears between E-cadherin levels and growth 
rates (fig. 4.14). E-cadherin levels appear to decrease as growth durations increase. This 
observation correlates with previous data sets suggesting that the faster proliferating cell 
populations not only contain higher proportions of subpopulations with higher self-organising 
capabilities but also that these subpopulations possess higher levels of E-cadherin. 
4.3 Subpopulation assessment 
Given the links noted between donor-dependent growth profiles, differing cell sizes and 
subpopulation proportions, it was speculated that the different subpopulations may also hold 
different osteogenic capacities; which, because of the varying donor-dependent subpopulation 
proportions, may in turn influence an individual’s bone formation potential. Whilst it was clear 
three distinct cellular arrangements of differing proportions were present in all MSC populations 
examined and differing osteogenic potentials could be speculated upon based on previously 
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conducted research from different laboratories361, the osteogenic potential of each subpopulation 
needed to be identified. 
To investigate this, the cellular arrangements, along with the TCP-produced monolayer controls, 
were histochemically stained for osteogenic markers (fig. 4.12 and 4.13). These data suggest that 
the subpopulations with more organisational traits correspondingly have a higher osteogenic 
capacity. As mentioned earlier, cell – cell contact mediated by E-cadherin is important during the 
early stages of embryonic development463 but it has also been shown to control the processes of 
early differentiation464. E-cadherin expression during early embryonic development is essential for 
further cadherin-11 expression following E-cadherin decline which is subsequently important for 
the further development of tissue-specific structures during the gastrulation phase464. Cadherin-
11 has also been shown to be specifically involved in osteoblast differentiation473–475. Whilst 
several in vitro studies have shown that the expression of cadherins can change during osteoblast 
differentiation, the most common cadherins expressed by osteoblasts are E-cadherin, N-cadherin 
and cadherin-11474,475. N-cadherin and cadherin-11 have both been shown to influence bone 
formation and mass476. Low N-cadherin levels have also been shown to correlate with adipogenic 
differentiation477. It can, therefore, be postulated that the expression of E-cadherin within certain 
subpopulations may have possibly increased the levels of other osteogenic-related cadherins 
during the differentiation processes resulting in the increased osteogenic capacity of those same 
subpopulations. 
With particular cellular arrangements appearing to have a higher differentiation capacity, logic 
would dictate that those donors with a higher percentage of sunflower-like- or aggregate-like-
arranged cells would correspondingly have a higher osteogenic capacity. 
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4.4 Mesenchymal stem cell aggregation 
4.4.1 Aggregate size and shape 
Each MSC population expectedly produced single aggregates when seeded in the wells of the 
F127-coated suspension culture but the size and shape of the aggregates differed. Whilst a 
number of the MSC populations produced spherical aggregates of a uniform size and shape, other 
populations produced irregularly-shaped aggregates of non-uniform sizes. 
When looking at the size of the aggregates, especially the combined average (mean ± standard 
error of the mean) aggregate size from both 96 hour and 168 hour cultures (fig. 4.16), a distinct 
junction becomes apparent. The three smallest aggregates did not differ in size from one another, 
nor did the four largest aggregates. Rather, they formed two distinct groups which ultimately 
differed in size from one another. Interestingly, these two distinct groups also correlated with 
growth rate. The smaller aggregates on average (mean ± standard error of the mean) had faster 
proliferation rates compared to the larger aggregates. Additionally, the aspect ratio 
measurements provided for some noteworthy data. After 96 hours in culture, many of the 
aggregate samples had considerable inner-variances in aggregate size ultimately diluting any 
mean aspect ratio differences from one donor to the next. This rendered any possible differences 
insignificant. After 168 hours, however, the majority of aggregate samples appeared to tighten 
and reduce their overall aspect ratio. This led to significant differences becoming apparent 
between a number of the aggregate samples reiterating the speculation that certain donors had a 
higher capacity for aggregation compared to others. These data suggest that each of the MSC 
populations evaluated possessed different aggregation capacities. Possible reasons behind these 
donor-dependent variabilities are discussed later. 
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4.4.2 Aggregate osteogenic potential 
Given that aggregate culturing has been shown to enhance osteogenesis (chapter 3), assessing 
the nodule formation capacity of multiple donors should include an evaluation of minerals 
associated with osteogenesis. Histochemical staining for Alizarin red and von Kossa allowed for 
the comparison of calcium ions and phosphate salts, respectively, indicating the deposition of 
minerals, over time. These data suggest that there are donor-dependent differences in 
aggregation capacity and possible subsequent osteogenic potential. 
4.4.3 Aggregate material assessment 
The aggregates formed using the F127-coated suspension cultures have also been microCT 
scanned for material evaluation. An increased aggregate density or volume of dense material is 
thought to indicate increased mineralisation and potential for bone formation. The aggregates 
from nine donors were microCT scanned after 168 hours in culture. Density measurements were 
taken for all nine donors; however, due to the lack of available higher threshold volume 
measurements, total volume measurements were taken for seven donors. 
A tentative explanation for the data described in fig. 4.16 and 4.25, which show the smallest 
aggregates had the lowest densities and the largest aggregates had the highest densities, could 
include two possible reasons. Firstly, the high E-cadherin expressive donor samples formed 
smaller and denser cellular aggregates which may have led to a low oxygen and nutrient exchange 
for the centrally located cells with subsequent lowered cell viability. Secondly, the donor samples 
with more densely packed cell populations may have been induced earlier into osteogenic 
differentiation (the phenomenon discussed in detail in chapter 3) with lower proliferation 
compared to the more loosely packed cell populations, the lower E-cadherin expressive donor 
samples. Over the following culture period, the loosely packed aggregates formed from the poor 
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E-cadherin expressive donor cells gained an advantage with higher cell numbers and a higher 
concentration of mineralising matrix. 
Encouragingly, however, the aggregate volumes confirm previous data suggesting that the 
aggregates formed from the MSCs of multiple donors produced aggregates of different sizes 
despite being formed using the same cell numbers, culture conditions and duration. This further 
compounds the observation that each MSC population possesses a different aggregation capacity. 
Given that the minerals required for bone formation are denser than the cellular or collagenous 
extracellular material of the aggregates, a more dense aggregate is thought to be indicative of an 
increased mineral content and subsequent bone formation potential. The considerable 
differences between the aggregate densities of individual donors suggest that those donors with 
higher densities would also have a correspondingly higher bone formation potential. The volume 
of dense material, material still present above a threshold of 130, correlates well with the 
previously discussed histochemical staining. That is to say, the three donors that were shown to 
possess the highest volumes of dense material also had the strongest staining for calcium and 
phosphate deposits after 168 hours in culture. 
4.4.4 Aggregation and donor-dependent E-cadherin levels 
A correlation appears to exist between E-cadherin fluorescence levels and aggregate size 
measurements after 168 hours in culture (two-way analysis of variance (ANOVA), p < 0.0001) (fig. 
4.18). This correlation does help to relate donor-dependent subpopulations with aggregation 
potential through E-cadherin levels. E-cadherin expression has previously been shown to be an 
indicator of subpopulation proportions and to be donor-variable but apparently also has links to 
aggregate size and shape. This study has demonstrated that MSC cultures contain differing 
quantities of cells expressing E-cadherin and, as mentioned, E-cadherin is required for embryonic 
blastocyst integrity463. Taken together and given that E-cadherin was found to be involved in 
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forming cellular aggregates478, it was conjectured that the different E-cadherin levels found in 
each MSC population of this study would result in different aggregation capacities. 
The correlation between aggregation and E-cadherin levels thus validates the hypothesis that a 
possible relationship exists between an individual’s subpopulation proportions and their 
aggregation capacities. It is noted, however, that no further correlations have been made 
between donor-dependent aggregation and donor-dependent osteogenic potential and further 
investigations are required if a more tangible link is to be conclusively proven. 
4.5 In vivo experiment 
4.5.1 Experiment observations 
The in vivo element of this study has provided some interesting results. H & E staining combined 
with post-termination imaging have shown that the monolayer samples were biologically active in 
vivo. Contrary to the in vitro examinations, the monolayer samples produced more material over 
the course of the experiment than expected. The aggregates also delivered some remarkable 
results. Whilst the majority of the small aggregates were still visible upon termination, many of 
the large aggregates appeared to disintegrate over the course of the experiment. Additionally, the 
chambers containing the small aggregates had more extracellular material after 8 weeks when 
compared to their large aggregate counterparts. The post-experiment aggregates on average 
(mean ± standard error of the mean) measured an approximate size of 80 μm and 220 μm for the 
small and large samples, respectively. With so many of the large aggregates being lost throughout 
the experiment, it is thought that all of the aggregates lost were possibly larger than 220 μm. This 
would suggest that the smaller the aggregate samples, the more biologically active they are over 
an 8-week period and that a size approaching 220 μm may be a critical cut off point for possible 
bone formation through aggregation. It has been suggested that the diffusion limit of oxygen is 
only 100 – 200 μm and so any tissue larger than this would require vascularisation479. 
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4.5.2 Microcomputerised tomography of post-in vivo samples 
Fig. 4.31 shows the measured volumes of two different thresholds acquired from whole chamber 
scans. At the lower threshold, the small aggregates were the best performing group in terms of 
material volume. The lower than expected volume of the large aggregate samples is thought to be 
as a result of the apparent disintegration of many of the aggregates. Conversely, the larger than 
expected volume of the monolayer controls is thought to be the result of a comparatively 
enhanced proliferation rate. The Neoveil mesh used to house the monolayer of cells could 
possibly have acted as a scaffold over the course of 8 weeks allowing for the cells to spread 
throughout the mesh, creating a volume of extracellular material. A similar trend was noted at a 
higher threshold of 170. These data would suggest that the small aggregates were more active in 
terms of creating extracellular material but also in creating dense, possibly mineralised, material. 
Previous in vitro studies have suggested that the large aggregates mineralised at a faster rate 
compared to their smaller counterparts over a short culture duration, but, whilst this is true, 
without an appropriate diffusion of oxygen and nutrients over a considerably longer culture 
duration, this accelerated mineralisation rate is rendered pointless, as indicated by the assumed 
disintegration of any aggregates larger than 220 μm. The smaller aggregates appeared in this case 
to outmanoeuvre the other test groups by remaining active and producing more material overall. 
In a comparative study, these data were also plotted against data acquired from rat femurs of 
different ages. Encouragingly, the material produced within this experiment was statistically 
similar in terms of specific density threshold volumes to that of 4 day old femurs. 
The individual samples were also assessed in the hope of confirming the observations discussed 
above (fig. 4.32). When attempting to measure the inner-chamber material, i.e. the original 
samples only minus the additional material produced throughout the experiment, several 
interesting observations became apparent. The monolayer controls alone did not produce a 
measurable volume at a threshold of 110 and were, therefore, excluded from further analysis. 
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When assessing the aggregate samples, perhaps unsurprisingly, the large aggregates had a larger 
total volume when compared to the small aggregates. The large aggregates also initially appeared 
to have a higher volume of dense material; however, such considerable errors of the mean 
rendered any possible mean differences insignificant. This subsequently led to both aggregate 
samples being statistically similar in terms of dense material per unit total volume. Given the 
compromised integrity of the large aggregates and the difficulty associated with trying to assess 
individual aggregates buried within considerable extracellular material, these individual data are 
not considered reliable enough to provide a concrete conclusion. 
In terms of eventual bone formation, the small aggregates appeared in this study to be most 
successful; although, the increased mineralisation rates of the large aggregates cannot be 
overlooked. Perhaps the ultimate solution would be to combine the attributes of both aggregate 
sizes; the increased mineralisation rates of the large aggregates with the diffusion capabilities and 
sustainability of the small aggregates. Perhaps the answer lies in vascularisation of the large 
aggregates. 
5. Conclusion 
MSC subpopulations were identified through different cellular arrangements, i.e. a monolayer 
arrangement, a sunflower-like arrangement and an aggregate-like arrangement, using a specific 
substrate, substrate X. The more organised arrangements, i.e. sunflower-like and aggregate-like 
arrangements, were shown to have higher E-cadherin expression levels and, therefore, a higher 
capacity for cell – cell interactions. Using histochemical staining, the more organised 
arrangements, i.e. sunflower-like and aggregate-like arrangements, were also shown to possess a 
higher aptitude for indicators associated with mineralisation. These data suggest that the 
proportions of these supposed subpopulations are donor-dependent and allow for the hypothesis 
that a donor with a higher proportion of sunflower-like or aggregate-like cells would 
correspondingly have a higher capacity for osteogenic development. Aggregation capacity was 
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also shown to differ between donors with a correlation being noted between aggregation and E-
cadherin levels which corroborates previously conducted studies suggesting that E-cadherin plays 
a role in aggregation. 
An additional element to this study has shown that aggregate size affects the mineralised matrix 
content and aggregate survival, similar to that of the MLO-A5 in vivo outcomes (previous chapter). 
Therefore, it is speculated that a combination of the chief characteristics of both aggregate sizes, 
i.e. increased mineralisation rates with sufficient diffusion capabilities, would most effective for 
potential bone formation. Taken together, our data suggest that donor-dependent growth 
profiles correlate with specific subpopulation proportions with differing osteogenic capacities 
which may be the result of E-cadherin expression levels. Logic, therefore, would tell us that 
quantifying an individual’s subpopulation proportions may help us to assess an individual’s bone 
formation capacity.  
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Chapter Five            
Promotion of Vascularisation 
via Co-Cultured Aggregation  
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Overview 
The vascularisation and potential bone formation of co-cultured cellular aggregates under 
mechanical loading was the primary focus of this study. We proposed to investigate the influences 
imparted by cellular aggregation and mechanical loading on inner-aggregate cellular 
arrangements and potential pre-vascularisation within mesenchymal stem cell (MSC) and human 
umbilical vein endothelial cell (HUVEC) aggregate co-cultures. In conjunction with cellular 
arrangements, this study intended to ascertain what effects such culturing techniques might have 
on mineralisation levels and prospective bone formation. In addition, aggregate formation 
technique was theorised as being influential with regards to construct vascularisation and bone 
formation; so, cellular aggregates were developed using two aggregate formation techniques, 
pellet culture aggregation and suspension culture aggregation, to ascertain if this parameter has 
significance. 
MSCs alone and MSCs co-cultured with HUVECs were aggregated and cultured under static and 
dynamically loaded culture conditions. Following aggregation, static culturing encompassed a 
standard cell culture approach, whilst hydrostatic loading was used to impart mechanical strain in 
a specifically designed chamber. Cellular arrangements and potential pre-vascularisation was 
assessed by monitoring inner-aggregate HUVEC arrangements to compare the static and loaded 
culture conditions, the aggregate formation techniques under both culture conditions, and the 
cellular composition of the aggregates from both aggregation techniques and under static and 
loaded culture conditions. Potential bone formation was assessed using microcomputerised 
tomography (microCT/µCT), again comparing the static and loaded culture conditions, and 
aggregate composition and formation technique under both culture conditions. 
 
 
184 
 
1. Introduction 
Large tissue-engineered bone grafts often suffer from poor core cell viability which subsequently 
leads to compromised graft integration and possible graft failure25. Uneven cell integration, 
cellular necrosis and eventual graft failure are the result of an inadequate supply of oxygen and 
nutrients323,347,348. Such an inhibition to the viability of implants poses a major obstacle to the 
progression and translation of tissue engineering349. In response to this, research is currently 
ongoing to both refine and enhance bone tissue engineering techniques and also to vascularise 
the resulting tissue-engineered constructs323,350. 
Naturally, the most effective bone regeneration techniques will replicate the in vivo processes 
known to develop and regenerate bone. Therefore, numerous cell types, biomaterials, culture 
conditions and combinations of such, have been rigorously investigated and documented. Various 
cell types have been used for tissue engineering bone grafts: bone marrow aspirates, lineage-
specific osteoblasts and differentiated stem cells145,146. When using bone marrow aspirates, bone 
tissue engineering has experimented with directly implanted aspirate as well as culture-expanded 
MSCs that were pre-differentiated prior to implantation228. MSCs are a logical choice for tissue 
engineering for a number of reasons. Chiefly, they have multipotent capabilities allowing them to 
differentiate into numerous cell types, e.g.  bone, muscle, fat and others480, they can be easily 
isolated via plastic adherence from a number of different sources, such as umbilical cord blood, 
liver and amniotic fluid, adipose tissue and bone marrow156,359, they can be separated and 
expanded whilst also maintaining a good level of stemness224,480, they have a stable phenotype in 
culture156 and exhibit low immunogenic characteristics which could allow for possible allergenic 
use146,481. The potential for MSCs to enhance bone fracture healing has been demonstrated in 
numerous preclinical animal models183,185,186,266 and clinical trials146, and are also known to 
encouragingly influence cohabiting cells derived from other tissues, such as skin, muscle, 
endothelial and renal epithelial layers175.  
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As previously mentioned, the vascularisation of bone tissue-engineered constructs becomes 
increasingly important if large grafts are required for substantial bone defects or injuries. For this 
reason, exploration into tissue vascularisation, and bone tissue vascularisation in particular, is 
being carried out with some very interesting theories and hypotheses being investigated. 
The co-culturing of cells is one method being explored for the vascularisation of tissue-engineered 
constructs. Endothelial cells (EC) for example, are being co-cultured with various other cell types 
in an attempt to achieve in vitro pre-vascularisation within scaffold constructs351–354. MSCs and 
ECs would appear to be a sensible combination for co-cultured constructs with the interactions 
between both cell types being a highly regulated process. Paying close attention to, and 
mimicking where possible, the in vivo bone vascularisation processes is as important as ever when 
co-culturing. It is thought that the most successful microvasculature formation to date was 
achieved with the delayed addition of MSCs to ECs encapsulated in collagen355. Such an 
experimental procedure was carried out because this arrangement was thought to better mimic 
the natural in vivo environment where MSCs are only recruited to the site of vascularisation after 
ECs have begun vascular construction355. 
Three-dimensional (3D) microenvironments offer an ideal environment for improved cell – cell 
communication enhancing cell – cell signalling, proliferation, differentiation and survival. Because 
of this, attempts have been made previously to use such constructs for the study of 
vascularisation. Taking advantage of such effects, a previous study seeded MSC aggregates onto 
porous polyurethane scaffolds and when compared with non-seeded scaffolds and scaffolds 
seeded with individual MSCs, an improved vascularisation and micro-vessel functionality was 
noted within the aggregate-seeded scaffolds482. In another series of in vitro and in vivo 
experiments, MSC aggregates were noted to have heightened cell survival and subsequent 
vascularisation. The aggregates, produced by a hanging-drop method, were compared to an MSC 
monolayer. Improved cell viability, amplified micro-vessel formation and lessened necrosis and 
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limb loss in ischemic mice were noted483. Whilst the aggregate culturing in that study may have 
augmented paracrine signalling and function in the cells, it was also noted that the aggregate 
structure itself may have helped to prolong the length of time the MSCs were present at the graft 
site through entrapment. 
Implanting MSCs in aggregate form would appear to enhance the stimulation of angiogenesis and 
neovascularisation with such a technique seemingly working well for implants of a smaller size or 
when used as a supportive role for osteogenesis. However, unmodified MSCs alone may not be 
sufficient for supporting vascularisation in large grafts349. Additional environmental conditions 
may help to further enhance the positive results seen thus far. 
The use of bioreactors may offer the environmental conditions required to enhance both the 
mineralisation of bone tissue-engineered constructs and also the vascularisation of such. 
Numerous studies have shown that bioreactors could provide the necessary growth environments 
for advanced tissue engineering and may also allow for the investigation of physical forces on cells 
and cell/scaffold constructs285. Under physiological conditions, loading placed on the bone 
through compression and/or tension via movement drives interstitial fluid flow through the 
lacunae of the bone resulting in the application of fluid sheer stresses257. This creates hydrostatic 
and dynamic shear forces detectable by the cells258–261. Such mechanical stimuli are known to 
influence embryonic bone formation262,263 as well as post-embryonic bone regeneration265. 
Therefore, replicating such physiological conditions should enhance or encourage bone tissue 
engineering and/or the vascularisation of such grafts. Given that dynamic culturing has been 
demonstrated to improve cell survival and mineralisation in both in vitro and in vivo studies266,267, 
numerous different types of bioreactors have been developed for bone tissue engineering, 
including perfusion bioreactors271–273, magnetic bioreactors274 and spinner flasks275, all with 
positive results. Bone formation and vascularisation is also well documented under such dynamic 
conditions277–283 and it is, therefore, proposed that the mechanical stimulation of a co-culture 
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system will encourage both osteogenic484,485 and endothelial486 differentiation for more healthy 
bone and vasculature. 
A hydrostatic bioreactor was used in this particular study because numerous previous studies 
have shown that hydrostatic loading is an important mechanical stimulus influencing the direction 
of cell fate in various tissues, such as the intervertebral disc, the vascular system, articular 
cartilage and bone276,284,285. The use of a hydrostatic bioreactor is interesting because the 
application of hydrostatic loading to a tissue-engineered construct is thought to not only provide 
physical forces but to also increase the transfer of small molecules, such as O₂ and CO₂, into the 
tissue matrix286. When using hydrostatic loading to pressurise a closed chamber containing a gas-
liquid interface, as is the case with the bioreactor used in this study, the solubility of O₂ and CO₂ is 
increased resulting in higher concentrations of dissolved gases in the medium284,287. pH levels and 
dissolved O₂ concentrations have been shown in numerous studies to influence cellular 
mechanisms, such as inter-cellular signalling, cell proliferation and differentiation288,289, as well as 
the cell cycle, apoptosis and protein synthesis290–295. Culturing osteoblasts in vitro under 
hyperbaric oxygen conditions has been shown to not only boost cell proliferation and 
differentiation but also to improve alkaline phosphatase (ALP) activity and collagen type I (COL 1) 
production leading to enhanced osteogenesis296. The use of such a bioreactor was, therefore, 
hoped to improve both mineralisation and vascularisation of the cellular aggregates studied here. 
With the advantages of 3D microenvironments being discussed in previous chapters, we decided 
to explore the vascularisation of such for large graft construction. The combination of cellular 
aggregation, cellular co-culturing and hydrostatic loading is thought to best represent the bone 
formation and regeneration processes observed in vivo and, thus, offers the best opportunity to 
study such process in vitro with the hope of creating viable large bone tissue-engineered grafts for 
possible implantation. 
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2. Materials and Methods 
This co-culture experiment was carried out on a total of six separate occasions with a minimum of 
three samples per variable each time. The parameters assessed in this chapter are outlined below 
in fig. 5.1. On all six occasions, aggregates containing MSCs alone were compared to MSC/HUVEC 
co-cultured aggregates under both loaded and static culture conditions. On three of the six 
occasions, the aggregation technique was also evaluated. 
 
Figure 5.1: A basic overview of the parameters investigated throughout the vascularisation chapter. 
2.1 Cell culturing 
There are two cell types used in this chapter: MSCs and HUVECs. 
2.1.1 Mesenchymal stem cells 
MSCs were isolated from MNCs and cultured following the protocols outlined in chapter 2, 
section 1.2. The proliferative medium used during MSC culturing is also described in the same 
section. The MSCs were cultured to passage three and used for the experiments described in this 
chapter at passage four. 
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2.1.2 Human umbilical vein endothelial cells 
One vial of HUVECs was acquired from a commercial source and cultured as described in chapter 
2, section 1.3. The specific HUVEC medium used for culturing is also described in the same 
section. HUVECs were cultured to passage three and used for the experiments illustrated in this 
chapter at passage four. 
2.2 Cell tracking 
Cell tracking was carried out in four separate experiments. On all four occasions, the HUVECs 
were tracked with a FITC-conjugated dye. On one occasion, the MSCs were also tracked, but with 
a TRITC-conjugated dye. Continued tracking of the MSCs in further experiments was not 
attempted because it was deemed unnecessary and unfruitful. The addition and use of cell 
tracking membrane dyes is described in full in chapter 2, section 3. 
2.3 Cell aggregation 
The ratio of MSCs to HUVECs (90 – 95% MSCs and 5 – 10% HUVECS) was chosen because 
Rouwkema and colleagues had previously demonstrated that a HUVEC proportion as low as 5% of 
the total cell number was capable of forming tube-like structures resembling vascularisation 
within the main aggregate body323. When a HUVEC proportion of more than 10% was used, 
structures appeared less elongated and more HUVECs could be seen in clumps rather than vessel-
like structures. The HUVEC proportion was decreased from 10% to 5% when 10% was deemed 
unnecessary. 
2.3.1 Aggregate formation 
The F127-coated suspension culture method for aggregate formation is described in full in 
chapter 2, section 4.1.1. The pellet culture method for aggregate formation is described in full in 
chapter 2, section 4.1.2. Both aggregation techniques used 1 x 10⁵ cells/aggregate. Aggregates 
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were made up of 100% MSCs or a co-culture of 90 – 95% MSCs and 5 – 10% HUVECs. Regardless 
of aggregation technique, the MSC only aggregates were formed using MSC proliferative/basal 
medium (chapter 2, section 1.2) and the MSC/HUVEC aggregates were formed using MSC 
proliferative/basal medium (chapter 2, section 1.2) and HUVEC basal medium (chapter 2, section 
1.3) at a ratio of 1:1 (adapted from Saleh et al.487). All aggregates were formed undisturbed for 48 
hours prior to use in any experiments. After 48 hours, the aggregates were encapsulated in 
collagen hydrogel before any further experiments were carried out. If any of the cells were 
fluorescently tagged, they were protected from light throughout the aggregation process. 
2.3.2 Aggregate measurements 
The dimensions of the aggregates, i.e. size and aspect ratio, were determined from a minimum of 
three samples per variable from one MSC population using the protocols described in chapter 2, 
section 10. 
2.4 Collagen encapsulation 
Collagen encapsulation was used to house the aggregates during the hydrostatic loading and 
static culturing phase of the experiments. Post-aggregation, the individual aggregates were placed 
into individual wells of a standard 24-well tissue culture polystyrene (TCP) plate. The aggregates 
were centred within the wells and any remaining media was removed immediately prior to 
encapsulation. The collagen gel was then formed with a concentration of 3 mg/ml using the 
protocol outlined in chapter 2, section 6. One ml collagen gel was added to each well. The 
gel/aggregate constructs were then placed into an incubator (37 °C and 5% CO2) for 24 hours. 
2.5 Further aggregate culturing 
The next phase of the experiment involved two different culture environments: static and loaded. 
Culture duration (7 – 10 days) was adapted from Rouwkema et al.401. The culture duration was 
increased from 7 days to 10 days with all samples having been cultured for 7 or 10 days. 
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2.5.1 Static culturing 
The gel/aggregate constructs intended for static culturing were kept in an incubator at 37 °C and 
5% CO2 for the remainder of the experiment (7 – 10 days). 
2.5.2 Hydrostatic loading 
The gel/aggregate constructs intended for hydrostatic loading were kept in the same incubator as 
their statically cultured counterparts. After the initial 24 hour period immediately following 
collagen encapsulation, the loaded samples were subjected to their first loading session. This was 
carried out using the protocol described in chapter 2, section 7. For 1 hour/day, these samples 
were hydrostatically loaded over the following 7 – 10 days. 
2.6 Aggregate termination 
After 7 – 10 days of loaded or static culturing, the aggregate samples were terminated. Those 
samples intended for microCT scanning were fixed with formalin for 1 hour; after such time, the 
formalin was removed and the samples covered with 1 ml phosphate buffered saline (PBS) to 
prevent them from drying out. Those samples intended for whole aggregate 
immunohistochemical staining were fixed with 4% paraformaldehyde (PFA) for 1 hour; after 
which, the fixative was removed and the samples stored in 1 ml PBS. Those samples intended for 
cryosectioning and immunohistochemical staining were not fixed until after they were sectioned. 
This meant that those samples intended for section staining were cryosectioned on the day of 
termination. 
2.7 Imaging 
2.7.1 Light microscopy 
Optical imaging for the monitoring of aggregate size, colour intensity and cellular outgrowth was 
carried out on a minimum of three samples per variable using the protocols and equipment 
192 
 
outlined in chapter 2, section 9.1. Pre-collagen encapsulation, imaging was carried out on the MSC 
only and MSC/HUVEC co-cultured suspension aggregates after 8 and 48 hours post-suspension 
culture seeding to monitor aggregate formation. Post-collagen encapsulation, imaging took place 
every 3 – 4 days to monitor cellular outgrowth from pellet and suspension aggregates under static 
and loaded culture condition. Over imaging of the samples was avoided so as to prevent photo 
bleaching of the fluorescently tagged cells. 
2.7.2 Epifluorescent imaging 
Epifluorescent imaging for cellular tracking and arrangement monitoring was carried out using the 
protocols described in chapter 2, section 9.2. Epifluorescent imaging was carried out immediately 
post-collagen encapsulation and again after 3 and 7 days of loaded and/or static culturing. Again, 
over imaging of the samples was avoided. 
2.7.3 Confocal imaging 
Confocal z-stacking was intended to monitor inner-aggregate cellular arrangement through the 
imaging of membrane dye-tagged cells. Confocal z-stacking was carried out using the protocols 
described in chapter 2, section 9.3. Z-stack imaging was carried out every 24 hours post-collagen 
encapsulation and immediately prior to each loading session. 
2.8 Microcomputerised tomography 
MicroCT was carried out in one experiment using a minimum of three samples per variable from 
one MSC population. It was used to quantify aggregate volume (mm³) and volume of dense 
material normalised to total aggregate volume. MicroCT scanning was carried out on the 
individual aggregates following the termination of each experiment using the protocol outlined in 
chapter 2, section 15.1.2. To allow for volume measurements to be acquired without interference 
from background collagen, the aggregated samples were carefully removed from their 
encapsulating collagen with a scalpel prior to scanning. The aggregates were placed in a 
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polystyrene holder, as described in chapter 2, section 15.1.2, immediately prior to scanning and 
were scanned as individual aggregates. The microCT scans were then evaluated using thresholds 
of 110 and 130. These thresholds were chosen because 110 would ensure that no background 
collagen could distort the results and 130 was the highest threshold where volume measurements 
were still obtainable from each sample tested. 
2.9 Cryosectioning 
Given the 3D nature of the aggregates, they were cryosectioned into 8 μm thick slices to allow for 
staining. Staining was intended to highlight the inner-aggregate structure and cellular 
arrangement. Cryosectioning was carried out on three separate occasions with a minimum of two 
samples per variable using the protocols outlined in chapter 2, section 8.3. Initially, the 
surrounding collagen gel was removed from around the aggregates prior to sectioning but this 
was later thought to hinder or lessen the obtainable data. Further samples retained enough of 
their surrounding collagen gel so as to house any cellular outgrowth. Because these samples were 
not fixed prior to sectioning, they were snap-frozen in liquid nitrogen immediately prior to 
cryosectioning. 
2.10 Immunostaining 
CD31 staining was used to identify the presence and spatial distribution of HUVECs located in 
and/or possibly around the aggregates. CD31 staining was carried out using the protocol 
described in chapter 2, section 13.1. Staining was conducted on two separate experiments using 
both whole aggregates and aggregate sections. Whole aggregates and aggregate sections were 
stained using this same protocol. 
2.11 Statistical analysis 
For aggregate measurements and microCT analysis, sample groups acquired from one experiment 
using single populations of MSCs and HUVECs were compared using independent t-tests and f-
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tests. A p-value below 0.05 was taken to indicate statistical significance. Graphically, statistical 
significance is indicated at four levels: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. 
3. Results 
3.1 Aggregate formation 
Both aggregation techniques formed aggregates of different sizes and shapes despite both 
techniques using the same cell numbers. Optical imaging has shown aggregate formation within 
the F127-coated suspension cultures over a period of 48 hours (fig. 5.2). After 8 hours in culture, 
multiple small aggregates were formed which subsequently joined together forming one large 
aggregate in each well. The shape of the final aggregates would lead one to believe that the 
multiple structures of the initial small aggregates were still present in the final aggregate form in 
many cases (fig. 5.2). 
 
Figure 5.2: Suspension culture aggregate formation. Optical images showing aggregates forming on a 1% F127-coated 
suspension culture after 8 hours and 48 hours in culture. The aggregates on the left contain MSCs only, whilst the 
aggregates on the right contain a co-culture of 97.5% MSCs and 2.5% HUVECs. Scale bar represents 400 μm. 
Fig. 5.3 shows the average (mean ± standard error or the mean) size of the aggregates 
immediately post-collagen encapsulation. The average (mean ± standard error of the mean) 
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suspension culture aggregate was 885 μm and the average (mean ± standard error of the mean) 
pellet culture aggregate was 497 μm (t-test, p = 0.0133). 
 
Figure 5.3: Aggregate measurements comparing both aggregation techniques. Shown is the average (mean) aggregate 
size (A) and aspect ratio (B) of the samples formed from both aggregation techniques immediately post-collagen 
encapsulation. Error bar represents standard error of the mean. * signifies p < 0.05. 
The formation of the pellet culture aggregates was not imaged over the initial 48 hour culture 
period due to the difficulty of imaging within a centrifuge tube. Fig. 5.3 shows the average (mean 
± standard error of the mean) aspect ratio of the aggregates immediately post-collagen 
encapsulation. The suspension culture aggregates had an average (mean ± standard error of the 
mean) aspect ratio of 1.23 and the pellet culture aggregates had an average (mean ± standard 
error of the mean) aspect ratio of 1.102). 
Considerable cellular outgrowth was also visible from the optical images. Such outgrowth could 
be seen from the static samples from the early stages of the experiment with a smaller amount of 
outgrowth being witnessed from the loaded samples (fig. 5.4 and 5.5). Measurements would 
suggest that the average (mean ± standard error of the mean) cellular outgrowth experienced by 
the aggregates under loaded conditions was approximately 10% of the original aggregate size 
regardless of the aggregation technique used to initially develop the aggregates. Whilst the 
average (mean ± standard error of the mean) cellular outgrowth experienced by the aggregates 
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under static conditions was difficult to accurately measure, it was thought to exceed 40% of the 
original aggregate size (data not shown). 
 
Figure 5.4: Suspension culture aggregates following 4 days of culturing. Optical images of aggregates following 4 days of 
culturing in collagen gel. The aggregates were formed in a 1% F127-coated suspension culture plate and contained a co-
culture of 90% MSCs and 10% HUVECs. Scale bar represents 400 μm. 
 
Figure 5.5: Pellet culture aggregates following 10 days of culturing. Optical images of MSC and MSC/HUVEC co-cultured 
aggregates following 10 days of culturing in collagen gel. The aggregates were formed from a pellet culture. This figure 
shows aggregates after both static (top) and loaded (bottom) culturing. The aggregates on the left contain MSCs only, 
whilst the aggregates on the right contain a co-culture of 95% MSCs and 5% HUVECs. 
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3.2 Cell tracking 
HUVEC arrangement, as monitored by the cell tracking dye, was difficult to evaluate via 
epifluorescent imaging given the 3D nature of the aggregates (fig. 5.6 and 5.7). That is to say, any 
particular cellular arrangement, tubular or otherwise, could not be accurately identified. Confocal 
z-stacking has given an insight into the cellular arrangement taking place within the whole 
aggregate samples that epifluorescent imaging could not (fig. 5.8, 5.9, 5.10, 5.11 and 5.12). 
 
Figure 5.6: Epifluorescent images of fluorescently-tagged HUVECs in MSC/HUVEC co-cultured suspension aggregates. 
Brightfield and corresponding epifluorescent images of aggregates following 3 days of static and loaded culturing. The 
aggregates were formed via suspension aggregation and contained a co-culture of 95% MSCs and 5% HUVECs. The 
fluorescence is emitted by the fluorescently-tagged HUVECs. The MSCs were not fluorescently-tagged. Scale bar 
represents 100 μm. 
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Figure 5.7: Epifluorescent images of fluorescently tagged HUVECs in MSC/HUVEC co-cultured suspension aggregates. 
Brightfield and corresponding epifluorescent images of aggregates following 7 days of static and loaded culturing. The 
aggregates were formed via suspension aggregation and contained a co-culture of 95% MSCs and 5% HUVECs. The 
fluorescence is emitted by the fluorescently-tagged HUVECs. The MSCs were not fluorescently-tagged. Scale bar 
represents 100 μm. 
Confocal z-stacks of HUVECs in both suspension culture and pellet culture aggregates taken 
immediately post-collagen encapsulation have shown that HUVEC arrangement within the 
suspension culture aggregates appeared to be arranged to the peripheries of the multiple small 
aggregates making up the final aggregate form. The HUVECs present in the pellet culture 
aggregates are thought to be more uniformly distributed throughout the aggregate bodies (fig. 
5.8). 
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Figure 5.8: Confocal images of fluorescently-tagged HUVECs in MSC/HUVEC co-cultured aggregates. Images were taken 
immediately following collagen encapsulation (pre-loading). The aggregates were formed using 95% MSCs and 5% 
HUVECs with both suspension culture and pellet culture techniques. The MSCs were not fluorescently-tagged. White 
boxes highlight areas of compartmentalisation within the suspension culture aggregates. 
As culturing continued, increased HUVEC arrangement was noted in both aggregate types, 
suspension culture and pellet culture alike; however, more so within the samples cultured under 
hydrostatic loading (fig. 5.9, 5.10, 5.11 and 5.12). 
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Figure 5.9: Confocal images of fluorescently-tagged HUVECs in MSC/HUVEC co-cultured aggregates. Images were taken 
following 3 days of hydrostatic loading. The aggregates were formed using 95% MSCs and 5% HUVECs with both 
suspension culture and pellet culture techniques. The MSCs were not fluorescently-tagged. White arrows indicate areas 
of tubular cellular arrangements. 
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Figure 5.10: Confocal images of fluorescently-tagged HUVECs in MSC/HUVEC co-cultured aggregates. Images were 
taken following 3 days of static culturing. The aggregates were formed using 95% MSCs and 5% HUVECs with both 
suspension culture and pellet culture techniques. The MSCs were not fluorescently-tagged. White arrows indicate areas 
of tubular cellular arrangements. 
After 7 days of culturing under loaded and static conditions, obvious differences were noted 
between the loaded and static samples (fig. 5.11). The loaded samples had significantly more 
tubular HUVEC arrangements when compared to the static samples. After 10 days of culturing, 
the samples undergoing loading were still showing increased HUVEC arrangement when 
compared to statically cultured samples for both aggregate formation techniques (fig. 5.12). The 
loaded suspension culture aggregates have shown the most obvious cellular arrangements 
followed closely by the loaded pellet culture aggregates. 
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The static suspension culture aggregates were also showing slightly more cellular arrangement 
when compared to the static pellet culture aggregates, which were showing no arrangement at all 
(fig. 5.12). That is to say, the loaded suspension culture aggregates were showing the most HUVEC 
arrangement, followed by the loaded pellet culture aggregates, the static suspension culture 
aggregates and finally the static pellet culture aggregates. 
 
Figure 5.11: Confocal images of fluorescently-tagged HUVECs in MSC/HUVEC co-cultured aggregates. Images were 
taken following 7 days under loaded and static culture conditions. The aggregates were formed via suspension 
aggregation using 95% MSCs and 5% HUVECs. The MSCs were not fluorescently-tagged. White arrows indicate areas of 
tubular cellular arrangements. 
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Figure 5.12: Confocal images of fluorescently-tagged HUVECs in MSC/HUVEC co-cultured aggregates. Images were 
taken following 10 days of loaded and static culturing. The aggregates were formed via both suspension and pellet 
aggregation techniques using 95% MSCs and 5% HUVECs. The MSCs were not fluorescently-tagged. White arrows 
indicate areas of tubular cellular arrangements. 
3.3 Immunostaining 
CD31 staining of aggregate sections corroborated previously conducted HUVEC tracking and 
confocal imaging. The loaded samples appeared to better maintain their initial spheroidal shape 
over the duration of the study, more so in the pellet culture aggregates. The static samples 
experienced sizeable cellular outgrowth and altered aggregate size and shape as a result (fig. 
5.13). Particular HUVEC arrangements appear far more distinct also. The HUVECs would appear to 
be most organised in the loaded samples. 
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Figure 5.13: Epifluorescent images of CD31-stained MSC/HUVEC co-cultured aggregate sections. Images were taken 
following 7 days under loaded and static culture conditions. The aggregates were formed via both suspension and pellet 
aggregation techniques using 95% MSCs and 5% HUVECs. The aggregate sections were stained for CD31 and Dapi. 
White dotted lines highlight possible tubular structures and white arrows highlight cellular outgrowth from the 
aggregate body. 
3.4 Aggregate density and material volume 
Aggregate density and volume were evaluated using microCT scanning after 10 days of culturing 
for the assessment of mineralisation (fig. 5.14). Three variables were compared for aggregate 
volume, dense material volume and volume of dense material normalised to total aggregate 
volume: suspension culture aggregation versus pellet culture aggregation (fig. 5.15), loaded 
versus static culturing conditions (fig. 5.16) and MSC aggregates versus MSC/HUVEC co-cultured 
aggregates (fig. 5.17). 
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Figure 5.14: MicroCT scan images showing suspension and pellet culture aggregates. Samples were produced from 
MSCs only (A) and MSC/HUVEC co-cultures (B). The suspension aggregate samples of MSCs only and MSC/HUVEC co-
cultures are shown under loaded and static culture conditions, whilst the pellet aggregate samples of MSCs only and 
MSC/HUVEC co-cultures are shown under loaded culture conditions only. 
3.4.1 Suspension culture aggregation versus pellet culture aggregation 
When evaluating the aggregate formation techniques, both culture aggregates had similar 
material volumes at a threshold of 110, 0.03 mm³ and 0.03 mm³ for the pellet and suspension 
cultures, respectively. At a threshold of 130, the suspension culture aggregates and pellet culture 
aggregates had dense material volumes of 0.002 mm³ and 0.001 mm³, respectively (fig. 5.15). 
Taking these values into account, it was possible to compare the volume of dense material 
normalised to total aggregate volume. The suspension culture aggregates and their pellet culture 
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counterparts had normalised dense material volumes of 0.071 mm³ and 0.047 mm³, respectively 
(fig. 5.15). 
 
Figure 5.15: MicroCT data comparing aggregate volume measurements. The average (mean) volumes of aggregates 
formed using suspension and pellet culture techniques at thresholds of 110 (A) and 130 (B). Also shown is the volume of 
dense material normalised to total sample volume (C). Data was collected using aggregates formed from MSCs only and 
MSC/HUVEC co-cultures (95% MSCs and 5% HUVECs) and cultured under loaded and static conditions. Error bar 
represents standard error of the mean. ** signifies p < 0.01 and **** signifies p < 0.0001. 
3.4.2 Loaded versus static culture conditions 
At a threshold of 110, the loaded and statically-cultured samples had material volumes of 0.031 
mm³ and 0.028 mm³, respectively (fig. 5.16). At a threshold of 130, the loaded and statically-
cultured samples had dense material volumes of 0.002 and 0.001 mm³, respectively (fig. 5.16). 
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The volume of dense material normalised to total aggregate volume values were 0.07 and 0.04 
mm³ for the loaded and statically-cultured samples, respectively (fig. 5.16). 
 
Figure 5.16: MicroCT data comparing aggregate volume measurements. The average (mean) sample volumes cultured 
under loaded and static conditions at thresholds of 110 (A) and 130 (B). Also shown is the dense material volume 
normalised to total sample volume (C). Data was collected using aggregates formed from MSCs only and MSC/HUVEC 
co-cultures in suspension and pellet aggregation cultures. Error bar represents standard error of the mean.    *** 
signifies p < 0.001. 
3.4.3 Mesenchymal stem cell only aggregates versus co-cultured aggregates 
At a threshold of 110, the MSC only aggregates and MSC/HUVEC co-cultured aggregates had 
material volumes of 0.025 mm³ and 0.034 mm³, respectively (fig. 5.17). When comparing the 
volume of dense material at a threshold of 130, the MSC only aggregates had a volume of 0.002 
mm³ compared to a volume of 0.001 mm³ for the MSC/HUVEC co-cultured aggregates (fig. 5.17). 
208 
 
When normalised to total aggregate volume, the volume of dense material then read 0.079 mm³ 
and 0.045 mm³ for the MSC only controls and the MSC/HUVEC co-cultures, respectively (fig. 5.17). 
 
Figure 5.17: MicroCT data comparing aggregate volume measurements. The volumes of MSC only and MSC/HUVEC co-
cultured aggregates at thresholds of 110 (A) and 130 (B). Also shown is the volume of dense material normalised to 
total sample volume (C). Data was collected using suspension and pellet culture aggregates cultured under loaded and 
static conditions. Error bar represents standard error of the mean. *** signifies p < 0.001 and **** signifies p < 0.0001. 
3.4.4 In vitro aggregates versus rat femur models 
The normalised volumes of dense material for each of the aggregate variables were compared to 
one another and also to rat femurs of various ages (fig. 5.18). Three variables stood out as being 
most influential in terms of dense material accumulation: aggregates composed of MSCs only, 
formed on a suspension culture substrate and cultured under loaded conditions. Whilst none of 
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the upper three variables differed from one another and none of the lower three variables 
differed from one another, both groups were deemed statistically similar. All of the in vitro 
aggregate samples were significantly lower, in terms of normalised dense material volume, than 
even the youngest of the rat femurs. 
 
Figure 5.18: Aggregate material measurements compared to rat femur material measurements. Shown is the 
normalised dense material volume of each experimental variable (A). These normalised values are also compared to the 
equivalent values derived from rat femurs of various ages (B). Data comparing loaded and static culture conditions were 
compiled from suspension and pellet culture aggregates formed using MSCs only and MSC/HUVEC co-cultured 
aggregates. Data comparing suspension and pellet aggregation techniques were compiled using MSC only and 
MSC/HUVEC co-cultured aggregates cultured under loaded and static conditions. Data comparing MSC only and 
MSC/HUVEC co-cultured aggregates were compiled using suspension and pellet aggregates cultured under loaded and 
static conditions. Error bar represents standard error of the mean. **** signifies p < 0.0001. 
3.5 Difficulties of imaging stained/tracked whole aggregates 
It should be documented that some interesting and possibly contradicting data sets were also 
obtained throughout this study. CD31 staining of the intact aggregates did not offer any insight 
into the inner aggregate HUVEC arrangement; rather, it failed to show any arrangement at all (fig. 
5.19 and 5.20). 
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Thankfully, however, some corroborating data can be obtained. Antibody penetration differed 
depending upon both aggregation technique and culture condition, suggesting that both initial 
aggregate density and the maintenance of such are highly influenced by the techniques discussed 
here. Penetration of the antibodies was less extensive in the pellet culture aggregates when 
compared to the suspension culture aggregates suggesting a higher aggregate density in the 
pellet culture samples. The antibody penetration was also lower in the loaded samples compared 
to the static samples, again suggesting a higher aggregate density through loading. Live/dead 
staining was also carried on whole aggregate samples but experienced similar dye penetration 
issues and so was not included in the results of this experiment. These data, at best, corroborate 
with the microCT density measurements noted previously. 
 
Figure 5.19: Confocal images of CD31-stained MSC/HUVEC co-cultured aggregates. Images were taken following 7 days 
under loaded culturing conditions. The aggregates contained 95% MSCs and 5% HUVECs and were formed using 
suspension and pellet aggregation techniques. The whole aggregates were stained for CD31 and mounted with a Dapi-
conjugated mounting medium. 
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Figure 5.20: Confocal images of CD31-stained MSC/HUVEC co-cultured aggregates. Images were taken following 7 days 
under static culturing conditions. The aggregate contained 95% MSCs and 5% HUVECs and were formed using 
suspension and pellet aggregation techniques. The whole aggregates were stained for CD31 and mounted with a Dapi-
conjugated mounting medium. 
Also, when both HUVECs and MSCs were tracked in both suspension- and pellet-cultured 
aggregates, HUVEC arrangement into any discernible pattern was more difficult to visualise (fig. 
5.21, 5.22, 5.23 and 5.24). The experimental set-up was the same as that used for previous 
experiments with the only difference being the MSCs were also fluorescently-tagged. There is no 
obvious reason for the data obtained from this particular experiment. The software used for the 
confocal z-stacking analysis had sequential settings enabled to prevent any “bleed through” 
between the two fluorescent markers, FITC and TRITC, so cross-contamination between images 
cannot be the issue. The precise reason for this observation is unknown. Again, however, these 
data corroborate previously noted observations suggesting that the main aggregate body was 
better maintained under loaded conditions compared to static conditions. 
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Figure 5.21: Confocal images of aggregates containing fluorescently-tagged MSCs and HUVECs. Images were taken 
following 7 days under loaded culturing conditions. MSCs were tagged with a TRITC-conjugated membrane dye, whilst 
HUVECs were tagged with a FITC-conjugated membrane dye. The aggregates contain 95% MSCs and 5% HUVECs and 
were formed using the suspension aggregation technique. 
213 
 
 
Figure 5.22: Confocal images of aggregates containing fluorescently-tagged MSCs and HUVECs. Images were taken 
following 7 days under loaded culturing conditions. MSCs were tagged with a TRITC-conjugated membrane dye, whilst 
HUVECs were tagged with a FITC-conjugated membrane dye. The aggregates contained 95% MSCs and 5% HUVECs and 
were formed using the pellet aggregation technique. 
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Figure 5.23: Confocal images of aggregates containing fluorescently-tagged MSCs and HUVECs. Images were taken 
following 7 days under static culturing conditions. MSCs were tagged with a TRITC-conjugated membrane dye, whilst 
HUVECs were tagged with a FITC-conjugated membrane dye. The aggregates contain 95% MSCs and 5% HUVECs and 
were formed using the suspension aggregation technique. 
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Figure 5.24: Confocal images of aggregates containing fluorescently-tagged MSCs and HUVECs. Images were taken 
following 7 days under static culturing conditions. MSCs were tagged with a TRITC-conjugated membrane dye, whilst 
HUVECs were tagged with a FITC-conjugated membrane dye. The aggregates contain 95% MSCs and 5% HUVECs and 
were formed using the pellet aggregation technique. 
4. Discussion 
The advantages of using 3D microenvironments (cellular aggregates) for tissue engineering has 
been discussed in previous chapters; therefore, using such environments for the study of 
vascularisation and mineralisation of constructs makes for sound experimental reasoning. This 
study intended to evaluate the enhancement effects of culture environments, e.g. hydrostatic 
loading, on vascularisation and mineralisation with the use of 3D cellular aggregates. The 
aggregates consisted of MSCs only and MSC/HUVEC co-cultures that were formed using two 
different methods: pellet culture aggregation and suspension culture aggregation. The suspension 
culture method comprised a simple F127-coated hydrophilic environment that encouraged the 
cells to remain in suspension (described in detail in chapter 3). Once suspended, the cells were 
free to aggregate and self-assemble into spheroidal structures. The pellet culture method, on the 
other hand, forced the cells into a cell pellet that subsequently became spheroidal. The 
suspension culture method was considered to be a less severe method for aggregation with the 
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cells aggregating or self-assembling of their own accord over a 48 hour period. The pellet culture 
method was less forgiving and forced the cells into a pellet through centrifugation. The aggregates 
were comprised mostly of MSCs (90 – 95%) which formed the main body of the constructs. The 
HUVECs were far fewer in number (5 – 10%) but their role was no less important. The intention 
was for the HUVECs to form vascular or tubular structures within the aggregate body. 
4.1 Aggregate formation, size and shape 
The first observation made was with regards to the structure of the aggregates depending upon 
which aggregate formation technique was used. The suspension culture method initially created 
multiple small aggregates that eventually joined together to form a single aggregate per well. 
Similar occurrences were noted when forming suspension culture aggregates using an MLO-A5 
cell line (chapter 3). The sometimes elongated and irregular shape of the aggregates formed using 
this technique suggested that the inner structure of the final aggregates still comprised the initial 
small aggregates. The pellet culture method, however, formed a single cell pellet immediately 
upon centrifugation with, what is suspected to be, a more uniform inner-aggregate structure. 
4.2 HUVEC arrangements and aggregate vascularisation 
If one considers the development of a viable vascular network a key component of bone 
formation, as is the case for in vivo bone regeneration, then the measurement of vascularisation 
through cellular arrangements becomes a crucial element for evaluating bone formation. 
4.2.1 Whole aggregate monitoring 
The initial aggregate structure appeared to influence cellular arrangement even prior to any 
further cultural conditions, i.e. loaded or static culturing. Confocal z-stacking has shown 
suspension culture aggregates with an enhanced HUVEC arrangement compared to the pellet 
culture aggregates. The small aggregates making up the final large aggregate of the suspension 
culture offered an inner-aggregate structure that was lacking in the aggregates of the pellet 
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culture method which is believed to aid HUVEC arrangement and subsequent vascularisation. 
Saleh and colleagues demonstrated a similar cellular arrangement to our own488. Their study too 
used a non-adherent or suspension culture to allow for the self-assembly of aggregates which 
were smaller than our own (3 x 10⁵ cells in total) but contained a larger proportion of HUVECs 
(50% of the total cell count). After 7 days in culture, the majority of the HUVECs were seen to be 
located around the periphery of the aggregates. These findings corroborate our own in the sense 
that the HUVECs in our study were predominantly located around the periphery of the smaller 
aggregates making up the inner structure of the large aggregates. A similar phenomenon was 
noted by Stahl et al. who cultured primary osteoblasts with human ECs489. One theory put forward 
to explain this cellular self-assembly is the differential adhesion hypothesis (DAH)490. The theory 
simply states that cells will aggregate to maximise adhesion and minimise energy with different 
cell types segregating according to cell – cell adhesion capabilities; those cells of a higher cohesion 
form the aggregate centre and those with a lower cohesion form the aggregate periphery. 
Culture conditions have also been seen to influence cellular arrangement. Within the suspension-
cultured aggregates, extensive HUVEC arrangement into tubular structures was clearly visible 
within the loaded samples, even within the early stages of the experiment. The pellet culture 
aggregates did not have the same level of HUVEC arrangement from the onset, but with 
continued loading, HUVEC arrangement into possible tubular structures did improve. Cyclic 
hydrostatic loading, therefore, positively influenced cellular arrangements in both aggregate 
types. Although the inner aggregate structure of the suspension culture aggregates allowed for 
minor initial HUVEC arrangement within the statically-cultured samples, this arrangement did not 
improve over the course of the experiment. Taking both aggregation techniques and culture 
conditions into account, it can be said that the suspension culture method allowed for a greater 
initial HUVEC arrangement compared to the pellet culture method and both techniques benefited 
from loaded culturing. The statically-cultured aggregates did not appear to develop tubular 
structures to the same degree. This may, in part, be due to VE-cadherin expression. VE-cadherin is 
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present at endothelial adherens junctions and has been reported to play an important role in the 
intercellular adhesion, differentiation, growth and migration of ECs278. The expression of such has 
also been shown to be upregulated under shear stress conditions491 making its increased 
expression under hydrostatic loading a likely contributor to the increased cellular arrangements 
noted in this study. 
4.2.2 Aggregate sections 
Aggregate sectioning and staining has offered a valuable insight for this study with even the 
sectioning itself offering some corroborative observations. The loaded samples appeared to 
better maintain their initial spheroidal structures throughout the study when compared to the 
static samples. This was largely due to the extensive cellular outgrowth noted from the statically-
cultured aggregates that was considerably less severe from the hydrostatically-loaded samples. 
Inner-aggregate cellular arrangements also differed between culture conditions. The 
hydrostatically-cultured aggregates appeared to have a more distinctive cellular arrangement 
compared to the statically-cultured aggregates. Tubular structuring of the HUVECs was notably 
more apparent in the loaded samples. The CD31-stained sections suggest that the pellet culture 
method of aggregation resulted in enhanced HUVEC arrangements into tube-like structures, and 
whilst this is entirely possible, it is the opinion of the author that the increased density of the 
pellet culture aggregates allowed for more intact sectioning and should the suspension culture 
aggregates have experienced as high quality sectioning, they too would have increased tubular 
arrangements. 
4.2.3 Combined interpretations 
Regardless of what criteria one uses for evaluating in vitro bone formation, it is clear that cellular 
aggregation combined with hydrostatic loading offers an invaluable model for the continued 
research into developing large bone tissue-engineered constructs. Cellular aggregation has been 
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discussed in depth in previous chapters; thus, its use here is considered advantageous. What is 
interesting, however, is how different aggregation techniques influenced levels of cellular 
arrangement and mineralisation. Which technique is better for graft development and 
subsequent implantation has yet to be conclusively shown but what this study has demonstrated 
is that in the quest for large implantable bone grafts, one should not only consider cellular 
aggregation but also the method of aggregation. In addition, mechanical loading has been shown 
to hold some influence over the production of dense material. Hydrostatic loading has been 
shown by previous studies to enhance mineralisation and bone formation386 but this study has 
shown some interesting results that allow for some thought provoking discussions. Increased 
cellular arrangements and varied levels of mineralisation were observed for samples cultured 
under mechanically-loaded conditions. 
4.3 Aggregate material volumes 
4.3.1 Aggregate formation technique 
At a threshold of 110, neither aggregate formation technique had a significantly higher aggregate 
volume in comparison to the other. At a threshold of 130, both aggregate cultures, again, had 
similar material volumes. However, the standard error of the mean for both aggregate samples 
was significantly different with the suspension culture aggregates having a far higher standard 
error (f-test, p < 0.0001). This notable difference is likely due to the way the aggregates were 
formed. The pellet culture aggregates were forcibly aggregated producing uniform aggregates, 
whilst the suspension culture allowed the aggregates to form of their own accord, thus, producing 
aggregates of a less uniform nature. This considerable variation in standard error is thought to 
have diluted the magnitude of the overall mean value differences, rendering them insignificant. 
Using both thresholds, 110 and 130, we were able to normalise the volume of dense material to 
total volume of collagenous material. In doing so, we saw that the suspension culture aggregates 
again contained a statistically similar percentage of dense material but a significantly higher 
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standard error of the mean (f-test, p = 0.002). All of the data, thus far, would suggest that, whilst 
both aggregation techniques were statistically similar in terms of dense material production, 
perhaps with a higher cohort this standard error could have been reduced and the difference 
between aggregation methods may have been seen. 
4.3.2 Culture environment 
Subsequent culturing conditions are thought to build upon these initial observations. When 
measuring the volume of dense material via microCT, the hydrostatically-loaded aggregates had a 
statistically similar volume of material compared to the statically-cultured samples. As was the 
case with the suspension culture aggregates, however, the loaded aggregates had a significantly 
higher standard error of the mean compared to the statically-cultured aggregates (f-test, p = 
0.0002). Whilst there are a number of occurrences believed to be responsible for these 
observations, the loading parameters were carefully selected and are thought to not have 
obstructed the acquired data in any way. Henstock et al.276 noted that bone formation was 
directly proportional to stimulation frequency and was independent of the degree of pressure 
applied. Therefore, the cyclic application of pressure is thought to be more relevant than the 
magnitude of the pressure itself. Airing on the side of caution, however, the pressure and 
frequency rate were still carefully chosen. The pressure used most closely replicates the pressure 
experienced by osteocytes in the canaliculi-lacuna system of load-bearing bones (270 kPa)474 and 
the frequency rate used is similar to many physiological processes, such as the human pulse rate 
(1 – 2 Hz) and bone/joint compression (0.3 – 3 Hz) under normal conditions276. 
Rather, the hydrostatic chamber itself and the position of the aggregate samples within such are 
thought to play more of a hindering role in the data mentioned above. It was noted by Reinwald 
and colleagues that when hydrostatically loading a hydrogel construct within a chamber, such as 
the one used in this study, the centre of the hydrogel experiences considerably lower fluid flow 
and stress levels when compared to the peripheries of the gel285. Given that all of the aggregate 
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samples for this study were placed centrally in their hydrogel housings, this observation could 
explain the lower than expected differences in dense material production between the loaded 
and statically-cultured aggregates. 
Another possibly influential observation made during the use of the hydrostatic bioreactor was 
that during the loading of the samples, substantial medium evaporation was experienced. This 
evaporation was noted to be unevenly distributed across the well plate. Those wells closest to the 
air inlet port suffered the most severe medium loss with evaporation lessening across the plate 
towards the air outlet port. Given the non-uniform distribution of fluid loss, evaporation was, 
therefore, most likely due to gas shear flow across the medium surface492; which can induce 
additional surface stresses in the medium493. In addition, given that the samples were 
encapsulated in collagen gel and that this collagen was never directly exposed to the flow of gas, 
it is difficult to say what effect shear flow might have had on the data sets discussed above. It is 
noted that this element of the discussion is speculative and no experiments have been carried out 
by the author to investigate the extent of these observations but this could explain the 
considerable standard error of the mean values acquired for the loaded samples. 
4.3.3 Aggregate constituents 
The microCT data has shown that the MSC/HUVEC co-cultured aggregates had a similar volume of 
material at a threshold of 110 compared to the MSC only aggregates. At a threshold of 130, both 
aggregate samples, again, had statistically similar material volumes but the MSC only aggregates 
had a significantly higher standard error of the mean (f-test, p < 0.0001). The normalised values 
followed a similar trend (f-test, p = 0.0003). Given that previous studies have demonstrated when 
ECs are cultured in contact with bone marrow stromal cells, they promote in vitro osteogenesis 
through the expression of several factors, such as bone morphogenetic protein 2 (BMP-2)494, and 
the intercommunication with osteoblast-like cell gap junctions (connexin 43)281,495, this data might 
initially seem contradictory. However, in a study conducted by Bidara and colleagues, significant 
222 
 
ALP upregulation was only recorded in the final week of this 21 day co-culture monolayer study 
which was conducted using a minimal HUVEC concentration of 25%496. 
In comparison, our study was only 10 – 12 days in duration and used only 5 – 10% HUVEC 
concentration. In another co-culture study, Saleh and colleagues noted increased osteogenesis 
through ALP activity after just 7 days in culture which significantly increased after 14 days in 
culture compared with non-HUVEC-containing controls488. This study too used MSC/HUVEC co-
cultured aggregates but with a 50% HUVEC concentration. The promotion of osteogenesis was 
noted by Bidara and colleagues to be cell ratio-dependent so it is entirely possible that the HUVEC 
concentration used in our study had not yet had enough time to significantly enhance 
osteogenesis. In terms of in vivo bone formation, the phenomenon noted in our study is perhaps 
not surprising. As mentioned previously, natural bone formation or regeneration follows vascular 
formation at the site of injury or defect. If we consider our model as an in vitro replica of in vivo 
bone regeneration, MSC differentiation would have been initially delayed by the surrounding 
environment which would have coincided with a shift from mineralisation to vascularisation 
within the aggregates. Also, the MSC/HUVEC co-cultured aggregates were cultured in only 50% of 
the osteogenic supplements that were enjoyed by the MSC only aggregates due to the 1:1 ratio of 
MSC osteogenic medium and HUVEC medium. This may have limited the availability of agents and 
minerals required for mineralisation but it is considered by the author that the presence and 
subsequent focus on the arrangement of HUVECs was a more limiting factor for initial 
mineralisation than the reduced availability of osteogenic supplements. Although speculative, it is 
believed that if our study duration was extended, the presence of HUVECs would most-likely have 
enhanced the mineralisation of the co-cultured aggregates over the MSC only aggregates. 
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5. Conclusions 
In conclusion, whilst bone formation cannot be decisively concluded upon for a number of 
reasons, cellular arrangements and possible vascularisation can be. How the aggregates were 
formed appears to affect the inner-aggregate architecture. This, in turn, affects levels of HUVEC 
arrangement. The suspension culture aggregates are thought to have had a more 
compartmentalised inner structure compared to the more homogeneous inner-structure of the 
pellet culture aggregates. This increase in self-assembled structural interest allowed for a higher 
degree of cellular arrangement within the aggregates. In addition, the aggregates cultured under 
hydrostatically-loaded conditions, regardless of aggregate formation technique, experienced a 
considerably higher level of cellular arrangement compared to those cultured under static 
conditions. Taking both aggregation method and culture conditions together for the evaluation of 
vascularisation, it would appear that the suspension culture aggregates cultured under 
hydrostatic loading offered the best environment for vascularisation, closely followed by the 
pellet culture aggregates cultured under hydrostatic loading, the suspension culture aggregates 
cultured under static conditions and the pellet culture aggregates cultured under static 
conditions. 
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Chapter Six               
Discussion and Conclusions 
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Overview 
This study attempted to develop novel tissue engineering approaches to enhance natural bone 
formation. Induction and control of various cell – cell interactions are the central basis of these 
approaches, including the initiation of early onset mineralisation, the maintenance of prolonged 
aggregate culturing, the self-sorting of mixed stem cell subpopulations and the promotion of 
simultaneous vascularisation and mineralisation. To do this, an aggregation model was first 
developed and mineralisation rates and patterns verified and studied. Secondly, an in vivo study 
was conducted using two cell types to confirm the observations noted during in vitro 
examinations and also to evaluate how the said observations would affect long term cell 
aggregate survival and possible bone formation in vivo. Thirdly, a technique was developed to 
investigate the segregation of mesenchymal stem cell (MSC) subpopulations and their possible 
influences on an individual’s osteogenic capacity. In addition, tissue vascularisation was also 
investigated using a co-culture aggregation model and mechanical loading. 
1. Discussion 
1.1 Cellular aggregate model 
It was hypothesised that cellular condensation and aggregate formation could greatly enhance 
bone tissue development through mimicking of the intramembranous ossification pathway. It was 
believed that bone cell aggregates could become the ossification centres for nodule development 
which would greatly reduce the time required for mineralisation. It has already been reported 
that aggregate culturing of MSCs can induce osteogenic differentiation3 through the mediation of 
specific cellular integrin interactions340; so, an aggregate model was investigated here. 
The modification of substrate chemistry can influence cellular aggregation allowing for greater 
control over aggregate size, number, gene expression and mineralisation rate4. Such a simple 
technique is thought to offer a deeper understanding of the mechanisms involved in natural bone 
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growth and regeneration which will allow for the refinement of current tissue engineering 
techniques or the development of new approaches to better mimic such in vivo processes for 
improved patient care. 
Two substrates were used in the first phase of this study to develop an aggregate model. The first 
was a commercially-available hydrophobic substrate (denoted as non-coated) and the second 
involved using the same commercially-available hydrophobic substrate coated with a Pluronic 
solution (F127) (denoted as coated) (adapted from Aydin et al.7). This coating created an 
extremely hydrophilic substrate. Each substrate, coated and non-coated, discouraged cell 
attachment and maintained the cell populations in suspension. In doing so, the cells attached to 
one another creating cellular aggregates. How the coated and non-coated substrates differed 
from one another is in the magnitude by which they repel cell attachment, thus, creating 
aggregates of different sizes, denoted as small and large. 
An MLO-A5 cell line was used with the aforementioned substrate modification technique to 
successfully develop an in vitro aggregate model to replicate the in vivo intramembranous 
ossification pathway for the study of developing mineralisation over time. Several modes of 
analyses are used to evaluate and compare the potential for bone development with some 
interesting observations being made. As was the case for previously conducted studies, 
mineralisation rates were influenced by aggregate size432. Ultimately, the large aggregates were 
seen to mineralise faster than their smaller counterparts and progress further down the bone 
formation pathway over just 72 hours (chapter 3). The size of the aggregate was also seen to 
influence where minerals were initially deposited within the aggregates themselves. That is to say, 
the smaller aggregates appeared to initially deposit minerals within the aggregate centre, whilst 
the larger aggregates deposited minerals on the aggregate periphery. As mentioned, peripheral 
mineral deposition was also noted by Schneider and colleagues446 suggesting regions of optimal 
cell – cell and cell – extracellular matrix (ECM) interactions differ depending upon aggregate size. 
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The F127-coated suspension culture was also used to form aggregates from multiple MSC 
populations acquired from different donors (chapter 4). Each cell population produced a single 
large aggregate as expected, the results of which are described in detail in chapter 4. What is 
interesting, however, is what observations can be made when we compare how each cell type, 
MLO-A5 cells and MSCs, compare to one another when seeded on the same substrate. Both cell 
types used the very same cells numbers per aggregate, 3 x 105 cells, but formed aggregates of 
differing circularities. This would suggest that the slower proliferating MSCs reacted in a more 
similar way to the differentiated cell line compared to the faster proliferating MSCs. In that, the 
faster proliferating MSCs produced aggregates that were more spherical in shape and the slower 
proliferating MSCs, along with the cell line, produced more irregularly-shaped aggregates. In 
addition, the differences between the standard error of the mean aggregate aspect ratio would 
suggest that the slower proliferating MSCs were, again, more similar to the cell line in terms of 
variation in aggregate shape compared to the faster proliferating MSCs. 
Taking both observations into account, it would appear as though the MSCs and MLO-A5 cell line 
reacted differently to the coated suspension culture. In addition, differences between the MSC 
populations themselves were also noted. The faster proliferating MSCs produced spherical 
aggregates of a standard circularity with little variation. The slower proliferating MSCs produced 
aggregates with an average (mean ± standard error of the mean) circularity more similar to that of 
the MLO-A5 cell line and also with a significantly higher variation in terms of reproducible 
circularity. 
There are a number of possible explanations for this phenomenon, chiefly among which are 
cadherins. Cadherins have been discussed in detail in chapter 4; therefore, it is speculated that 
the different cell types may express varying levels of different cadherins. E-cadherin expression 
has been shown previously to precede cadherin-11 expression464, and whilst several in vitro 
studies have shown that the expression of cadherins can change during osteoblast differentiation, 
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the most common cadherins expressed by osteoblasts are E-cadherin, N-cadherin and cadherin-
11474,475. Osteoblasts have been shown to mainly express N-cadherin and cadherin-11, however, 
which have both been shown to influence bone formation and mass476. In addition, E-cadherin has 
been noted previously to be an influential factor in forming cellular aggregates478. It is, therefore, 
thought that MSCs may express more E-cadherin, whereas the MLO-A5 cell line may express more 
N-cadherin and/or cadherin-11. Additionally, the faster proliferating MSCs, D3737A, have been 
shown to express significantly higher E-cadherin levels compared with the slower proliferating 
MSCs, D2884D (chapter 4). 
1.2 In vivo examinations 
Whilst the observations made during the development of the aforementioned model were 
certainly interesting, they were only relative to the onset of mineralisation or the initial stages of 
mineralisation. A key question remained at this point and that was how aggregate size would 
affect long term aggregate survival, mineralisation and/or bone formation. An 8-week in vivo 
investigation was, therefore, carried out with the hope of shedding light on the potential for long 
term aggregate survival and bone formation using two different cell types. Both cell types, MLO-
A5 cells and MSCs, were used for this study with similar observations being noted for both. The 
initial observations made post-termination are described in detail in chapters 3 and 4. 
Comparisons between data obtained from both cell types are also made in chapter 4. 
1.3 Mesenchymal stem cell subpopulations 
The use of modified substrates may also offer a route for further investigations into individual-
specific cellular biology, thus, allowing for more accurate patient assessment and personalised 
treatment strategies. This study investigated the possibility that MSCs isolated from human bone 
marrow mononuclear cells (MNCs) contain donor-dependent subpopulations that may play a role 
in determining an individual’s osteogenic capacity. Using a novel substrate, substrate X, a new 
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protocol was developed for the identification of suspected subpopulations which encompasses a 
simple technique allowing the cells to self-sort into identifiable cellular arrangements, denoted as 
a monolayer arrangement, a sunflower-like arrangement and an aggregate-like arrangement. 
Each arrangement is thought to represent a separate subpopulation. 
The proportions of these specific cellular assemblies are thought to be donor specific and may 
correspond with an individual’s bone formation potential. The different arrangements were 
assessed for E-cadherin levels indicating that the more organised arrangements, i.e. sunflower-
like and aggregate-like arrangements, had higher E-cadherin expression levels and, therefore, a 
higher capacity for cell – cell interactions. 
The osteogenic potential of each cellular subpopulation was also assessed using histochemical 
staining and showed that those subpopulations with a higher aptitude for self-organisation, again, 
had a higher aptitude for indicators associated with mineralisation. Multiple analyses suggest that 
the proportions of these supposed subpopulations are donor-dependent allowing for correlations 
to be made between growth profiles, cell sizes, E-cadherin levels and osteogenic capacities. These 
data allow for the hypothesis that a donor with a higher proportion of sunflower-like or 
aggregate-like cells would correspondingly have a higher capacity for osteogenic development. 
1.4 Aggregate vascularisation 
The vascularisation and mineralisation of cellular aggregates was also investigated within this 
project. We explored the influences imparted by aggregate formation techniques and mechanical 
loading on inner aggregate cellular arrangements (construct pre-vascularisation) and 
mineralisation levels (potential bone formation) within MSC and human umbilical vein endothelial 
cell (HUVEC) aggregate co-cultures. The aggregate samples were formed using two different 
aggregation techniques, suspension culture aggregation and pellet culture aggregation, and were 
cultured under two different culturing conditions, hydrostatically-loaded culturing and static 
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culturing. Clear differences could be seen when comparing both the aggregate formation 
techniques and culture conditions for possible effects on cellular arrangements for construct pre-
vascularisation and mineralisation levels for bone formation. 
How the aggregates were formed influences the inner aggregate architecture which, in turn, 
affects levels of HUVEC arrangement. Taking both aggregation methods and culture conditions 
together, it would appear that the suspension culture aggregates cultured under hydrostatic 
loading offered the best environment for vascularisation and mineralisation, closely followed by 
the pellet culture aggregates cultured under hydrostatic loading, the suspension culture 
aggregates cultured under static conditions and the pellet culture aggregates cultured under 
static conditions. 
2. Conclusions 
In conclusion, using simple yet novel substrate chemistry modifications has allowed for the 
development of a number of models for the assessment of various parameters intended for 
refined bone tissue engineering. A cellular aggregate model was established using a murine cell 
line and found that larger aggregates mineralised at a faster rate and initially deposited minerals 
towards the periphery of the aggregates, whilst smaller aggregates mineralised at a slower rate 
and deposited minerals within the aggregate centres. Gene expression patterns also differed 
depending upon aggregate size suggesting cellular maturation was influenced by cell – cell 
interactions. In conjunction, an in vivo study was carried out using the same cell line alongside a 
primary cell culture, MSCs, to evaluate how aggregate size would affect possible bone formation 
post-long term implantation. As with the in vitro studies, the data obtained suggested aggregate 
size strongly influenced aggregate survival rate with larger aggregates appearing to disintegrate 
over the course of the experiment. The reasons behind these data are thought to be focused on 
oxygen and nutrient supply giving rise to the concept of an optimal aggregate size for smaller 
grafts or implants, or the need for enhanced perfusion within larger grafts or implants. In addition 
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to aggregation, substrate chemistry modification was used to identify possible MSC 
subpopulations. Three subpopulations are thought to have been identified through distinct cell 
attachment arrangements. Each of these subpopulations was shown to possess different 
differentiation potentials and E-cadherin levels. The proportions of the subpopulations were 
quantified in numerous individual donors and were shown to correlate with aggregation 
potential. These data suggest that subpopulation proportions are donor-dependent and could 
correlate with an individual’s bone formation capacity. Another study undertaken throughout this 
project involved the simultaneous assessment of vascularisation through cellular arrangements, 
and mineralisation. This study found that aggregation technique strongly influenced the level of 
cellular arrangements as did culturing technique. That is, the model developed as part of this 
project created aggregates with enhanced cellular arrangements compared to the conventional 
aggregation technique, and hydrostatic loading enhanced cellular arrangements more so than the 
static equivalents. A conclusion was difficult to draw for levels mineralisation given the short 
duration of the study. 
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Chapter Seven                
Future Work  
233 
 
Overview 
Numerous novel techniques have been developed throughout this project but, whilst the 
preliminary research has been fruitful, continued investigations are required to refine current 
protocols and ensure progression. 
1. Further mesenchymal stem cell investigations 
The current subpopulation identification protocols should be investigated further to advance this 
novel technique. The current study required a large number of mesenchymal stem cells (MSCs) 
which meant a correspondingly high passage number, passage three. Whilst this allowed us to 
compare and correlate our assessment technique with previously conducted research, the next 
step would be to refine our current protocols. To do this, MSCs would be used from multiple 
donors as before but with a dramatically reduced cell number. If we can obtain the same level of 
validation from a minimum number of cells, 0.5 x 106 for example, and a lower passage number, 
passage one for example, this would significantly reduce the time required to culture a functional 
cell population. In addition, with cellular arrangements on substrate X being noted to have fully 
formed within just hours of seeding, reducing the time required to identify and quantify the 
subpopulations and their proportions, to just 24 hours for example, would allow for the 
assessment of the osteogenic potential within an MSC population to be conducted at a much 
faster rate. Also, a more objective and reproducible identification and quantification technique 
needs to be developed. Whilst the current technique was sufficient to develop the initial 
protocols and validate our preliminary research, a more robust and accurate identification and 
quantification technique is required to reduce the time required for patient assessment whilst 
simultaneously increasing reproducibility and decreasing inter-institute variabilities. This would 
initially require an accurate definition of what the three cellular arrangements look like which will 
allow for their accurate identification. Perhaps, an imaging technique alongside software 
programming would be the next step in accurately measuring the subpopulation proportions. All 
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in all, these refinements would dramatically reduce the time require for patient assessment whilst 
also increasing the accuracy and reproducibility of the assay. This would ultimately allow for this 
technique to be used within a clinical setting as a cheap, but effective, diagnostic tool. The 
assessment of an individual’s bone formation or regeneration capacity would allow for patient 
specific treatments to be used, improving a patient’s ability or likelihood to recover from acute 
bone loss or injury. 
In addition, isolation and further enrichment of specific subpopulations identified using our 
current technique would be beneficial to both clinicians and companies dedicated to the mass 
production of MSCs for cellular therapy purposes. An isolation technique could be developed to 
separate those subpopulations identified as being most osteogenic in capacity. This would require 
an investigation into enzymatic, non-enzymatic and physical cleaving agents and techniques that 
would allow for the very specific division of particular cells from a population of multiple 
subpopulations. Once isolated, however, those cells could be further cultured to give a patient the 
best possible treatment; or within a commercial setting, it can be used to increase the therapeutic 
potential of mass-produced MSCs. Isolated cell populations should be evaluated in vivo to not 
only validate their therapeutic capacities but also the isolation process itself. 
2. Aggregate vascularisation 
Another interesting area that deserves further investigation is the prospect of pre-vascularised 
aggregates. How vascularised aggregates compare to their non-vascularised equivalents once 
implanted in vivo for example, would be a beneficial study for the continued development of large 
tissue constructs. The aggregation techniques established throughout this project could be used 
to create both vascularised and non-vascularised aggregates that can then be evaluated and 
compared for their bone formation potentials. 
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